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1.1 Synopsis of thesis
The purpose of this thesis was to investigate the enzymatic sources of, and stimuli for, 
reactive oxygen species (ROS) production in human vascular cells and blood vessels. 
In particular, the possibility that vasoactive hormones, such as angiotensin II (Ang II), 
might stimulate vascular ROS production was also explored.
Internal mammary arteries (IMA) and saphenous veins (SV) were collected at the 
time of coronary artery bypass surgery. Initial validation studies demonstrated that 
lucigenin-enhanced chemiluminescence was a sensitive and specific method for 
quantification of superoxide (O 2 ) concentrations in these blood vessels. The 
enzymatic sources of ROS generation were NAD(P)H oxidase, xanthine oxidase and 
in some, but not all, patients, nitric oxide synthase. Superoxide production was greater 
in IMA than in SV, whereas the amount of superoxide dismutase protein was 
quantitatively similar in these blood vessels.
In subsequent studies, treatment of IMA with pharmacological concentrations of Ang 
II (1 micromolar, 1 nanomolar) for 1 and 4 hours was associated with an increase in 
O2’ production. Treatment of IMA with picomolar, or physiological, concentrations of 
Ang II tended to increase O2' production. Further studies demonstrated that this was 
an Ang type 1 (ATi) receptor-dependent, NAD(P)H oxidase-mediated pathway. 
Furthermore, inhibition of the AT2 receptor did not prevent Ang II-stimulated increase 
in O2' production in IMA, suggesting that this receptor does not contribute to O2' 
generation in human arteries.
Immunodetection studies for the NAD(P)H oxidase phox subunits were performed in 
IMA. Using monoclonal antibodies and antisera, p22phox, gp91 phox (or a 
homologue), p67phox and p47 phox protein subunits were identified within the 
endothelium, vascular smooth muscle cell layer and adventitia. Xanthine oxidase was 
identified in the endothelium and adventitial layers of IMA. In this chapter, studies of 
the effects of Ang II on the abundance of cDNA transcripts of the subunits of 
NAD(P)H oxidase are reported. In subsequent molecular studies, it was demonstrated 
that treatment of human vascular cells arid intact IMA with 1 micromole of Ang II for 
4 hours led to an increase in the abundance of cDNA transcripts of p22phox, which
was attenuated by co-treatment with either actinomycin D, an inhibitor of gene 
transcription, or losartan, an ATi receptor antagonist.
In other studies, the possiblity that Ang II-stimulated O2' production might contribute 
to vascular tone in human subcutaneous resistance arteries (SRA) was investigated. 
Isometric tension studies failed to demonstrate any positive effect of Ang II on the 
contractile response of SRA to norepinephrine. One reason for this may be the 
relatively minor contribution of nitric oxide to the vasorelaxant response of these 
arteries.
An investigation of the effect, if any, of demographic characteristics, risk factors for 
atherosclerosis, and individual drug therapies, on vascular O2' production in the IMA 
of 79 patients was also performed. Multivariate analyses demonstrated that increasing 
age was weakly associated with increased vascular O2' production whereas treatment 
with an angiotensin converting enzyme inhibitor or ATi receptor antagonist was 
independently associated with reduced vascular O2' concentrations.
In summary, O2’ production is greater in IMA than in SV. Several enzymes capable 
of generating ROS are distributed throughout the wall of these arteries. NAD(P)H 
oxidase is a major source of O2' generation. The activity of this enzyme is enhanced 
by Ang II, through a mechanism which involves and increase in gene transcription 
and protein synthesis. This may be clinically important as inhibitors of the renin- 
aldosterone-angiotensin system may reduce vascular O2 ' production.
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Act D Actinomycin D
ACE-I Angiotensin converting enzyme inhibitor
ACh Acetylcholine
ALP Allopurinol
Ang II Angiotensin II
ARA Angiotensin receptor antagonist
AT Angiotensin receptor
CL Chemiluminescence
DETCA Diethyldithiocarbamate
DNA Deoxyribonucleic acid
DNAse Deoxyribonulcease
DPI Diphenyleniodonium
ED Endothelial denudation
EDRF Endothelium -  derived relaxant factor
ELISA Enzyme -  linked immunosorbent assay
eNOS Endothelial nitric oxide synthase
FADH reduced flavin adenine dinucleotide
xxi
GAPDH Glyceraldeyde -  3- phosphate deydrogenase
HMG-CoA 3-Hydroxy-3-methylglutaryl coenzyme A reductase.
HUVEC Human umbilical vein endothelial cell
IMA Internal mammary artery
iNOS Inducible nitric oxide synthase
JAK Janus kinase
Kb Kilobase
Kd Kilodalton
L-NAME N^-Nitro-L-arginine methyl ester
LVEF Left ventricular ejection fraction
mRNA messenger ribonucleic acid
NAD(P)H reduced nicotinamide adenine dinucleotide phosphate
NE Norepinephrine
NO Nitric oxide
NOS Nitric oxide synthase
NYHA New York Heart Association
O2* Superoxide
PCR Polymerase chain reaction
PE Phenylephrine
Phox phosphate oxidase
RAAS Renin angiotensin aldosterone system
RNA Ribonucleic acid
RT Reverse transcriptase
RTPCR Reverse transcription polymerase chain reaction
SHR Spontaneously hypertensive rat
SHRSP Spontaneously hypertensive stroke -  prone rat
SH3 SRC Homology 3
SOD Superoxide dismutase
SRA Subcutaneous resistance artery
STAT Signal transducers and activators of transcription
SV Saphenous vein
TBARS Thiobarbituric acid-reactive substances
VSMC Vascular smooth muscle cell
XOR Xanthine oxidoreductase
1 Introduction
Reactive oxygen species (ROS) are being increasingly recognised as pleiotropic 
chemicals which participate in multiple metabolic reactions. Cell growth and behaviour 
can be modulated by ROS, which have a variety of differing biological effects. 
Increased vascular ROS production can result in reduced bioavailable nitric oxide with 
pathophysiological effects such as impaired endothelium-dependent relaxation, which 
are features of disease states such as hypertension and coronary heart disease.
The purpose of this thesis is to investigate the enzymatic sources of and stimuli for ROS 
production in human vascular cells and blood vessels. In particular, the possibility that 
vasoactive hormones, such as angiotensin II (Ang II), might stimulate vascular ROS 
production will also be explored.
1.1 Reactive oxygen species: basic biochemistry
ROS are oxygen-containing chemicals, which may have a single unpaired electron. A 
free radical is defined as any chemical species capable of independent existence that 
contains one or more unpaired electrons (Halliwell and Gutteridge 1988). However, not 
all ROS are free radicals. For example, hydrogen peroxide and singlet oxygen are ROS, 
however neither of these chemicals have single unpaired electrons, and are therefore not 
free radicals.
Free radicals are formed by the loss or gain of a single electron. The characteristic 
properties of free radicals include:
A chemical species with a single unpaired electron
Chemically unstable and usually highly reactive
Low chemical specificity
Autocatalytic: diverse reaction products produced 
Generated in vitro and in vivo
In the ground state, molecular oxygen contains two unpaired electrons in parallel states
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of spin, which contrasts with other stable organic molecules which typically have paired 
electrons in anti-parallel spin states. Oxygen (O2) is therefore an electron acceptor. 
Together with its high midpoint redox potential (which leads to maximal energy 
conservation in redox reactions) and its solubility in aqueous solutions, oxygen is an 
ideal candidate for the transfer of electrons during oxidative phosphorylation (Figure 
1.1) (Bunn and Poyton 1996; Fridovich 2001).
Figure 1.1 Steps in the 4 electron reduction of molecular oxygen to water by 
mitochondrial oxidase enzymes.
The reduction of oxygen to water in the mitochondria is, however, frequently 
incomplete, resulting in the generation of reactive oxygen intermediates, such as '(V  
and the hydroxyl radical ( OH). ROS are, therefore, a heterogeneous group of reactive, 
intermediate chemical species. Other examples of chemicals which have similar in vivo 
activity include the reactive nitrogen species, such as nitric oxide ( NO) and the sulphur- 
derived thiyl radicals. Interestingly, NO is a very stable radical, and may exist as a free 
entity in vivo.
In vivo, ROS have important physiological effects. The reaction of NO with O2’ in vivo 
is a function of both the kinetics of this reaction and the relative tissue concentrations of 
these ROS. Ordinarily, endogenous SOD activity modulates O2" availability (Gupte et 
al 1999), such that concentrations of 02* are within the picomolar range, and reaction 
with NO is minimised (Figure 1.2).
Catalase/peroxidase
e + 2 H +  e - + H + H 20  e + H +
ONOO- 
(peroxy nitrite) 
SOD 
h2o 2 
(hydrogen peroxide)
Figure 1.2 Schematic diagram representing the inactivation of superoxide (O 2 ) by 
either nitric oxide ( NO) or superoxide dismutase (SOD).
If either NO or O2’ concentrations become elevated to within the nanomolar range then 
these two radicals may react to form peroxynitrite (Table 1.1) (Fridovich 2001; Wolin
2000).
Table 1.1 Oxidative reactions
Oxidative Reaction Enzyme Rate constant (M 'V 1)
O2 + electron —» O2" oxidase 00 X 0
O2 + O2 —> H2O2 + O2 SOD 2 x l 0 9
0 2'+  N O -^O N O O ' 7 x 10^
Superoxide may also be metabolised to secondary ROS. Superoxide is dismutated to 
hydrogen peroxide (H2O2), which in turn, forms the hydroxyl radical (OH) and 
hydrogen peroxide anion (OH‘) via the Fenton reaction:
NO
• 0 2‘ +
3
H2O2 + Fe2+ -» Fe3+ + OH + OH
The Fenton reaction may occur at biologically important rates. In the liver, micromolar 
concentrations of hydrogen peroxide and divalent iron may lead to the generation of 
4.58 x 1013 hydroxyl radical per second, roughly equivalent to 500 radicals per 
hepatocyte per second (Halliwell and Gutteridge 1988). Superoxide is readily converted 
into the hydroperoxyl radical ( HO2 ), which is a much more reactive oxidant (Fridovich
2001).
1.2 Methods of measurement of vascular superoxide 
concentrations
Given the pleiotropic biological effects of ROS, there has been considerable interest in 
the development of methods for their measurement. These include in vitro methods 
based on chemiluminescence, cytochrome C reduction, electron spin resonance and 
fluorescence. These methods differ widely in their specificity and sensitivity for 
individual ROS, their utility for laboratory and clinical research, including ease of use 
and cost.
1.2.1 Chemiluminescence
Chemiluminescence may be defined as the light emission which accompanies the 
generation of reaction products, such as ROS. There is therefore a background light 
emission by cells, and in particular by activated phagocytes, which is most likely due to 
the conversion of chemical energy present in ROS to photons of light, occurring on the 
metabolism of ROS to less active forms (Halliwell and Gutteridge 1988). This light 
emission may be enhanced by the addition of a luminophore, a compound which emits 
light under certain conditions of chemical excitation, thereby releasing energy resulting 
a return to ground state.
Luminophores, such as firefly luciferin, are naturally occurring compounds. Lucigenin, 
or bis-A-methylacridinum nitrate, and luminol, 5-amino-2,3-dihydro-1,4- 
phtalazinedione, are luminophores which have been used to measure as O2' and OH, 
respectively. Lucigenin was first described as a tool to measure as O2 ' by 
Gyllenhammar (1987), previously, as O2' was measured by the cytochrome C reduction 
method. Luminol is a non-specific luminophore as it reacts with a variety of different 
ROS (Halliwell and Gutteridge 1988). Alternatively, lucigenin, has been found to
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luminesce under conditions attributed to O2’ generation (Gyllenhammar 1987). For 
example, Gyllenhammar (1987) reported that in cell-free conditions, the lucigenin- 
enhanced chemiluminescence signal associated with the xanthine (20 pmol/L) -xanthine 
oxidase (0.03 U) reaction was completely inhibited by the addition of treatments to 
specifically remove O2'. This was done both by the addition of superoxide dismutase 
(SOD) which catalyses the dismutation of O2' to hydrogen peroxide (H2O2) and 
molecular oxygen (O2), and by the addition of 4,5-dihydroxy-l,3-benzene-disulphonic 
acid salt (Tiron) which scavenges O2’. Furthermore, the addition of catalase, an enzyme 
which converts H2O2 to H20  and O2 , had no effect on this signal, suggesting that neither 
H2O2 nor OH, an intermediate by-product of this reaction, do not contribute to 
xanthine/xanthine oxidase -  induced lucigenin-enhanced chemiluminescence.
Lucigenin reacts with superoxide to form a dioxetane intermediate which decays by a 
light emitting process (Spasojevic et al 1999; Spasojevic et al 2000; VasquezVivar et al 
1997). This can be represented by the following steps:
1) LC2+ + e' -> LC+ Formation of lucigenin radical by univalent reduction
2) LC+ + O2’ -» dioxetane Formation of dioxetane intermediate
3) Dioxetane decomposition into two molecules of TV-methylacridone, one of which is 
electrically excited.
4) Emission of a photon from the excited acridone state with return to ground state.
Lucigenin itself has been reported to generate O2' because of redox cycling at higher 
concentrations (Liochev and Fridovich 1997; Liochev and Fridovich 1998; Vasquez­
Vivar et al 2000; Skatchkov et al 1999; VasquezVivar et al 1997). The reason for this is 
the propensity for the LC+ radical to undergo auto-oxidation. Lucigenin may therefore 
be responsible for O2’ generation and this has been confirmed by in vitro cyclic 
voltametry studies in aqueous solutions (Spasojevic et al 2000).
As a result of these observations, other workers have undertaken studies to confirm
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whether or not lucigenin-enhanced chemiluminescence is a valid method for 
quantification of O2’ generation in biological systems (Li et al 1998a; Skatchkov et al
1999). In studies by Li et al (1998a) three methods were used to investigate the 
specificity of lucigenin-enhanced chemiluminescence for the detection of O2" 
generation and its relationship with lucigenin concentration. Their studies of O2" 
generation in cultured monocytes included sensitive measurement of lucigenin- 
enhanced chemiluminescence using a Berthold LB9505 luminometer, SOD-inhibitable 
ferricytochrome C reduction at 550 nm, O2 consumption by O2 polarography, and O2" 
production by 5-(diethoxyphosphoryl)-5-methyl-l-pyrroline-/V-oxide (DEPMPO) spin 
trapping. They demonstrated that low concentrations of lucigenin (i.e. <50 pmol/L) 
were associated with constant, reproducible measurements of O2" concentrations, 
however, lucigenin concentrations at, or above 50 pmol/L, were associated with 
incremental increases in signal, or O2' concentrations. This was also reflected by 
increments in O2 consumption and DEPMPO spin trapping. These data suggest that in 
an aqueous environment, lucigenin is itself reduced when present in higher 
concentrations, leading to an enhanced chemiluminescence signal. These effects can be 
explained by the ability of lucigenin to undergo redox cycling when present in 
sufficiently high concentrations. When the effect of addition of either xanthine/xanthine 
oxidase, at concentrations of 4pg/ml and 0.5 mmol/L, respectively, or lipoamide 
dehydrogenase NADH, at concentrations of 10 pg/ml and 0.5 mmol/L, respectively, to 
these cells was assessed, a lucigenin concentration-effect was observed only with the 
NADH system. The authors concluded that the availability of the lucigenin cation 
radical, and therefore the potential for redox cycling, was dependent on both the 
concentration of lucigenin and the experimental condition. Furthermore, the lucigenin 
concentration at which redox cycling does not occur should therefore be determined for 
any particular experimental condition.
1.2.2 Electron spin resonance spectroscopy
Electron spin resonance (ESR) spectroscopy is an electromagnetic technique which can 
be used to detect and quantify free radical activity (Halliwell and Gutteridge 1988). An 
unpaired electron has a spin of either +1/2 or -1/2, and therefore behaves as a small 
magnet. If it is exposed to an external magnetic field, the electron will align itself in 
opposition to that field, in either a parallel or anti-parallel alignment. If an appropriate 
electromagnetic field is applied, this energy will be absorbed by the free radical, causing 
a shift in the single electron’s energy state. This absorbance can be measured by an ESR
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spectrometer. In fact, the spectrometer actually measures the derivative of absorbance, 
that is the rate of change of absorbance:
AE = gp H
where A E is the difference in energy between the two energy levels of the electron, 7/is 
the applied magnetic field, p  a constant known as the Bohr magneton, and g is the 
‘splitting factor’ which for a free electron is a constant of 2.00232. Absorption spectra 
have typical patterns according to the chemical species that is being detected. These 
spectra are known as ‘hyperfine structures’.
ESR spectroscopy is a highly sensitive technique for the measurement of free radicals. 
It may be used to detect free radicals at concentrations as low as 1 x 10'10 mol/L. One 
limiting factor for the use of this method is that many free radicals are highly labile, and 
may not exist for long enough to be reliably measured by this technique. A variety of 
methods have been developed in order to overcome this problem, including flow 
systems, low-temperature solid matrix systems, and spin trapping. This latter approach 
causes the labile radical to react with a spin-trap compound to form a radical which has 
a longer half-life. An ideal ‘spin-trap’ is a compound which will react specifically with 
the radical of interest, to form another radical which is more stable, and has a 
characteristic ESR spectrum. DEMPO is a spin trap which reacts with both OH and O2 ' 
to form products with different ESR spectra. In this case, ethanol can be used to 
specifically quench OH radicals, therefore" eliminating this radical’s ESR spectra to 
leave that of O2". ESR spectroscopy may be used to measure 0 2 ’ concentrations in 
biological systems in a highly specific manner (Li et al 1998a).
The use of this technique, however, is limited by a number of factors (Halliwell and 
Gutteridge 1988). Cellular reducing agents, such as vitamin C, may reduce the spin-trap 
compound to give an ‘ESR-silent’ species. ESR spectroscopy is also very expensive 
because of the type of equipment and reagents that are required. Furthermore, this 
equipment may occupy a considerable area of laboratory space. Additionally, such 
experiments are also very time-consuming to perform.
1.2.3 Cytochrome C reduction
Superoxide production can also be assessed by the cytochrome C reduction method. In 
this case, the generation of O2' is measured indirectly by the reduction of
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ferricytochrome C at 550 nm. Non - O2’ dependent reduction of cytochrome C can be 
corrected for by deducting all activity not inhibited by the addition of SOD. However, 
the integrative nature of this method makes the study of dynamic response patterns 
difficult. In order to overcome this problem, chemiluminescence techniques, which have 
wider applicability and higher sensitivity, have received greater attention.
1.2.4 Oxidative fluorescent microtopography
Superoxide concentrations may also be measured in biological systems by fluorescent 
techniques. Fluorescent dyes, which are membrane permeable, can be used in 
conjunction with image analysis technology to measure both intra and extracellular 
ROS concentrations. Oxidative fluorescent microtopography is a technique which 
allows the in situ localisation of 02* in intact blood vessels (Carter et al 1994; Miller et 
al 1998). Hydroethidine (HEt) is a dye, which is oxidised in the presence of O2 ' to 
ethidium bromide (Et). The dye is topically applied to sections (approximately 50mm 
width) of blood vessels and the fluorescence can then be assessed microscopically after 
exciting at 585nm wavelength. The intensity and localisation of the oxidised HEt, which 
reflects 0 {  production, can then be observed. This method of analysis is affected by 
fluctuations in both temperature and pH, and the fluorescent signal decays with time. 
Quantification of ROS concentrations using fluorescent techniques is, therefore, only 
semi-quantative, however, these techniques can yield useful qualitative information on, 
for example, the location and distribution of ROS production in a blood vessel wall.
1.3 Sources of vascular superoxide production
Superoxide may be produced by a variety of enzyme reactions in vivo. In experimental 
animals, the main enzymatic sources of O2* production within the vascular wall are 
nicotinamide adenine dinucleotide phosphate (NAD(P)H) oxidase (Bouloumie et al 
1997; Mohazzabh et al 1994; Pagano et al 1995) xanthine oxidase (Mugge et al 1994 ; 
Ohara et al 1993), and nitric oxide synthase (NOS) enzyme (Holland et al 1990; Kerr et 
al 1999; McIntyre et al 1997). The cellular sources of vascular 0 2 ’ production in 
animals are the endothelium (Brandes et al 1997; Kerr et al 1999) (Mohazzabh et al 
1994), vascular smooth muscle cells (VSMC) (Miller et al 1998; Mohazzab and Wolin
1994) and fibroblasts within the adventitia (Wang et al 1999). The cellular and 
enzymatic sources of ROS production in human blood vessels have not been fully 
explored.
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1.3.1 NADP(H) Oxidase
NAD(P)H oxidase is ubiquitous throughout eukaryotic cells, but a plasma membrane- 
bound form has been demonstrated to be responsible for transmembrane electron 
transport (Morre and Brightman 1991). This enzyme catalyses the transfer of electrons 
from reduced pyridine nucleotides (NADH and NADPH) to molecular oxygen (O2), 
which results in the formation of O2". Other characteristic features of this enzyme 
include resistance to cyanide, which distinguishes it from mitochondrial oxidases, and 
activation by ligands, such as hormones (Morre and Brightman 1991). In teleological 
terms, phagocyte NAD(P)H oxidase is host-protective. The importance of vascular 
NAD(P)H oxidase in relation to cardiovascular physiology is not yet clear.
1.3.1.1 Physical chemistry of NAD(P)H oxidase
The enzyme was initially isolated from and studied in neutrophils. The enzyme is 
formed by the aggregation of a minimum of 5 proteins (Figure 1.3): a plasma membrane 
cytochrome b558 which is composed of a glycoprotein 91 kilodalton (Kd) phosphate 
oxidase (gp91phox) and a 22 Kd (p22) phox, two cytosolic proteins, p47phox and 
p67phox and a cytosolic G protein (either racl or rac2).
These four cytosolic proteins physically associate with the cytochrome to form the 
membrane-bound NAD(P)H oxidase (Babior 1999; Cross and Jones 1991). The protein- 
protein interactions are made possible by the presence of Src homology 3 (SH3) 
domains and polyproline motifs. These are small protein loci known to mediate 
interactions between proline-rich proteins (Fuchs et al 1996; Ren et al 1993) The 
mechanisms involved in the activation of NAD(P)H oxidase by metabolites of 
arachidonic acid were investigated by Sumimoto et al (1994). Both p47phox and 
p67phox contain SH3 domains (Leto et al 1990). In these studies, the mechanisms of 
assembly of the phox subunits were investigated by treating phagocytes with 
arachidonic acid (AA), in the presence and absence of a p47phox - SH3 domain fusion 
protein (anti-p47-SH3 antibody). Binding studies of p47 phox to either a monoclonal 
antibody directed to this protein or to p67phox, were also performed. These 
investigations demonstrated that p47phox SH3 fusion protein only bound to native 
p47phox in the presence of AA. In the absence of AA, p47phox SH3 fusion protein only 
bound to native phox if the phagocytes had been pre-treated with a p47phox binding 
protein tagged with SH3. Taken together, these observations suggest that treatment with 
AA induces a change in conformation of the p47phox protein, therefore exposing its
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SH3 domain (i.e. p47phox-SH3). Further studies demonstrated that p47phox only bound 
to p67phox in the presence of arachidonic acid. This suggests that arachidonic acid may 
have similar effects on p67phox.
Membrane
gp91 p22
p47NAD(P)H NADP
SH3
Cytoplasm
Figure 1.3 Vascular NAD(P)H oxidase, which is constituted by the aggregation of the 
cytoplasmic and membrane subunits. P47phox (phosphate oxidase) and p67phox, along 
with the small GTPase, rac-1, are cytoplasmic subunits. P40phox, another cytoplasmic 
subunit, facilitates the assembly of these proteins. Gp91phox and p22phox, which 
together form cytochrome b.^g, constitute the locus of electron transfer.
In other studies, p47-SH3 was demonstrated to bind to the cytoplasmic domain of 
p22phox (expressed as a fusion protein), this being prevented by a single amino acid 
substitution (Gin for P ro -156) in p22phox. This amino acid substitution occurs in some 
patients with chronic granulomatous disease who have an inactive membrane 
cytochrome b558 (Dinauer et al 1991), illustrating the importance of this interaction for 
phox assembly and NAD(P)H oxidase activation. By contrast, gp91phox does not have 
a binding site for p47-phox (Dinauer et al 1987).
In addition, a sixth protein, p40phox, may also physically associate with NAD(P)H 
oxidase (Wientjes et al 1993). P40phox is a cytosolic protein which is bound to 
p67phox and p47phox (Rinckel et al 1999). Phosphorylation of p40phox, which is
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subject to regulation by GTPases (Rinckel et al 1999), facilitates translocation of this 
protein, along with p47phox and p67phox, to the cell membrane, thus resulting in the 
formation of NAD(P)H oxidase. The formation of this enzyme occurs as a result of 
tyrosine kinase-mediated phosphorylation of its cytosolic protein subunits (Fuchs et al 
1997). Interestingly, topological studies by (Fuchs et al 1996) led to the hypothesis that 
p40phox may also serve to prevent spontaneous interaction of these subunits.
More recently, it has been established that approximately 90% structural homology 
exists between the cytochrome b558 subunits (gp91phox and p22phox) of rat neutrophil 
and endothelial cell NAD(P)H oxidases (Fukui et al 1995; Bayraktutan et al 2000). In 
rat endothelial cells, however, these subunits have a predominatly subcellular location 
being within the endoplasmic reticulum rather than in the plasma membrane, as is the 
case in neutrophils (Bayraktutan et al 2000). At a tissue level, however, differences in 
the distribution of gp91phox within the vascular wall have been demonstrated. This 
protein can be detected at the mRNA and protein level in endothelial and adventitial 
cells, but gp91phox is undetectable using these techniques in rat VSMC (Gorlach et al 
2000; Suh et al 1999). Alternatively, VSMC express a protein, noxl (for NAD(P)H 
oxidase - I ;  or non-phagocvtic oxidase) which has 56% homology with gp91phox. This 
homologous protein may also be coupled with p22phox to form the membrane 
cytochrome b558 subunit, and support electron transport, in these cells (Lassegue et al 
1999; Suh et al 1999). There are now several homologues (noxl, nox4 and gp91phox) 
described in the nox family (Lambeth et al 2000). These data pertain to studies 
undertaken in rat VSMC and the existence, and abundance, of nox family members in 
human vascular cell types is not known.
The activated form of plasma membrane NAD(P)H oxidase is responsible for the 
univalent reduction of O2 to 0 2’ (Cross and Jones 1991; Morre and Brightman 1991). 
Electron transport by NAD(P)H oxidase occurs on the membrane-bound cytochrome 
b558 complex, which transfers a single electron from NADH or NADPH to molecular 
02:
NAD(P)H + 2 0 2 NAD(P)+ + H+ + 2 0 2'
As the cytochrome b558 is a transmembrane protein, it may accept electrons from both 
intracellular and extracellular reducing equivalents. Superoxide production is maximal 
in conditions of both high oxygen tension and NAD(P)H concentration, such that 
oxygen consumption by this pathway will increase. The redox potential of this reaction
is low (Em = -245mV), such that this cytochrome has a greater propensity than any other 
cytochrome to reduce molecular oxygen to O2’ (Cross and Jones 1991). NAD(P)H 
reducing equivalents are generated by the pentose phosphate pathway. The extracellular 
release of electrons depolarises the cell membrane, which is counterbalanced by the 
concomitant release of H+ ions. This enzyme therefore generates superoxide in a low- 
output constitutive manner, in contrast to the high-output bursts of phagocytes.
1.3.1.2 Biochemistry of NAD(P)H oxidase
What is the role of membrane-bound NAD(P)H oxidase in the generation of O2" ? 
Studies of NAD(P)H oxidase activity have used a number of pharmacological 
antagonists to characterise the biological effects of this enzyme. For example, O2’ 
generation by endothelial cell NAD(P)H oxidase is inhibited by quinone analogs, such 
as Coenzyme Q, flavoprotein inhibitors, such as quinacrine and diphenyleneiodonium 
(DPI), and cytosolic subunit assembly inhibitors, such as apocynin (Holland et al 2000).
In neutrophils, 'O2" is released into the phagocytic vacuole where it has a bactericidal 
effect. In non-phagocytic cells, NAD(P)H oxidase serves as a disposal mechanism for 
intracellular electrons. Vascular NAD(P)H oxidase-dependent O2’ production may also 
have a protective role. This enzyme may also serve as an oxygen-sensor in the 
vasculature (Bunn and Poyton 1996; Goligorsky 2000). In this case, vascular tone and 
blood flow may be modulated by alteration in NAD(P)H oxidase-dependent 'O2’ 
production (and NO removal), according to variation in oxygen tension in both blood 
and the vessel wall. The concept of NAD(P)H oxidase as an oxygen sensor has attracted 
some controversy (Bunn and Poyton 1996). For example, the neuronal stimulus to 
ventilation during hypoxia occurs through an inhibition of (V-sensitive K+ channels in 
the cells of the carotid body where NAD(P)H oxidase is present in abundance (Bunn 
and Poyton 1996). During in vitro studies, inhibition of NAD(P)H oxidase by treatment 
of these cells with the flavin-dependent enzyme inhibitor, DPI, reduced the hypoxia- 
induced discharge of these cells, implicating this enzyme as an oxygen sensor (Cross 
and Jones 1991). One argument against this hypothesis include the fact that mice 
lacking the gp91phox subunit of NAD(P)H oxidase have both appropriate K+ channel 
inhibition and pulmonary artery vasoconstriction to hypoxia (Archer et al 2000). 
Furthermore, that patients with chronic granulomatous disease, an inherited disorder 
which results in the deletion of one of the protein subunits of NAD(P)H oxidase, are 
normoxaemic and have normal respiration (Bunn and Poyton 1996) also mitigates 
against NAD(P)H oxidase acting as an oxygen sensor.
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The phox subunits seem to play different roles in NAD(P)H oxidase activation. Cross et 
al (1999; 2000) studied the potential roles of the cytosolic proteins for NAD(P)H 
oxidase activity. They used the SOD-inhibitable cytochrome c reduction assay in order 
to measure O2" production by purified neutrophil membranes (i.e. containing 
cytochrome b558 (p22phox and gp91phox) and neutrophil cytosol in a cell-free system. 
The relative contribution of individual cytosolic protein subunits of NAD(P)H oxidase 
was assessed by the addition of recombinant phox proteins to the neutrophil 
membranes. Addition of either p47phox or p67phox proteins to the reaction mixture 
resulted in an increase in O2’ production, whereas this was not observed when p40phox 
recombinant protein was added. In this case, the addition of p40phox was associated 
with a very small rise in O2' production, but only in the presence of p47phox. Further 
experiments confirmed that p40phox promoted O2" production by p47phox. The 
phosphorylation and binding of p40phox may facilitate the conformational changes 
necessary for p47phox binding and activation of NAD(P)H oxidase. This thesis is 
supported by in vitro observations by Fuchs et al (1997) who demonstrated that in 
promyelocytes, p40phox was phosphorylated even in a resting state, and that on 
activation, additional phosphorylation of this protein occurred, which correlated with 
0 {  production by these cells. Furthermore, after O2" production by NAD(P)H oxidase 
had declined, p40phox was observed to be dephosphorylated.
The importance of membrane and cytosolic proteins for '(>2’ production by NAD(P)H 
oxidase has been investigated in a number of physiological studies of vascular 
phenotypes such as cell hypertrophy or NO-regulated myogenic tone in resistance 
arteries. Genetic manipulation, by either transfection of antisense p22phox DNA in rats 
(UshioFukai et al 1996), immunodepletion of p67phox in rabbits (Pagano et al 1997a), 
or knockout of gp91phox in mice (Gorlach et al 2000), have all demonstrated these 
subunits to be functionally important for both NAD(P)H oxidase and Ang II-dependent 
O2' production (UshioFukai et al 1996), (Pagano et al 1997a). It would appear, 
therefore, that these subunits are crucial elements for NAD(P)H oxidase-dependent 
ROS generation. The functional importance of these and other components of this 
enzyme, such as p47phox, rac 1 and noxl, in human blood vessels remain to be 
explored.
NAD(P)H oxidase is ligand-sensitive, such that O2" production by this enzyme may be 
affected by a variety of hormones, cytokines and lipid metabolites (Cross and Jones 
1991; DeKeulenaer et al 1998a). This enzyme is therefore activated by physiological 
and pathophysiological stimuli and, as such, O2* production may serve as a second
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messenger response. Furthermore, vascular NAD(P)H oxidase activity can be inhibited 
by treatment with glucocorticoids, the mechanism for this effect being a steroid-induced 
down-regulation of p22phox transcription (Marumo et al 1998). Disease states, such as 
endotoxaemia, have been associated with pro-oxidant induced vascular damage 
(Brandes et al 1999). This suggests that the therapeutic effect of treatments such as 
glucocorticoids may be in part mediated through inhibition of pro-oxidant enzymes.
1.3.2 Xanthine oxidase
1.3.2.1 Physical chemistry
Xanthine oxidoreductase (XOR) is a molybdenum-containing enzyme which may exist 
in one of two interconvertible forms, xanthine dehydrogenase (XDH) or xanthine 
oxidase (XO). XOR is primarily involved in purine catabolism, whereas XDH, which is 
the predominant form, preferentially reduces NAD+ and does not generate ROS 
(Harrison 2000). By contrast, XDH may be converted to XO by Ca2+ - calmodulin 
dependent proteolysis. This reaction also occurs in vivo in the context of ischaemia- 
reperfusion. In this case, XO catalyses the conversion of hypoxanthine to xanthine, 
resulting in the reduction of molecular oxygen to O2'. Moreover, Sanders et al. (Sanders 
et al 1997) recently demonstrated that XOR has NADH oxidase activity as it may 
oxidise NADH, leading to increased production of O2' (Figure 1.4).
Xanthine, and other purines
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Mo
NADH
FAD Fe/S
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NAD+ NADH
Mo - molybdenum; Fe/S - Iron/sulphur; FAD - Flavin adenine dinucleotide; NADH - 
Reduced nicotinamide adenine dinucleotide;02- oxygen; 0 2 - Superoxide;
H20 2- Hydrogen peroxide.
Figure 1.4 Schematic representation of electron transfer catalysed by XOR. This
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enzyme may use both NADH, xanthine and other purines as reducing substrates. 
Allopurinol, an inhibitor of XOR and uric acid production, inhibits O2’ generation at 
the molybdenum site, but does not prevent flavin-dependent O2" generation.
1.3.2.2 Biochemistry of xanthine oxidase
XOR protein is widely distributed in a variety of cell types. In humans, it is recognised 
to be abundant in mammary, hepatic, and intestinal epithelial cells. XOR protein is also 
present in cardiovascular tissues and has been identified in the heart (Abadeh et al 
1992) and in cultured vascular endothelial cells (Rouquette et al 1998). Using 
immunofluorescent techniques with confocal microscopy imaging, Adachi et al (1993) 
identified this protein both within the cytosol and on the external aspect of these cells. 
This suggests that these cells can synthesise XOR protein (Rouquette et al 1998). It is 
postulated that the XOR protein present on the external aspect of the cell surface may 
arise either as a result of secretion from the cytosol or by binding of circulating protein 
in the blood (Harrison 2000).
XOR enzyme activity in human plasma has been measured in healthy subjects 
(Yamamoto et al 1996), in hepatic (Ramboer and Piessins 1972) and rheumatic disease 
(Miesel and Zuber 1993), and in ischaemia-reperfusion (Friedl et al 1991; Tan et al
1995). This activity may be relevant to the pathophysiology of these diseases, given the 
potential of XOR for ROS generation. Interestingly, antibodies to XOR, rather than the 
protein itself, have also been measured in the blood of healthy human subjects 
(Benboubetra et al 1997). Benboubetra et al. (Benboubetra et al 1997) used an enzyme- 
linked immunosorbent assay (ELISA) to measure anti-human XOR antibodies in the 
sera of 258 subjects. They found that anti-human XOR IgM was 36.7±25.1 pg/mL and 
anti-human XOR IgG was 4.2±2.6 pg/mL representing 3% and 0.04% of total serum 
IgM and IgG respectively. Anti-human XOR antibody concentrations were significantly 
lower in women under the age of 50 years, however the reasons for this were not clear. 
Further studies demonstrated that XOR activity could be inhibited by treatment with 
anti-XOR antibody and that XOR in these sera samples was predominatly present in the 
form of immune complexes formed by association with these antibodies. The 
teleological function of circulating anti-XOR may be, therefore, to bind and neutralise 
XOR in the blood. This thesis is supported by the fact that the majority of blood XOR is 
bound to anti-XOR antibody, forming immune complexes, and that plasma activity of 
this enzyme is low (Yamamoto et al 1996).
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In other studies, plasma concentrations of anti-human XOR were found to be increased 
in patients with an acute myocardial infarction (Benboubetra et al 1990; Harrison et al 
1990). This may represent an adaptive response, however, the blood concentrations of 
XOR protein in cardiovascular and other disease states are not known. Moreover, it has 
been hypothesised, that the plasma activity of XOR may become biologically important 
in disease states where the plasma concentrations of this protein exceed those of the 
antibody binding proteins (Benboubetra et al 1990; Harrison et al 1990).
The XOR protein has been shown to bind to cell surface heparin-like 
glycosoaminoglycans. Studies by Adachi et al (1993) using cultured porcine aortic 
endothelial cells, column chromatography and antisera to human XOR, demonstrated 
that heparin may also bind XOR within a physiological pH range. The association 
between XOR protein and heparin could be inhibited by co-treatment with protamine, a 
heparin binding protein (Adachi et al 1993). In other studies by the same group, 
injection of intravenous heparin into healthy human subject was associated with a rapid 
increase in plasma concentrations of XOR.
That XOR is present within, and on the surface of, vascular cells suggests that ROS 
generated by this protein may be involved in cell signalling (Harrison 2000). XOR may 
also have an important role in the tissue damage which arises after ischaemia- 
reperfusion (McCord 1985). Adenosine triphosphate, which accumulates in ischaemia, 
undergoes anaerobic catabolism, which leads to the accumulation of hypoxanthine. In 
the hyperoxic conditions of reperfusion, XOR may then convert hypoxanthine to uric 
acid and O2'. This then may be one important pathway for excessive ROS production in 
ischaemic vasculature (McCord 1985).
By contrast, urate is an anti-oxidant. Urate suppresses ROS-induced vascular damage 
by, for example, reaction with peroxynitrite (a product of the reaction of NO with 0 2 ')- 
This generates a variety of metabolites, some of which are nitrovasodilators, and 
therefore prevents protein nitration by peroxynitrite (Reiter et al 2000). Urate is also an 
anti-oxidant in human plasma (Ames et al 1981)
The production of XOR is quantitatively most abundant in the liver and intestine 
(Harrison 2000). XOR is, however, implicated in ROS-induced injury within the 
cardiovascular system (de Jong et al 2000; Dowell et al 1993; Gimpel et al 1995; 
Harrison et al 1990; Hori et al 1991; Nielsen et al 1994; Weinbroum et al 1995; 
Yokoyama et al 1990). This then raises the question as to the origin of XOR in the
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cardiovascular system. Is XOR synthesised within cardiac and vascular tissues, where it 
may then be responsible for ROS generation, or alternatively, is XOR generated within 
hepatic and intestinal tissues, from which it may then be released into the circulation 
and bind to cardiovascular cells? Neilson et al (1996) investigated this question in a 
rabbit model of hepatic ischaemia and intestinal reperfusion. In this model, hepatic 
ischaemia was induced by occlusion of the supra-hepatic descending aorta for 40 
minutes by use of a balloon catheter, followed by a 2-hour period of reperfusion. 
Venous blood samples were obtained at baseline and during reperfusion in the 
intervention group. Plasma XOR activity increased during reperfusion compared with 
baseline (729 +/- 140 mu U/ml, mean +/- standard error of the mean vs. 132 +/- 18 mu 
U/mL; p < 0.001). This was associated with increased plasma concentrations of hepatic 
enzymes such as aspartate aminotransferase, alanine transferase, and lactate 
dehydrogenase. In further studies undertaken to control for any possible effect of the 
surgical procedure (but without causing hepatic ischaemia), suprarenal-inffahepatic 
occlusion had no effect on plasma concentrations of alanine transferase.
In further studies, these investigators explored the possibility that increased release of 
hepatic and intestinal XOR could be associated with distant lung injury (Nielsen et al 
1994). Pretreatment with tungstate, an inhibitor of XOR, reduced XOR activity and 
ameliorated liver and intestinal injury. Lung injury, manifested by increased 
bronchoalveolar lavage (BAL) protein concentration, BAL lactate dehydrogenase 
(LDH) activity and increased lung oedema, was associated with liver injury and 
circulating XOR activity. XOR inactivation significantly decreased BAL protein 
concentration, BAL LDH activity, and lung oedema. This suggests that remote lung 
injury may be modulated by hepatic injury leading to an increased production of 
circulating XOR.
Recently, XOR gene expression was compared between mice and humans (Xu et al
2000), in order to determine the basis for the low XOR activity in humans relative to 
non-primate mammalian species. The expression of XOR in human hepatocytes and 
vascular cells was found to be markedly lower than those of mice. Studies of both 
transcription rates and core promoter activity of this gene in the human cells 
demonstrated that the human XOR gene contains both repressor and activator binding 
regions which regulate core promoter activity, which may explain the low expression of 
this protein in human cells.
The pathways leading to XOR protein synthesis within human vascular cells and tissues
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are poorly understood. Data on the presence or absence, and possible functional 
importance of XOR protein in human blood vessels, are lacking. As yet, the 
concentrations of XOR in the blood of healthy humans and patients with cardiovascular 
disease are unknown. The putative role of XOR in the pathophysiology of 
cardiovascular disease makes investigation of these questions important.
1.3.3 Nitric oxide synthase
Nitric oxide exists as three distinct redox forms, nitroxyl anion (NO'), the nitrosonium 
cation (NO+), and the nitric oxide free radical ( NO) (Nelli et al 2000). Although, NO' is 
a potent relaxant of vascular and non vascular smooth muscle, it appears to do so 
indirectly, through conversion by copper-containing enzymes to NO (Nelli et al 2000). 
Although nitric oxide synthase (NOS) is a major source of NO, paradoxically, this 
enzyme may also generate the NO -  scavenger, O2'. Neuronal (Xia et al 1996), 
inducible and endothelial NOS (Xia et al 1998) are all capable of O2 ' production. NOS 
will switch to generate 0 2 ' rather than NO in conditions where L-arginine and/or 
tetrahydrobiopterin, both of which are essential for NO synthesis, are deficient (Heinzel 
et al 1992; Pou et al 1992). As is the case for NO synthesis, O2' production by NOS is 
a function of intracellular free Ca2+-dependent regulation of calmodulin kinase (Xia et 
al 1998). The versatility of ROS production by NOS is implicated in a number of 
vascular disease states, such as hypercholesterolaemia and heart failure, whereby a 
functional deficiency of L-arginine has been reported (Hirooka et al 1994; Stroes et al 
1997). This suggests, therefore, that NOS may itself be dysfunctional and contribute to 
the pathophysiology of vascular damage.
1.4 Endogenous systems for superoxide removal
Superoxide may also be removed by endogenous scavenging enzymes, such as SOD 
(McCord and Fridovich 1969), catalase, peroxidase and by low molecular weight anti­
oxidants such as vitamins C & E.
1.4.1 Endogenous enzymatic scavenging systems
SOD catalyses the dismutation of two 0 {  radicals to one molecule of H2O2 and one 
molecule of molecular O2 :
2 ’O2 + 2H+ —> H2O2 + O2
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Three mammalian SOD proteins exist (Figure 1.5); copper/zinc SOD (Cu/Zn SOD) 
(McCord and Fridovich 1969), manganese SOD (Mn SOD), these being the intracellular 
isoenzymes, and extracellular SOD (EC-SOD) (Marklund 1982). These proteins are 
coded by three different genes.
Sod2 (11 kb)
Sod1 (11 kb)
Chrom 6q25
Chrom 21q22.1
NF-kB
Chrom 4
I II
Sod3 (5.9kb)
NF-kB - Nuclear factor kappa B; SOD - superoxide dismutase; kb - kilobase 
Chrom - chromosome; SOD1- Cu/Zn SOD; SOD2 - MnSOD; SOD3 - EC-SOD
Figure 1.5 The chromosomes which contain the genes for the three isoforms of 
superoxide dismutase (SOD) protein: copper/zinc SOD (Cu/Zn SOD), manganese SOD 
(Mn SOD), these being the intracellular isoenzymes, and extracellular SOD (EC-SOD) 
proteins.
Mn-SOD and Cu/Zn SOD are located within the mitochondria and cytosol respectively, 
and are major vascular isoenzymes which are important for both scavenging vascular 
O2" and enhancing the bioavailability of endothelial NO (Li et al 1995). EC-SOD has a 
high molecular weight (135,000), is composed of four non-covalently bound subunits 
each containing a copper atom. It is hydrophobic, and binds readily with proteoglycans, 
such as heparin (Sandstrom et al 1992), which suggests an. affinity of this isoenzyme 
for cell membranes (Marklund 1982). The rate constant of the EC-SOD / O2’ 
dismutation reaction was originally determined to be 1 x 10'9 Mol/s (Marklund 1982). 
EC-SOD and cytosolic, or Cu-Zn, SOD are inhibited by diethyldithiocarbamate 
(DETCA), a copper chelating agent (Heikkila et al 1976; Mian and Martin 1995), which 
may be used in pharmacological studies to inhibit SOD activity.
Catalases are haem-containing enzymes which convert H2O2 to O2 and water.
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Peroxidases are again mostly haem-containing enzymes which utilise a variety of 
reducing substrates, such as NADH, to convert H202to water (Fridovich 2001).
1.4.2 Endogenous non-enzymatic scavenging systems
Glutathione, or GSH, has a sulphydryl group, which enables it to scavenge hydroxyl 
and singlet oxygen radicals (Halliwell and Gutteridge 1988). Glutathione is abundant 
within cells, and is therefore an important intracellular anti-oxidant
2 GSH + oxidant <-» GSSG + reduced oxidant
An excess of GSSG, and consequently an imbalance in the GSH/GSSG ratio, occurs in 
situations of excess ROS activity. This is associated with abnormal cell metabolism, 
such as impaired protein synthesis (Halliwell and Gutteridge 1988). Excess activity of 
enzymes which metabolise glutathione, such as glutathione peroxidase (which oxidises 
glutathione), are therefore important in determining intra-cellular anti-oxidant activities 
(Mugge et al 1991a). In addition, thiyl radicals are formed when glutathione scavenges 
hydroxyl radicals, or when glutathione is oxidised by peroxidases. Thiyl radicals are, 
however, less reactive than hydroxyl radicals.
Uric acid is one other endogenously produced anti-oxidant. Uric acid is the end-product 
of purine metabolism and is present in human extracellular fluids, such as plasma, at 
concentrations of 0.25 -  0.4 mmol/L. Humans, unlike some other species, do not have 
urate oxidase, which appears to have been ‘lost’ during our evolutionary development. 
Consequently, urate is excreted in the urine. The abundance of uric acid in the human 
body may be advantageous, as it is a powerful scavenger of hydroxyl and peroxyl 
radicals, and singlet oxygen. Like GSH, however, the by-products of these reactions are 
themselves, weak radicals. Uric acid has important extracellular anti-oxidant activity, 
and in particular, inhibits lipid peroxidation by binding iron and copper ions into forms 
incapable of generating free radicals.
In vivo, ascorbic acid (vitamin C) and alpha-tocopherol (vitamin E) have ROS 
scavenging activities (Halliwell and Gutteridge 1988). Ascorbic acid is a water-soluble, 
reducing agent. It is present in human plasma at concentrations of 50 -  200 pmol/L and 
has a second order reaction rate with O2" of 2.7 x 105 M'V1 at a physiological pH of 
7.4. Dehydroascorbate is produced as a result of this reaction, which ultimately breaks 
down to form oxalic and threonic acids. Vitamin C is an important scavenger of ROS,
2 0
such as O2" and OH, in vivo. This activity is concentration dependent. Furthermore, 
vitamin C is oxidised in the presence of transition metals, such as Fe3+ and Cu2+, 
forming H2O2 and OH as by-products of these reactions. Vitamin C is ubiquitous 
throughout the human body and, for example, this vitamin has important anti-oxidant 
activity in the eye. It is present in high concentrations in the lens, cornea and aqueous 
humour of day-living mammals ( 1 - 2  mmol/L), whereas in nocturnal animals, such as 
cats and rodents, vitamin C is much less abundant. Vitamin C is also an important anti­
oxidant in cardiovascular tissues. Low plasma concentrations of vitamin C, and 
therefore inadequate endogenous anti-oxidant activity, have been reported to predict an 
increased risk of cardiovascular morbidity (Vita et al 1998).
By contrast, vitamin E is lipid soluble and reacts very slowly with O2 ' in aqupous 
solutions. Nevertheless, vitamin E, which is present in various blood lipoproteins, does 
have important in vivo anti-oxidant activity by preventing lipid peroxidation. Other 
important endogenous anti-oxidants include certain extracellular proteins (Halliwell and 
Gutteridge 1988). These include albumin, and the acute phase proteins, such as 
caeruloplasmin and haptoglobin. By contrast, although haemoglobin has high affinity 
for NO and 0 2\  this protein may also be a source of ROS in vivo. The haem product of 
this oxidation reaction, methaemoglobin, is unable to bind O2'. Methaemoglobin 
represents approximately 3% of total haemoglobin in red blood cells. The O2' produced 
during this reaction must be removed by endogenous scavenging systems in these cells, 
such as Cu/Zn SOD, catalase and glutathione.
Haem -  Fe2+ - O2 -> O2' + haem -  Fe3+
SOD ^
H2O2 O2* H2O
Catalase
or
Glutathione
1.5 Physiological effects of ROS activity
1.5.1 Regulation of vascular tone and blood flow: the regulation o f 
bioavailable nitric oxide by superoxide and other ROS
Blood vessel tone is regulated by a variety of humoral and endothelium-derived relaxant
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factors [Figure 1.6] (Mombouli and Vanhoutte 1995), the most important of which is ' 
NO (Moncada and Higgs 1993). NO is generated by three isoforms of the NOS. NO 
rapidly decomposes in vivo, having a half life of approximately 1-6 seconds 
(Brovkovych et al 1999). NO is metabolised by either interaction with other ROS, such 
as 0 {  (Gryglewski et al 1986), or through catalysis by transition metals to nitrite and 
nitrate (Vallance and Collier 1994). A major physiological effect of NO is its 
interaction with the haem moiety of soluble guanylate cyclase leading to the activation 
of this enzyme, an increase in cyclic GMP, and a reduction in intracellular calcium 
concentrations. This in turn leads to relaxation of vascular smooth muscle cells (VSMC) 
(Waldman and Murad 1988).
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Vallance et al (1989) investigated the role of NO in the regulation of blood flow in 
healthy humans in vivo., using strain-gauge plethysmography. This is a technique which 
can be used to measure forearm blood flow using a mercury-filled, silastic strain-gauge 
placed on the widest part of the forearm, and connected to a plethysmograph calibrated 
to measure percent change in volume (Greenfield et al 1963; Hokanson et al 1975). For 
each measurement, a cuff is placed on the upper forearm and inflated to a supravenous 
pressure (e.g. 40 mmHg) to occlude venous outflow, and a wrist cuff is inflated to 
supra-systolic pressures to exclude hand circulation. Serial measurements of arterial 
flow can be taken and averaged during any one measurement period, and expressed as 
mL per minute per 100 ml of forearm volume. The brachial artery (non-dominant arm) 
can be cannulated for the purposes of pharmacological studies. One advantage of local 
infusion of vasoactive compounds is that they do not attain concentrations within the 
systemic circulation to cause any important effect.
Studies by Vallance et al (1989) of forearm blood flow in healthy subjects demonstrated 
that intrabrachial artery infusion of an inhibitor of NOS, N° monomethyl-L-arginine (L- 
NMMA), was associated with a reduction in basal and agonist (ACh)-augmented blood 
flow. This inhibition could be reversed by co-infusion of L-arginine. These observations 
demonstrated that NO is continuously synthesised from arginine in human blood 
vessels in vivo, where it has an important role in the regulation of basal and agonist- 
stimulated blood flow (Vallance et al 1989).
The inactivation of endothelium-derived relaxant factor (EDRF), subsequently 
determined to be NO (Palmer et al 1987), by ROS is a key factor in the regulation of 
vascular tone (Vallance and Collier 1994). Gryglewski et al (1986) developed an in 
vitro model which allowed for the differentiation between the effects of different 
substances on the release, action and stability of EDRF. In these studies, a 
chromatographic column of microbeads coated in 7-14 day-old cultured porcine aortic 
endothelial cells was perfused with physiological buffer solution maintained at 37°C. 
This buffer contained indomethacin to inhibit the production of prostaglandins in these 
cells. The column effluent was then used to superfuse three strips of dendothelialised, 
rabbit thoracic aorta. There was a predetermined temporal delay of 1 -  3s between 
perfusion of the column and the vascular strips. In this study, superfusion of 
nitroglycerin (20 -  200 nM), an endothelium-independent nitrovasodilator, and 
bradykinin (20 nM), was shown to relax all of the aortic strips (Gryglewski et al 1986), 
whereas co-infusion haemoglobin (a scavenger of EDRF/NO) attenuated these 
relaxations. Reduction in effluent O2 ' concentrations, by superfusion of the column with
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SOD (5 -  30 U/ml), induced vasorelaxation. Furthermore, co-infusion of bradykinin 
with SOD markedly enhanced the vasorelaxant response previously observed with 
bradykinin, whereas, by contrast, co-infusion of bradykinin with catalase had no 
additional vasorelaxant effect. These data were the first to support the concept that O2’ 
destroys EDRF/NO in intact blood vessels.
1.5.1.1 Endogenous regulation of vascular superoxide concentrations 
and NO bioavailability: role of superoxide dismutase
Omar et al (1991) subsequently investigated the possibility that vasodilator responses 
might be regulated by the activity of endogenous SOD. Isometric tension studies of 
endothelium-dependent and -independent nitrovasodilator responses were performed in 
calf coronary arteries preconstricted to potassium. They found that both ACh- and 
nitroglycerin-dependent, but not endothelium-derived prostaglandin-mediated, 
vasorelaxation was abolished by inhibition of SOD through pretreatment of these 
arteries with 10 mmol/L of DETCA. This effect was abolished when the arteries in bath 
were exposed to severe hypoxia (p02 =10 mmHg) or co-treatment with 300 nmol/L of 
SOD. In other studies, endothelial and smooth muscle cells were cultured from these 
blood vessels and O2' concentrations in these cells were determined using lucigenin- 
enhanced chemiluminescence. Treatment of both cell types with DETCA resulted in 
increased O2' concentrations in both cell types, this being inhibited by co-treatment 
with SOD. Taken together, these observations indicate that agonist-dependent 
regulation of vascular tone may be influenced by the activity of endogenous SOD, 
which modulates bioavailable concentrations of O2’ and NO. In addition, Omar et a l
(1991) demonstrated that nitrovasodilator responses were inhibited by DETCA, which 
suggests that guanylate cyclase may be directly inhibited by O2*. These investigators 
also demonstrated that vascular smooth muscle cell guanylate cyclase activity is 
regulated by O2".
The role of endogenous SOD in the regulation of bioavailable NO was also investigated 
by Mian and Martin (Mian and Martin 1995). In isometric tension studies in rat aortae, 
pre-treatment of aortic rings with SOD (1 -  300 u/ml) induced a concentration- 
dependent relaxation of phenylephrine (PE)-induced increase in vascular tone, which 
was inhibited by co-treatment with NG-nitro-L-arginine (l-NOARG, 30pM), an inhibitor 
of NOS. By contrast, SOD had no such effect in dendothelialised rings. In subsequent 
studies, pre-treatment of aortic rings with 0.1 mmol/L of DETCA (a lower 
concentration than in those other studies described above (Omar et al 1991)) augmented
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PE-induced, but inhibited L-NMMA-induced, tone. By contrast, this concentration of 
DETCA only slightly attenuated ACh-induced vasorelaxation. These effects were 
reversed by treatment with exogenous SOD (10 -  300 U/ml). These observations 
suggest that tonic production of endothelium-derived NO is protected from destruction 
by O2’ as a result of the activity of endogenous Cu/Zn SOD. Alternatively, the lack of 
effect of DETCA on agonist-induced vasorelaxation suggests that endogenous Cu/Zn 
SOD has a bimodal O2' scavenging action, predominately limited to protecting basal 
NO synthesis.
1.5.2 Studies o f SOD activity in human blood vessels
SOD protein content and activity has been quantified in human blood vessels obtained 
at autopsy, and compared with those of various other mammals. Using 
spectrophotometric and chromatographic techniques, Stralin et al (1995) demonstrated 
that EC-SOD was most abundant in human aortae and left anterior descending coronary 
artery (LAD) and less so saphenous veins (SV). By contrast, although CuZnSOD was 
most abundant in aortae, this isoform was more abundant in SV than in LAD. 
Furthermore, the amount and activity of these SODs was greater in human aortae than 
in cow, pig, dog, cat, rabbit, rat or mouse aortae. Immunostaining studies of EC-SOD in 
human blood vessels and vascular cells demonstrated this enzyme to be present 
throughout the blood vessel walls and evident in cultured VSMC and fibroblasts. This 
study my be criticised on the basis that human tissue was obtained up to 48 hours after 
the individuals died, and the causes of death were not detailed. Furthermore, Western 
blotting, which is the most accurate method of protein quantification, was not used. 
Nevertheless, these observations do suggest that SOD is abundant and functional within 
human blood vessels, and more so compared with lower mammals.
Isometric tension studies in human conduit blood vessels performed in our laboratory, 
using the response to treatment with SOD as an indirect assessment of O2’ production, 
demonstrated that increased O2' production may contribute to impaired endothelium 
dependent vasorelaxation (Hamilton et al 1997).
1.5.2.1 NO metabolism: bioactivity of peroxynitrite
On the other hand, diffusible NO may be inactivated by O2' (Rubanyi and Vanhoutte 
1986a) to form peroxynitrite (Beckman 1993), which occurs readily and has a rate 
constant of 1010 mmol/L/s_1(Fridovich 2001; Reiter et al 2000). This reaction is the
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major path for NO metabolism at physiological pH (Reiter et al 2000), and it therefore 
out-competes that of SOD for O2’, which has a rate constant of 2 xlO9 M“V  
(Koppenol 1998). Dismutation of O2’ will therefore occur in situations where O2', 
achieves micromolar concentrations, such as in ischaemia reperfusion (Vinten-Johansen
2000). Rate limiting steps for the formation of peroxynitrite include the diffusion rates 
of NO and O2', and the availability of molecular oxygen. Cw-peroxynitrite is 
preferentially formed from NO and 0 2 ', which is most likely due to the greater stability 
of the N -0 bond in the cis conformation of this molecule (Reiter et al 2000).
Peroxynitrite is a highly reactive, and damaging intermediate. It has an important 
regulatory effect on vascular smooth muscle cell contractility and blood vessel tone 
(Rubanyi and Vanhoutte 1986b). It also has mild oxidative properties (Radi et al 1991), 
and is both negatively inotropic and a vasodilator (Ku et al 1992). Peroxynitrite may 
also oxidise lipoproteins, and oxidised lipoproteins can in turn inhibit endothelial Gj- 
protein and function (Liao 1994). Peroxyntrite readily oxidises tyrosine, to form 
nitrotyrosine (Reiter et al 2000), which can be measured in blood and tissues (Vinten- 
Johansen 2000). Spectrophotometric studies undertaken by Beckman’s group using a 
stop-flow closed gas tonometer system, which allows for injection of reagents with 
consecutive spectrophotometric measurements, determined that peroxynitrite formed at 
a physiological pH causes tyrosine, and therefore protein, nitration (Reiter et al 2000). 
Chronic production of peroxynitrite can lead to the subsequent nitration of vascular 
proteins, such as Mn-SOD (MacMillanCrow et al 1996), which may contribute to the 
development of atherosclerosis (White et al 1994).
Peroxynitrite may have other harmful effects. Recent studies in isolated, working rat 
hearts treated with interleukin-1 p, interferon-y, and tumour necrosis factor-a, or vehicle, 
demonstrated that these cytokines caused marked impairment of myocardial contractile 
function, compared with controls (Ferdinandy et al 2000). This was associated with 
enhanced myocardial activity of XOR and NAD(P)H oxidase, and increased myocardial 
concentrations of O2'. Furthermore, the perfusate obtained from these hearts had higher 
concentrations of nitrotyrosine and dinitrotyrosine, which are metabolites of 
peroxynitrite. The production of these metabolites was associated with the development 
of myocardial dysfunction. All of these effects were attenuated by treatment with the 
NOS inhibitor, N° -nitro-L-arginine, the O2’. scavenger, Tiron, or a catalyst of 
peroxynitrite decomposition, 5,10,15,20-tetrakis-[4-sulfonatophenyl]-porphyrinato- 
iron[III]. These observations suggest peroxynitrite has myodepressant properties, 
possibly arising through protein nitration. This may be of pathophysiological relevance
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in situations of cytokine activation, such as heart failure.
Peroxynitrite may also be metabolised to other reactive oxidative intermediates, such as 
the hydroxyl radical ( OH), which may also affect vascular tone. This radical has, for 
example, been demonstrated to induce activation of soluble guanylate cyclase in VSMC 
(Mittal and Murad 1977).
1.5.3 ROS-mediated regulation o f vascular cell growth and 
hypertrophy
In vitro studies have demonstrated that both 0 {  and hydrogen peroxide affect VSMC 
growth. Rao and Berk (1992) showed that in VSMC exposed to ROS generated by the 
xanthine/xanthine oxidase reaction there was an increase in DNA synthesis, which 
could be attenuated by the addition of either catalase, which removes hydrogen 
peroxide, or SOD, which scavenges O2". These effects were mediated through an 
increase in protein kinase C-dependent proto-oncogene expression. Similar studies have 
also demonstrated that this effect is concentration dependent, such that hydroxyl 
radicals may also induce apoptosis (Li et al 1997a). These in vitro data suggest that 
these growth-regulating activities may operate in vivo.
1.5.4 ROS activity in host defence mechanisms
ROS are generated by and participate in a variety of biological reactions in vivo. 
Phagocytes generate 0 2 ’, as part of the ‘respiratory burst’ reaction, originally described 
by Balridge and Gerrard (1933). The bactericidal activity of quiescent neutrophils and 
macrophages is activated on exposure to pathogens. This results in the rapid 
consumption of NAD(P)H reducing equivalents, by non-mitochondrial NAD(P)H 
oxidase, and a burst of O2’ production. Abnormalities in the structure and composition 
of the NAD(P)H oxidase protein complex result in deficiencies of cell killing, a feature 
of chronic granulomatous disease (Segal and Jones 1978). This raises the possibility 
that, in teleological terms, constitutive ROS production by vascular cells may have a 
cell-protective effect.
ROS activity is also implicated in a variety of other pathophysiological processes, such 
as neurodegenerative diseases, and aging (Warner 1994).
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1.6 Pathophysiological effects of increased vascular ROS 
activity
Excess ROS activity, also known as ‘oxidative stress’, is associated with a variety of 
pathophysiological processes. Vascular smooth muscle cell proliferation and 
hypertrophy, processes known to be important in atherosclerosis, may be promoted by 
increased O2’ activity (Miller et al 1998). Other processes which are redox-sensitive 
and are believed to be important for the development of atherosclerotic plaques include 
activation of matrix metalloproteinases (Rajagopalan et al 1996a), mitogen-activated 
kinases (Baas and Berk 1995; Clerk et al 1998), and vascular cell adhesion molecules 
(VCAM) (Marui et al 1993). Excess ROS activity may also promote increased rates of 
vascular cell apoptosis, which may have deleterious effects in vascular remodelling 
(McMurray et al 1990).
1.6.1 ROS as intracellular signalling messengers
ROS are involved in modulating a variety of intracellular signalling pathways for 
vascular cell growth regulation (Irani 2000). For example, Frank et al. (Frank et al 
2000a) recently demonstrated in VSMC that the activity of PYK2, an intracellular 
tyrosine kinase, is redox sensitive, suggesting that ROS regulate tyrosine kinase- 
induced trophic effects.
ROS may also serve as second-messengers for ATi receptor activation. Activation of 
these pathways is an integral link between ATi receptor activation and nuclear 
transcriptional changes leading to cell growth (Marrero et al 1997). However, the 
mechanism whereby activation of the G-protein coupled ATi receptor might lead to 
activation of tyrosine kinases, such as JAK2, is not clear. Although JAK2 may bind 
with the ATi receptor, this physical association does not directly lead to JAK2 
activation (Ali et al 1998). Alternatively, Simon et al (1998) demonstrated that JAK2 
activation is dependent on the activity of ROS. These observations raise the possibility 
that ROS may act as intermediates between distinct signalling pathways. The janus 
kinase (JAK) and signal transducers and activators of transcription (STAT) signalling 
pathway activates early growth response genes, and may be a mechanism whereby Ang 
II influences vascular and cardiac growth, remodelling and repair (Berk and Corson 
1997; Hefti et al 1997).
For this reason, Schieffer et al (2000) recently investigated the possibility that ROS
2 9
may act as signalling messengers for ATi receptor activation of JAK and STAT factors 
in rat aortic VSMC. Treatment of these cells with 10 pmol/L of Ang II stimulated an 
increase in the concentrations of both O2’ and the cytokine, interleukin 6 (IL-6). Both of 
these effects were abolished by co-treatment with either 10 pmol/L of the ATi receptor 
antagonist, losartan, or DPI (maximal inhibition attained at a concentration of 100 
pmol/L), or by inhibition of p47phox by electroporation of p47phox antibodies into 
these cells. Similarly, treatment of these cells with Ang II led to JAK2, STAT 1 a/p  and 
STAT3 tyrosine phosphorylation, which could also be inhibited by treatment with 
losartan, DPI or electroporation of p47phox antibodies. In other studies, these 
investigators demonstrated that treatment of rat VSMC with either 10 pmol/L of 
AG940, a selective antagonist of JAK2, or STAT 1 a/p  antisera, prevented Ang II- 
induced synthesis of IL-6. These studies demonstrated that in rat VSMC, Ang II- 
induced, NADP(H) oxidase dependent O2" production may be important for activation 
of the JAK/STAT cascade. This may, in turn, lead to an increase in production of the 
cytokine IL-6.
In other studies in rat VSMC, Viedt et al (2000) reported that ATi receptor-induced 
ROS production stimulated JNK and p38 MAP kinase, but not ERK1/2, leading to an 
increase in AP-1 binding DNA. Inhibition of p22phox activity by treatment with either 
a specific antibody or antisense DNA abolished ATi receptor-induced JNK and p38 
MAP kinase activation, and reduced AP-1 DNA binding. In this study, treatment with 
Ang II -  induced ERK1/2 activation by a tyrosine kinase, PKC- and MEK-dependent 
pathway. Taken together, these findings demonstrate that ROS are critical signalling 
factors for apparently uncoupled signalling cascades, such as the G-protein coupled ATi 
receptor and soluble tyrosine kinases, such as JAK2 or MAPK. Interestingly, the 
involvement of ROS in non-receptor kinase activation (Rao 1996), raised the possibility 
that ROS may mediate ATi receptor-induced epidermal growth factor receptor (EGFR) 
activation (Eguchi and Inagami 2000a).
This possibility has recently been explored by Ushio-Fukai et a l (Ushio-Fukai et al
2001). In these studies, pretreatment of VSMC with anti-oxidants prevented Ang II- 
induced tyrosine phosphorylation of the EGFR, but not EGF-induced phosphorylation 
of its own receptor. Alternatively, direct treatment of these cells with hydrogen 
peroxide, and the superoxide generating compound LY83583, in the absence of any 
other ligand, was associated with a concentration-dependent increase in EGFR 
phosphorylation. These observations suggest that ROS may induce EGFR
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phosphorylation through activation of an upstream intermediary, rather than activation 
of EGFR-kinase. In this case, redox-sensitive candidates include Ca2+ (Suzuki and Ford 
1999), PYK2 (Frank et al 2000b) and c-Src (Eguchi and Inagami 2000b; Griendling et 
al 2000). Further studies by Ushio-Fukai et al. (2001) in VSMC demonstrated that 
EGFR transactivation could be prevented by inhibition of either tyrosine kinases, or c- 
Src kinases, or by Ca chelation, but not by Jak2 kinase or PI3K inhibtion. In addition, 
transfection of these cells with an adenovirus containing DNA for a kinase-inactive 
form of c-Src lead to inhibition of the activity of c-Src compared to inactive (Ad.LacZ) 
control transfected cells. These data suggest that c-Src is an upstream effector for Ang 
II-induced EGFR transactivation by tyrosine phosphorylation.
The activity of nuclear factor kappa B (NFkB) is also regulated by ROS (Barnes and 
Karin 1997), suggesting the possibility that ATi receptor-induced ROS production 
(Rajagopalan et al 1996b) may lead to activation of NFkB. This thesis has been recently 
investigated by Pueyo et al (2000), who demonstrated that ATi receptor-induced 
activation of NFkB, which was associated with enhanced VCAM-1 expression, is a 
redox sensitive pathway. In these studies, NFkB activation was associated with the 
breakdown of cytoplasmic IkB proteins, this being inhibited by treatment with either the 
non-specific anti-oxidant, pyrrolidinedithiocarbamate, or rotenone, which is an inhibitor 
of mitochondrial respiration. By contrast, treatment with SOD failed to attenuate Ang 
II-induced IkB degradation. The mechanism of ROS-induced IkB degradation is not 
known. Taken together these findings suggest that ATi receptor activation stimulates 
mitochondrial ROS production, which in turn may trigger IkB degradation, NFkB 
activation and endothelial cell recruitment of monocytes. This is one process whereby 
ATi receptor activation could contribute to vascular inflammation and atherosclerosis.
1.7 ROS in vascular disease states: mechanisms of production 
and functional importance
ROS have been implicated in the pathogenesis of a variety of disease states, and may be 
particularly important in the pathophysiology of cardiovascular disease. Increased 
vascular O2' production can lead to reduced bioavailable nitric oxide and impaired 
endothelium-dependent relaxation (Grunfeld et al 1995; Nakazono et al 1991; Rubanyi 
and Vanhoutte 1986b) which can be evident in disease states such as hypertension 
(Nakazono et al 1991), hypercholesterolaemia (Creager et al 1990), atherosclerosis 
(Cox et al 1989), diabetes (Calver et al 1992a), and heart failure (Kubo et al 1991). In
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this section, the role of ROS in a variety of vascular disease states will be discussed.
1.7.1 Renin angiotensin aldosterone system activation and vascular 
superoxide production
Some of the vasoactive effects of hormones, such as Ang II, are similar to those of 
ROS. For example, treatment of vascular smooth muscle cells with Ang II will result in 
hypertrophy and hyperplasia of these cells (Berk et al 1989; Haller et al 1996). 
Furthermore, chronic treatment of experimental animals with Ang II results in not only 
hypertension, but also vascular hypertrophy and endothelial dysfunction in these 
animals (Griendling et al 1997). These overlapping physiological effects raise the 
possibility of a functional interaction between Ang II and ROS production.
This hypothesis was initially explored by Wilson (1990), who observed that chronic 
treatment of rats with Ang II resulted in hypertension and vascular hypertrophy, which 
was associated with increased vascular ROS production. The possibility that Ang II 
might directly stimulate ROS production was explored by Griendling et a l (1994). In 
these studies, treatment of cultured rat VSMC resulted in increased O2' production, 
which could, in turn, be prevented by co-treatment with an inhibitor of NAD(P)H 
oxidase. Further studies identified this enzyme to be bound to the plasma membrane of 
these cells (Griendling et al 1994).
In rats chronically infused with pressor and non-pressor doses of Ang II, increased 
vascular NAD(P)H oxidase 0 2 ’ production contributed to both the impaired 
endothelium-dependent vasorelaxation and hypertension evident in these animals 
(Rajagopalan et al 1996b). Importantly, these effects were abolished by co-treatment 
with an Ang type 1 receptor antagonist (ARA), implicating this receptor in Ang II- 
stimulated superoxide production. In a similar study, the hypertensive effects of Ang II 
were attenuated by co-infusion with liposomal SOD (Laursen et al 1997).
Further studies by Zafari et al (2000) from Griendling’s group demonstrated that the 
Ang II-stimulated activation of NAD(P)H oxidase occurred through release of 
arachidonic acid metabolites, which triggered protein kinase C activation. This in turn 
led to phosphorylation of the phox subunits and activation of NAD(P)H oxidase. 
Further work by Ushio-Fukai et al (1996) in the same group demonstrated that 
transfection of anti-sense p22phox cDNA into rat cultured VSMC abrogated the Ang II- 
stimulated increases in O2' concentrations, hypertrophy of these cells or subsequent
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H2O2 production. These observations implicated p22phox subunit as a key element in 
NAD(P)H oxidase-dependent O2' production and H2O2 as a mediator of the trophic 
effects of Ang II. Furthermore, work in cultured rat VSMC treated with the SOD 
inhibitor, DETCA, demonstrated that O2' conversion to H2O2 was also important for 
Ang II-stimulated VSMC hypertrophy (Zafari et al 1998). Similar observations were 
made in studies of VSMC which stably over-expressed catalase, an enzyme which 
catalyses the breakdown of H2O2 to water (Zafari et al 1998). These studies clearly 
demonstrated a novel, functionally important relationship between vasoactive hormones 
and ROS generation, and raise the possibility that renin-aldosterone-angiotensin system 
(RAAS) activation evident in human vascular disease states may result in enhanced 
ROS activities.
Interestingly, Ang II-stimulated ROS generation may not be endothelium dependent. In 
studies performed by Rajagopalan et al (1996b), denudation of the endothelium from 
the aortic rings of Ang Il-infused rats failed to prevent the rise in O2’ production 
stimulated by treatment with this hormone. That is to say, Ang II-stimulated O2’ 
production may occur within the smooth muscle and/or adventitial layers. This thesis is 
supported by comparable findings from studies by Miller et al. (1998) in a rabbit model 
of atherosclerosis.
Recently, Lang et a l (2000) demonstrated an association between increased circulating 
plasma Ang II concentrations and enhanced NAD(H) oxidase activity in a guinea pig 
model of left ventricular hypertrophy. These findings suggest that in disease states 
where chronic activation of the renin angiotensin aldosterone system (RAAS) is 
evident, increased plasma and tissue concentrations of Ang II may contribute to the 
increased ROS activity that has been observed in chronic heart failure and coronary 
heart disease (McMurray et al 1990).
Pagano et a l (1997a; 1998) explored the potential importance of adventitial O2’ 
production in the modulation of vascular tone (Pagano et al 1997b; Wang et al 1999; 
Wang et al 1998). This group identified adventitial fibroblast NAD(P)H oxidase to be 
an important source of O2" in both rabbit and rat aortae. Studies of particulate fractions 
of rabbit aortae demonstrated that immunodepletion of p67phox markedly reduced 
NAD(P)H oxidase activity, this being restored by the addition of recombinant p67phox 
(Pagano et al 1997a). These studies demonstrated that p67phox has an obligate role for 
electron transport in this enzyme. Furthermore, incubation of Ang II-treated aortae with 
actinomycin D, an inhibitor of transcription, and cycloheximide, an inhibitor of protein 
synthesis, both attenuated Ang II-stimulated O2' production (Wang et al 1999). These 
data suggest that Ang II augments NAD(P)H oxidase-mediated O2* production by
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enhancing the abundance of messenger ribonucleic acid (mRNA), through an increased 
rate of transcription. This in turn may lead to increased amounts of the protein and 
enhanced capacity of the enzyme for O2* production (Pagano et al 1998).
These investigators also demonstrated using rat aortae under isometric tension that 
adventitial O2" production, by inactivating NO and therefore modulating vascular tone, 
is functionally important source of ROS generation (Wang et al 1998). Furthermore, the 
angiotensin type 1 receptor antagonist (ARA), losartan, inhibited Ang II-stimulated 
superoxide production in rat thoracic aortae, however, losartan had no such effect in 
rabbits (Pagano et al 1997a; Wang et al 1999). That Ang II-stimulated 0 2 ' production in 
rabbits could be inhibited by the non-specific (non-ATi non AT2 receptor) receptor 
antagonist, [sar1,Thr8]-Ang II suggests that important species differences may exist in 
this pathway. These observations raise the question as to whether or not Ang II might 
stimulate O2 ' production in human blood vessels. This question remains to be answered 
and is therefore the subject of the present investigation.
7.7.2 ROS activation in hypertension
1.7.2.1 Studies in experimental animals
In a model of genetic hypertension, the stroke prone spontaneously hypertensive rat 
(SHRSP), investigations in our laboratory, demonstrated that markedly decreased NO 
bioavailability is due to an excess production of O2 ' within the endothelium, compared 
with normotensive control animals (Grunfeld et al 1995; McIntyre et al 1997; Kerr et al 
1999).
Zalba et al (2000) recently demonstrated in the SHR, that increased O2 ' production in 
homogenates of aorta is associated with an increased abundance of p22phox mRNA, as 
determined by reverse transcription polymerase chain reaction (RTPCR) techniques. 
Furthermore, the observed activation of NAD(P)H oxidase and impaired endothelium- 
dependent responses in the aortae of these animals were normalised by treatment with 
the ARA, irbesartan. As discussed above, Rajagopalan et al (1996b) demonstrated the 
functional importance of increased vascular O2’ production in an Ang II-induced model 
of hypertension.
These observations were recently supported in studies by Brovkovych et al. (1999) in 
which a porphyrinic microsensor was used to quantify NO production in endothelium 
obtained from spontaneously hypertensive (SHR) and Wistar-Kyoto (WKY) control
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rats. This electrochemical method was originally developed by Malinski and Taha
(1992) for the direct electrochemical detection of NO either in vitro or in vivo. The 
microsensor is 2-3 pm in diameter and 5-7 pm in length and selectively detects NO on 
the basis of current generated by the oxidation of NO. The sensor can be positioned up 
to 10 pm from a single cell and the specificity of the signal can be confirmed by 
inhibition of NOS on treatment with L-Af-monomethyl-L-arginine (L-NMMA). Using 
these techniques, Brovkovych et al (1999) found that after treatment with calcium 
ionophore to stimulate NOS, NO concentrations were higher for WKY than SHR (910 
± 40 and 580 ± 35 nmol/L, respectively; n=6, p<0.005). In the presence of 100 U/mL of 
polyethylene glycol-SOD (PEG-SOD), NO concentrations in the endothelium of WKY 
rats increased by 8% however, an increase of 83% was observed for NO concentrations 
in the endothelium of SHR rats. This observation supports the concept that vascular, or 
endothelial, cell 0 2 ' production is greater in hypertensive rats, compared with 
normotensive controls, leading to a reduction in bioavailable NO in the SHR/SHRSP.
1.7.2.2 Studies in humans
In humans, in vivo strain gauge plethysmography studies demonstrated that the NO - 
dependent forearm vasodilator response to intrabrachial arterial infusion of 
acetylcholine (ACh) was impaired in 18 hypertensive patients compared to controls 
(Panza et al 1990). In this particular study, the maximal forearm blood flow response to 
infusion of ACh was 9.1 ±5 ml/min in hypertensive patients compared to 20.0±8 ml/min 
in the controls (P<0.0002). This difference was not due to decreased sensitivity of 
guanylate cyclase to NO, because the vasodilator response to the exogenous NO donor, 
sodium nitroprusside, was preserved. These observations suggest that in hypertensive 
subjects there is an abnormality in endothelium-dependent vasorelaxation. These 
findings were supported by observations in other studies by Calver et al (1992b), who 
demonstrated that the forearm vasoconstrictor response to L-NMMA infusion was 
reduced in untreated hypertensive patients compared to controls, suggesting a reduction 
in basal NO bioavailability in hypertension. These observations raise the possibility that 
reduced NO bioavailability in the blood vessels of hypertensive patients may be due to 
increased removal of NO, as a result of enhanced ROS generation in essential 
hypertension.
The reasons for enhanced vascular ROS activity in human hypertension may be due to 
genetic abnormalities causing altered expression of the enzymes responsible for ROS 
production or removal (see section 1.7). This possibility is supported by recent
observations which suggested a heritable basis for the impaired endothelium-dependent 
vasodilation which may be present in the offspring of hypertensive parents (Zizek et al
2001). These authors studied flow-mediated brachial artery dilatation in both 
hypertensive and normotensive individuals (normotensive offspring of hypertensives 
and normotensive controls), and found it to be impaired in both the patients and in their 
normotensive offspring, compared to controls. The reasons for this are not entirely 
clear. Although the blood pressure of the hypertensive offspring was within the normal 
range, it was significantly higher than that of controls. These observations suggest a 
close relationship between blood pressure and endothelial dysfunction, and raise the 
question as to whether there may be a genetic basis, or heritable risk, for endothelial 
dysfunction in hypertension.
The possibility that the presence of hypertension per se, might directly result in 
abnormal endothelial function was investigated in studies by Paniagua et al (2000). 
They isolated human subcutaneous resistance arteries (SRA) from gluteal fat biopsies, 
and then cannulated and perfused these arteries at 37°C in a pressure-flow organ bath. 
SRA diameter was measured directly from amplified digital images. Endothelium -  
dependent and -independent vasodilator responses were assessed by treatment of SRA 
with ACh (10‘9 to 10-4 mol/L) and sodium nitroprusside (10'9 to 10"4 mol/L) after 
exposure of SRA to incremental vascular pressures of 50, 80, and 120 mmHg for 1 
hour. The dilator response of SRA to ACh was attenuated by exposure to higher 
intravascular pressures (mean vasodilation, 62%, 49%, and 26% at 50, 80, and 120 
mmHg, respectively), whereas the responses to SNP were not affected. These 
observations suggest that exposure to increased intravascular pressures, such as occurs 
in hypertension, may directly lead to endothelial dysfunction.
One mechanism underlying hypertension-induced endothelial dysfunction may relate to 
pulsatile stretch of vascular cells. Studies by Howard et al (1997) in porcine aortic 
endothelial cells (PAEC) and VSMC demonstrated that cyclic, or pulsatile, stretch of 
cells grown on elastic membranes resulted in an increased production of lipid peroxides, 
which could be further enhanced by treatment with NADH/NADPH. These 
observations suggest that the activity of NAD(P)H oxidase is upregulated by 
mechanical stimuli, such as pulsatile stretch. This may be one further pathway 
underlying enhanced vascular ROS production in hypertension.
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1.7.3 Diabetes
Diabetes is one other vascular disease in which oxidative stress is recognised (Maxwell 
et al 1997; Opara et al 1999). Hattori et al (1991) observed that ACh -dependent 
vasorelaxation was impaired in aortic segments obtained from streptozotocin-induced 
diabetic rats, compared to normal controls. This impairment was improved by pre­
treatment of these blood vessels with SOD (60 U/ml), but not catalase (600 U/ml) or 
allopurinol (10 mmol/L). By contrast, vasorelaxation responses to the endothelium -  
independent vasodilator, sodium nitroprusside, were similar in the two groups. These 
observations suggest that impaired endothelium-dependent vasorelaxation in these 
diabetic animals may be due to increased vascular O2' concentrations, as a result of 
either increased ROS generation or reduced removal, leading to in turn, a reduction in 
bioavailable NO. The lack of effect of either catalase or allopurinol suggests that 
neither H2O2 or xanthine oxidase contribute to the impaired endothelium-dependent 
responses in these animals.
Impaired endothelium-dependent vasorelaxation may also be present in diabetic patients 
(Calver et al 1992a). In fact, hyperglycaemia directly induces ROS production in 
vascular cells and anti-oxidant treatment of these cells prevents the protein glycation 
that occurs on their exposure to high glucose concentrations (Giardino et al 1996; 
Nishikawa et al 2000). Nishikawa et al (2000) recently demonstrated in bovine aortic 
endothelial cells that the deleterious effects of hyperglycaemia, namely protein kinase C 
activation, protein glycation and increased glucose flux, were attenuated by normalising 
mitochondrial ROS concentrations through inhibition of mitochondrial electron 
transport. Experimental studies in human cultured aortic endothelial cells have also 
demonstrated that exposure to high glucose concentrations stimulates increased vascular 
O2’ production by eNOS (Cosentino et al 1997). Furthermore, in experimental rats, 
hyperinsulinaemia has been demonstrated to directly increase vascular O2’ production 
(Kashiwagi et al 1999).
1.7.4 Hypercholesterolaemia
Increased vascular O2 ' production also contributes to endothelial dysfunction in 
hypercholesterolaemic rabbits (Mugge et al 1994; Ohara et al 1993). This appears to be 
due, in part, to increased removal of NO by O2' (Mugge et al 1994). Furthermore, 
treatment of these rabbits with PEG-SOD for 1 week, therefore reducing vascular O2' 
concentrations, was associated with an improvement in endothelium-dependent
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vasodilator responses in these animals (Mugge et al 1991b). Hypercholesterolaemia in 
humans is associated with abnormal vascular function, even in the absence of end-organ 
damage, such as, for example, atherosclerosis. Creager et al (1990) used strain-gauge 
plethysmography techniques to study forearm blood flow in 13 young, 
hypercholesterolaemic patients (age range 24 -  45) and 11 healthy controls (age range 
22 -  43). Basal forearm blood flow was comparable between the two groups. They also 
found, however, that the vasodilator responses to infusion of either methacholine, an 
endothelium-dependent vasodilator, or sodium nitroprusside, an endothelium- 
independent vasodilator, were impaired, compared to controls. These observations 
suggest that abnormalities in both endothelial and vascular smooth muscle cell function 
may be present in hypercholesterolaemia, predating the development of atherosclerosis. 
One possible reason for this may be due to increased vascular ROS production in 
hypercholesterolaemia (Mugge et al 1994; Ohara et al 1993).
Stokes et al (2001) recently characterised the importance of NAD(P)H oxidase- 
dependent ROS production as a pro-inflammatory pathway in an animal model of 
hypercholesterolaemia. In these studies, mice transgenic for either p47phox 
(heterozygous p47phox +/- or homozygous p47phox -/-) or CuZn-SOD (SOD TgN) 
were placed on either a normal diet (ND) or high cholesterol diet (HCD) for 2 weeks. 
The microvascular damage associated with hypercholesterolaemia involves leucocyte- 
endothelial cell adhesion (Scalia et al 1998), which are processes known to be redox 
sensitive (Marui et al 1993). Stokes et a l (2001) studied the effects of 
hypercholesterolaemia in these transgenic mice using intravital microscopy of 
cremasteric muscle postcapillary venules. Venular leucocyte adherence and emigration 
were quantified by videoimaging. They demonstrated that wild-type, SOD non-TgN and 
SOD TgN HCD mice had 2-3-fold higher serum cholesterol concentrations than ND 
mice. This was associated with more than doubling of the number of adherent 
leucocytes in the postcapillary venules of both WT and SOD non-TgN HCD groups, 
compared with the ND mice. By contrast, TgN mice that overexpressed CuZn-SOD 
exhibited a significantly reduced number of adherent and emigrated leukocytes when 
placed on the HCD diet, compared to the wild type and non-TgN mice. In order to 
investigate the role of NAD(P)H oxidase in hypercholesterolaemia-induced leucocyte 
adherence and emigration, mice heterozygous and homozygous for p47phox were 
placed on HCD or ND. The HCD-induced increases in leucocyte adherence and 
emigration in WT and heterozygous TgN p47phox mice did not occur in p47phox -/- 
mice. Interestingly, mean cholesterol concentrations were higher in the p47phox TgN 
mice than in WT. The observations that enhanced 0 {  scavenging, as occurred in the
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SOD TgN mice, and inhibition of NAD(P)H oxidase-dependent O2 ' generation, as 
occurred in the p47phox homozygous TgN mice, prevented the microvascular 
inflammatory changes associated with hypercholesterolaemia, suggests that NAD(P)H 
oxidase-dependent O2’ generation is involved in mediating hypercholesterolaemic 
vasculopathy and atherosclerosis.
1.7.5 Atherosclerosis
Individuals with hypertension and high plasma concentrations of cholesterol and 
glucose are at risk of developing atherosclerosis. In pathological terms, atherosclerosis 
is a focal abnormality which occurs at a site of high shear stress in a large conduit or 
elastic artery. An atherosclerotic plaque is characterised by an accumulation of 
macrophages and T lymphocytes and extracellular matrix tissue, hyperplasia of intimal 
smooth muscle cells and neovascularisation (Alexander 1995). The pathogenesis of 
atherosclerosis involves accumulation and modification of lipids within the blood vessel 
wall (Steinberg et al 1989), induction of pro-inflammatory genes such as vascular cell 
adhesion molecule (VCAM) (Marui et al 1993), increased cellular proliferation (Gong 
et al 1996), alteration in VSMC phenotype (Rao and Berk 1992) and impaired 
endothelial function (Mugge et al 1991b; Ohara et al 1995; White et al 1994). All of 
these processes may be promoted by an increase in ROS activity (Alexander 1995). For 
example, low-density lipoprotein (LDL) is not readily sequestered by macrophages. 
After exposure to endothelial cells, however, LDL becomes oxidised (oLDL), and in 
this form, is recognised by the macrophage scavenger LDL receptor. Macrophages can, 
therefore, readily sequester oLDL, which results in their transformation into lipid-laden 
‘foam cells’, which are a pathological feature in atherosclerosis (Alexander 1995). Lipid 
peroxidation by-products, such as lisophosphatidylcholine, are amphipahthic 
compounds that directly impair G-protein dependent signal transduction, leading to 
impaired endothelium-dependent vasorelaxation (Flavahan 1992).
1.7.5.1 Studies of atherosclerosis and ROS activity in animal models
Studies in animal models of atherosclerosis demonstrated that activation of the RAAS 
may be one important mechanism leading to increased ROS activity, atherosclerosis and 
vascular damage (Wamholtz et al 1999). These investigators used an animal model of 
atherosclerosis, in which healthy rabbits were fed either a high cholesterol diet or 
normal diet in the presence or absence of concomitant treatment with either an ARA or 
a calcium channel blocker. The latter treatment served as a positive anti-hypertensive
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control. Vascular O2" production, as measured by lucigenin-enhanced 
chemiluminescence, was greater in hypercholesterolaemic rabbits compared to controls. 
This difference was abolished by either de-endothelialisation of the aortic segments 
from hypercholesterolaemic rabbits, or treatment of these segments with an inhibitor of 
NAD(P)H oxidase, DPI. In isometric tension studies, ACh-induced relaxation in 
vascular rings pre-constricted to PE was attenuated in hypercholesterolaemic animals, 
compared to controls. This difference was not evident in high cholesterol animals 
treated with the ARA. Endothelium-dependent vasodilation was not modified by 
calcium channel blockade in cholesterol-fed animals. Receptor binding studies 
demonstrated that aortic membrane ATi receptor density was greater in high cholesterol 
animals compared to controls. In addition, histological analysis of atherosclerotic 
plaques in arteries from cholesterol fed animals demonstrated a reduction in lipid 
content and macrophage infiltration in animals treated with an ARA, compared to those 
that were not. These findings suggest that hypercholesterolaemia is associated with 
increased vascular O2" production, endothelium-dependent dysfunction and 
atherosclerosis. The mechanism underlying this appears to be cholesterol-induced ATi 
receptor-dependent, NAD(P)H oxidase activation, principally occurring within the 
vascular endothelium.
One other mechanism which may also contribute to enhanced vascular O2' production 
in atherosclerotic arteries is the presence of shear stresses, which are known to be potent 
stimuli for vascular O2’ production (DeKeulenaer et al 1998b; Howard et al 1997). In 
vitro studies in cultured HAEC and VSMC plated in a closed loop flow system 
demonstrated that alteration in physiological levels of laminar shear stress (0.6 to 15 
dyne/cm2) increased rates of gene transcription and protein synthesis of CuZn SOD in 
HAEC, compared to control cells (Inoue et al 1996). This was not the case, however, in 
VSMC, which suggests that in some circumstances, certain vascular cells may have 
inadequate anti-oxidant scavenging properties.
The effect of SOD deficiency on lipid peroxidation has been investigated using a rat 
model of dietary copper restriction (Lynch et al 1997). Male weanling Sprague-Dawley 
rats were fed a diet deficient in copper and zinc and received either copper replacement 
in their drinking water, or copper-deficient drinking water. They were then sacrificed 
after 5 weeks. Isometric tension studies in aortic segments obtained from these animals 
demonstrated comparable contractile responses to potassium and PE, but deficient 
relaxation responses to ACh. This was associated with a 68% reduction in vascular 
CuZnSOD activity and a 58% increase in vascular O2' concentrations in the copper
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deficient animals compared to controls. In addition, the plasma concentrations of 
esterified F2-isoprostanes, which are stable products of arachidonic acid autoxidation 
(Morrow et al 1990), were also measured. Plasma F2-isoprostane concentrations in 
control animals and copper-deficient animals were 263 ± 40 pg/mL and 665 ± 1 56  
pg/mL (p<0.05 vs control), respectively. This study may have benefited from additional 
investigations to assess whether or not treatment with exogenous SOD might have 
prevented these abnormalities in copper-deficient rats. Nevertheless, it does provide 
information on how a functional deficiency in SOD, leading to an excess activity of 
ROS, may lead to lipid peroxidation, which is a critical process in atherosclerosis.
Studies by Fukai et al (1998) have suggested, paradoxically, that vascular SOD protein 
content and activity may be increased in atherosclerosis. In this study, vascular tissues 
obtained from either apo E-deficient mice, a model of atherosclerosis, or controls, were 
homogenised. EC-SOD protein quantification studies were undertaken by western 
analysis and SOD activity was determined by monitoring the inhibition of the rate of 
XOR-mediated reduction of cytochrome c. These investigators found that although total 
aortic SOD activity was similar between apo E-deficient mice and controls, specific 
assays of EC-SOD activity revealed greater activity of this enzyme in the aortae of apo 
E-deficient mice. Western analysis demonstrated a three-fold increase in the amount of 
this isoenzyme in the aortae of apo E-deficient mice, compared to controls. 
Immunodetection studies demonstrated EC-SOD to be most abundant in intimal 
macrophages in the aortae of apo E-deficient mice, which was in contrast to control 
aortae, in which macrophage EC-SOD staining was absent. The observation that 
vascular EC-SOD may be increased in atherosclerosis suggests a compensatory, 
adaptive process. In this case, the principal oxidants generated from these macrophages 
would be H2O2 and OH. These products are more stable than 0 2\  and as H20 2 is 
uncharged, may penetrate more readily into cells. Importantly, however, total vascular 
SOD activity was similar between the apo E-deficient mouse and controls, suggesting 
that a deficiency in ROS scavenging is not a primary phenomenon, at least in this model 
of atherosclerosis.
1.7.5.2 Studies of atherosclerosis and ROS activity in human blood 
vessels
Atherosclerosis results in impaired endothelium-dependent vasodilator responses in 
human arteries. In vivo studies of coronary artery vasomotor responses by Ludmer et al 
(1986) demonstrated that in segments narrowed by the presence of atherosclerosis,
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intra-coronary infusion of ACh resulted in vasconstriction, whereas normal segments 
dilated in response to ACh. In other studies by this group, coronary artery flow- 
mediated dilatation in response to intra-coronary infusion of adenosine, a direct smooth 
muscle vasodilator, was less in segments affected by atherosclerosis, compared to non­
affected segments (Cox et al 1989). By contrast, the dilator response to infusion of 
nitroglycerin was comparable between the diseased and normal segments. This suggests 
that rather than a generalised impairment of dilator function, a selective abnormality in 
endothelial function was present in atherosclerotic arteries. Further studies by this group 
demonstrated that selective endothelial dysfunction may also be evident at bifurcation 
points, compared to straight sections, in atherosclerosis-free coronary arteries 
(McLenachan et al 1990). This observation raised the question of whether endothelial 
dysfunction may pre-date the development of atherosclerosis, which is prone to occur at 
the branch points of these arteries.
Huraux et al (1999) first quantified O2' concentrations in human IMA and investigated 
the relationships between IMA O2' concentrations, endothelial function and risk factors 
for atherosclerosis. Superoxide concentrations were quantified by lucigenin-enhanced 
chemiluminescence and endothelial function was assessed by isometric tension studies 
in IMA preconstricted with the thromboxane A2 analogue, U46619, followed by
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cumulative concentration response curves (CRCs) with ACh (10' to 10' mol/L). In 
parallel studies, endothelial-independent relaxation was assessed using CRCs with 
nitroglycerin (10'10 to 10'6 mol/L). Immunohistochemical analyses of IMA from 26 
patients demonstrated that that the endothelium of these blood vessels was uniformly 
intact and free of atherosclerosis. Huraux et al (1999) found that vascular O2 ' 
concentrations ranged from 669 to 12,309 counts per minute per mg tissue (mean 4589 
± 554 Counts/min/mg) and endothelium-dependent relaxation to ACh were highly 
variable, with values ranging from 0% to 89%. Step-wise multivariate analysis was 
reported to reveal that O2’ concentrations were related to hypercholesterolaemia, 
although the numeric data were not actually reported in the paper. Overall, however, the 
variability observed in vascular O2’ concentrations and vasorelaxation responses could 
not be explained qualitatively or quantitatively by either risk factors or drug therapy 
(Huraux et al 1999).
Activation of the RAAS may also be important for the development of atherosclerosis 
in human arteries. Immunohistochemical studies in normal and atherosclerotic human 
coronary arteries have demonstrated increased immunoreactivity of angiotensin 
converting enzyme (ACE) in diseased arteries (Diet et al 1996). In normal arteries, ACE
was only evident in luminal and adventitial vasa vasorum endothelium, whereas in 
arteries affected by atherosclerosis, ACE immunoreactivity was also evident in 
macrophages (foam cells) and T-lymphocytes. In arteries in which the atherosclerosis 
was more diffuse, ACE immunoreactivity was also more abundant and immunoreactive 
Ang II was also evident. This raises the question as to whether ACE inhibition might be 
associated with anti-atherosclerotic effects. This question was recently investigated in a 
randomised, placebo-controlled clinical trial of the angiotensin convertin enzyme 
inhibitor (ACE-I), quinapril (Mancini et al 1996). In TREND (Trial on Reversing 
ENdothelial Dysfunction) 105 patients with atherosclerotic coronary artery disease were 
randomised to 40mg of quinapril per day (n=51), or placebo (n=54), for 6 months. 
Coronary endothelial function was assessed by measurement of the change in coronary 
artery diameter consequent to infusion of ACh using quantitative coronary angiography, 
both at baseline and after 6 months. The constrictive responses to ACh were comparable 
in both groups at baseline. After 6 months, only the quinapril group showed any 
improvement in response to incremental concentrations of acetylcholine (4.5+/-3.0% 
[mean+/-SEM] versus -0.1+/-2.8% at 10'6 mol/L and 12.1+/-3.0% versus -0.8+/-2.9% at 
10*4 mol/L, quinapril versus placebo, respectively; overall P=0.002). These observations 
suggest that inhibition of the RAAS can improve endothelium-dependent vasomotor 
responses in the coronary arteries of patients with coronary atherosclerosis. The 
mechanisms for this effect may include enhanced bioavailable NO through, for 
example, anti-oxidant effects, and potentiation of bradykinin (Wamholtz et al 1999).
SOD activity may also be abnormal in the coronary arteries of patients with coronary 
atherosclerotic disease. Landmesser et al (2000) studied endothelium-derived EC-SOD 
isoenzyme activity, stimulated by bolus injection of heparin, both in ex vivo 
atherosclerotic coronary arteries obtained from 10 deceased patients and 10 control 
subjects, and in vivo in cubital venous blood from 35 other patients with CHD and 15 
age-matched controls. Flow-mediated, or endothelium-dependent, radial artery dilator 
responses were also measured in these, patients by high-resolution ultrasound. In vivo 
studies were performed after intravenous, systemic infusion of either vehicle, L-NMMA 
(7 pmol/min), vitamin C (25 mg/min), or both.
In the ex vivo studies of vascular EC-SOD activity, infusion of a single bolus of heparin 
(5000 U or 1000 U) resulted in enhanced EC-SOD activity in the coronary arteries in 
non-atherosclerotic rings, compared to diseased rings (control subjects: 126 ± 14; CHD: 
63 ±11 U/mg of protein; p<0.01). Cubital venous blood EC-SOD activity was reduced
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in patients with atherosclerotic CAD compared to healthy controls (control subjects: 
14.5 ± 1.1; CHD: 3.8 ± 1.1 U/mL/min; p<0.01). Furthermore, the activity of EC-SOD 
in cubital venous blood correlated positively with flow-dependent vasodilation (r=0.5; 
p<0.01) and negatively (r=0.6; p<0.01) with the effect of vitamin C on flow-dependent 
vasodilation in radial arteries in these patients. In other words, enhanced endothelium- 
dependent flow-responses were associated with greater EC-SOD activity. Furthermore, 
the ROS-scavenging effect of vitamin C was greater in patients with less EC-SOD 
activity. Limitations of this study include the fact that a bolus injection of heparin will 
only stimulate the release of a fraction of total vascular EC-SOD. Nevertheless, these 
observations suggest that vascular EC-SOD activity may be reduced in patients with 
CHD and this may be related to enhanced ROS activity and abnormal endothelium- 
dependent blood flow responses in these patients.
1.7.6 ROS and coronary artery vein graft stenosis
Coronary artery bypass graft surgery is performed on symptomatic and prognostic 
grounds in patients with flow-limiting coronary atherosclerosis (Fisher 1983). At 
present, optimal long-term graft patency is attained with left internal mammary artery 
bypass grafting. However, only one such artery may be used, and usually three grafts 
are required, so the saphenous vein in the leg is the alternative vessel for grafting other 
stenosed coronary arteries. Unfortunately, long-term outcomes are related to vessel type 
as graft patency is approximately 90% at 10 years in IMA grafts compared to less than 
50% for saphenous veins (Fisher 1983). The reasons for premature vein graft failure are 
thought to be due to remodelling within the vein wall with the development of 
neointimal hyperplasia and focal stenoses. Reasons for this include the limited potential 
of veins for neovascularisation, thus rendering the graft prone to ischaemia, and the 
arterialised blood pressure within these venous grafts. Vein graft stenosis in CABG 
patients therefore presents a major clinical problem.
Channon’s group developed their interest in the pathobiology of vein conduits, by 
utilising a rabbit model of venous bypass grafts in normocholesterolaemic normotensive 
rabbits (West et al 2001). Their aim was to study the mechanisms of vascular O2 ' 
production in these vessels in relation to the development of vein graft stenosis. These 
experimental venous grafts are characterised by smooth muscle cell proliferation.
Male New Zealand rabbits underwent surgical interposition bypass grafting of the 
jugular vein onto the ipsilateral carotid artery. In other words, this jugular vein was 
inserted as a conduit between proximal and distal ends of the carotid artery. In control
4 4
studies, other animals underwent surgical isolation and mobilisation of the jugular vein, 
including ligation and diathermy of side branches, however these veins were replaced, 
and were not used as venous conduits for arterial blood. The graft and control veins 
were harvested 28 days after surgery. Vascular O2" concentrations were measured by 
lucigenin-enhanced chemiluminescence, using lucigenin concentrations of either 5 or 
250 pm. In situ generation of O2* production was qualitatively evaluated by use of the 
oxidative fluorescent dye, dihydroethidium, on 30 pm tissue sections. Quantification of 
NADP(H) oxidase subunits in vascular homogenates was also undertaken by western 
immunoblotting techniques with monoclonal antibodies to p22phox and p67phox. In 
this case, portions of vascular homogenates, equalised for protein content, were boiled 
in loading buffer containing 100 mM dithiothreitol, separated by SDS-PAGE, and 
transferred to nitrocellulose membranes. Immunohistochemical studies were also 
performed using these antibodies.
Forty blood vessels from 28 animals were studied. Superoxide concentrations were 
unchanged in control jugular veins which had undergone surgical manipulation, but not 
bypass grafting. Alternatively, the native vein grafts were found to have substantially 
increased vascular O2* concentrations (19.9 ± 3.3 vs. 8.4 ± 2.3 relative light units per 
second per milligram of tissue [RLU/s/pg]; p<0.01; n=l 1), compared to control jugular 
veins. This difference in O2’ concentrations between graft and control veins was 
attenuated by treatment with 350 U/mL of SOD for 30 minutes. These observations 
support the assertion that this difference was a function of increased vascular O2* 
production. Interestingly, removal of the endothelium had no effect on vascular 
superoxide concentrations, suggesting that either the media or adventitia, (or both) of 
the vein grafts were the site of enhanced ROS production.
Further investigations in these tissues demonstrated that inhibition of NAD(P)H oxidase 
in these vein grafts with 100 pmol/L of DPI was associated with a substantial reduction 
in '02* concentrations. Studies of substrate-enhanced venous O2’ production were also 
undertaken. In this case, treatment of vascular homogenates with both NADH and 
NADPH were associated with increases in vein O2 ' production, which could be 
inhibited by co-treatment with DPI. In additional studies to identify the subcellular 
location of NAD(P)H oxidase, almost all of the NAD(P)H oxidase activity was 
localised to the particulate fraction of the cell (1.27 ± 0.73 [basal cytosolic] vs. 89.0 ± 
25.4 [membrane] RLU/s/pg and 3.85 ± 0.58 [cytosolic + NADH] vs. 466 ± 108 
[membrane + NADH] RLU/s/pg, p<0.05 in each case). Taken together, these data 
demonstrate that NAD(P)H oxidase is an important source of ROS generation in venous
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bypass grafts. This enzyme is predominately located within cell membranes, rather than 
the cytosol.
Concentrations of p22 and p67phox proteins were three fold greater in vein grafts 
compared to control jugular veins. Furthermore, correlations were demonstrated 
between protein p22 and p67phox protein concentrations and vein graft superoxide 
concentrations (n=9 vessels; for p22phox, r^=0.50, P<0.05; for p67phox, ^=0.78, 
P<0.005), suggesting that the increase in O2' concentrations in vein grafts may be 
related to the increase in the NAD(P)H oxidase enzyme protein subunits.
Subsequently, immunohistochemistry studies were undertaken to investigate the 
number, location and type of cells expressing p22phox subunit in jugular veins and vein 
grafts. Alpha actin is a marker for VSMC, and smoothelin is a marker of smooth muscle 
cell differentiation. Vein grafts showed marked intimal hyperplasia, with a more modest 
increase in medial thickness. Staining for smoothelin demonstrated an increase in 
VSMC differentiation. Cells staining positive for p22phox were present in greatly 
increased numbers in vein grafts. Dihydroethidine staining was reported to demonstrate 
greatest superoxide production in the intimal layer. Immunostaining for macrophages 
and neutrophils with RAM 11 and CD 18 revealed similar staining patterns between 
veins or vein grafts. It was concluded that the predominate cell type responsible for 
enhanced vascular O2 ' production in vein grafts is intimal or de-differentiated VSMC. 
These observations should be interpreted with some caution as hydroethidine 
fluorescence is a qualitative technique which does not give reproducible measurements 
of O2’ concentrations.
These studies demonstrate that vein grafts are subject to intimal hyperplasia, which may 
contribute to loss of graft patency. These pathological changes are associated with 
increased vascular ROS production, predominately due to NAD(P)H oxidase activation 
in these blood vessels. The reasons for this, although not explored in this study, may be 
due to an increase in transmural pressure in vein grafts carrying arterialised blood, and 
the lack of new vessel formation in these blood vessels. This thesis is supported by in 
vitro studies which demonstrated that enhanced cyclic strain can promote enhanced- 
vascular ROS generation (Howard et al 1997). Taken together, these observations raise 
the question as to whether or not strategies to reduce NAD(P)H oxidase-dependent O2' 
generation in vein grafts may have therapeutic potential. The clinical importance of vein 
graft stenosis mandates further human investigations.
4 6
1.8 Oxidative stress in chronic cardiac failure
1.8.1 Studies in experimental animals
Enhanced myocardial ROS activity is one of several abnormalities which are implicated 
in the pathogenesis of left ventricular dysfunction and heart failure (Dhalla et al 1996 ; 
Li et al 1995). One such study was undertaken in experimental mutant mice which 
lacked the gene for Mn-SOD (Li et al 1995). Mn-SOD is important for scavenging ROS 
generated as by-products of oxidative phosphorylation. Homozygous mice fatigued 
rapidly, and died within 10 days of birth. Pathological abnormalities in these animals 
included a dilated cardiomyopathy, muscle wasting, hepatic steatosis and metabolic 
acidosis. Cytochemical analyses demonstrated a reduction in mitochondrial enzymes 
involved in oxidative phosphorylation, such as succinate dehydrogenase and aconitase. 
These enzymes are highly sensitive to oxidative damage (Zhang et al 1990). Taken 
together, these observations demonstrate that enhanced mitochondrial ROS production 
may result in direct damage to mitochondrial enzymes involved in cell respiration. This 
in turn may lead to metabolic acidosis, abnormal fatty acid metabolism, cardiomyopathy 
and cardiac failure.
Ide et al (1999a) demonstrated that myocardial O2 ' production was enhanced in a 
murine model of heart failure, and that one possible source of myocardial ROS 
production was the mitochondrial electron transport enzyme system. Developing their 
studies in this model, this group subsequently investigated the role and consequences of 
myocardial-ROS generation on mitochondria structure and function (Ide et al 2001). 
Mice underwent either left anterior descending coronary artery ligation or sham- 
operation. The presence of impaired or normal left ventricular function was confirmed 4 
weeks later using echocardiography. Myocardial oxidant status was characterised by 
ESR spectroscopy and quantification of lipid peroxide concentrations. Mitochondrial 
enzyme activities and DNA were also quantified. Features consistent with oxidant stress 
were identified in animals with left ventricular dysfunction, compared to controls. Copy 
number, or DNA template availability, of mitochondrial DNA and mitochondrial RNA 
expression was also found to be reduced compared to controls. Furthermore, 
mitochondrial enzyme activities (complexes I, III and IV) encoded by mitochondrial 
DNA were downregulated, compared to those other mitochondrial enzymes (complex 
II/Mn-SOD and citrate synthase) encoded by nuclear DNA. Mitochondrial size, shape 
and number were also abnormal in mice with ventricular dysfunction, compared to
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controls. These data demonstrate that in this murine heart failure model, there is 
evidence of myocardial oxidative stress and mitochondrial lipid peroxidation, in 
association with abnormalities in mitochondrial morphology and function. Although 
this study could not establish a causal relationship between ROS activity and 
mitochondrial damage, other studies have demonstrated that mitochondria lack proteins 
such as histones (Clayton 2001), which are protective against ROS. Mitochondria are 
therefore prone to the accumulation of DNA oxidation products under conditions of 
oxidative stress (Giulivi et al 1995). In addition, mitochondria in other cell types, such 
as cultured vascular endothelial and smooth muscle cells, have also been shown to be 
sensitive to ROS-mediated damage (Ballinger et al 2000; Hill and Singal 1996; Hill and 
Singal 1997).
Other studies by Dhalla et al (1996) in a guinea pig model of left ventricular 
dysfunction induced by aortic banding, demonstrated that even the early features of 
compensatory left ventricular hypertrophy were accompanied by a reduction in 
myocardial content of anti-oxidant enzymes, such as SOD and catalase. These animals 
were also randomised to receive either vitamin E or placebo. Treatment of these animals 
with vitamin E improved both myocardial and blood anti-oxidant enzyme 
concentrations and histological features of cardiomyocyte damage. Although anti­
oxidant supplementation did not prevent left ventricular dysfunction in these animals, 
these data do suggest that oxidative stress may be an early process in the transition from 
cardiac hypertrophy to cardiac failure.
More recently, Bauersachs et al (1999) investigated the pathophysiology of vascular 
dysfunction in heart failure using a rat model of left ventricular dysfunction secondary 
to myocardial infarction. They found that there was increased NADH-dependent 
vascular 0 {  production and impaired endothelium-dependent vasodilation, which could 
be improved by pre-treatment with exogenous SOD. Taken together, these findings 
suggest that endothelial dysfunction in ischaemic heart failure may be in part 
attributable to enhanced NADH-oxidase dependent ROS production which, in turn, may 
result in a reduction in bioavailable NO.
1.8.2 Studies in humans which demonstrate evidence of oxidative 
stress in CHF
In vivo studies of endothelium -dependent and -independent coronary vasodilation in 
patients with dilated cardiomyopathy, have demonstrated a selective impairment of
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ACh-induced increase in coronary blood flow, compared to that obtained after infusion 
of adenosine (Treasure et al 1990). This original observations suggested that endothelial 
dysfunction may be evident in CHF patients, possibly due to enhanced ROS activity.
Studies by McMurray et al (1993) confirmed that ROS activity was increased in the 
blood of patients with heart failure secondary to coronary artery disease, compared to 
controls. Plasma malondialdehyde, a marker of lipid peroxidation, is elevated in chronic 
heart failure (DiazVelez et al 1996), and is related to exercise-intolerance (Nishiyama et 
al 1998). In other studies, increased plasma concentrations of malondialdehyde, and 
decreased concentrations of glutathione, vitamin C and E, were correlated with both 
NYHA functional class (Chamey et al 1997; Keith et al 1998) and plasma 
concentrations of the cytokine, tumour necrosis factor alpha (Keith et al 1998).
CHF is a state characterised by a number of processes that may promote ROS 
generation in vivo. These pro-oxidant pathways include cytokine activation (Berry and 
Clark 2000; Cross and Jones 1991; DeKeulenaer et al 1998a), mitochondrial 
dysfunction (Ide et al 1999b), recurrent hypoxia-reperfusion (Ferrari et al 1998), 
possibly genetic abnormalities (Guzik et al 2000a) and activation of the RAAS (Berry 
and Clark 2000). There are a number of potential cellular sources implicated in 
enhanced ROS generation in CHF. For example, it has recently been demonstrated that 
CHF patients may have increased leucocyte O2' production (Ellis et al 2000), which is, 
in turn, related to severity of disease, as measured by NYHA functional class (Ellis et al 
1998). Other sources of enhanced ROS generation in human CHF are both the 
myocardium (Dieterich et al 2000) and peripheral blood vessels (DiazVelez et al 1996).
1.9 Genetic variation, NAD(P)H oxidase and cardiovascular 
pathophysiology
A number of polymorphisms have now been identified in the genes which code for the 
individual proteins which collectively constitute the NAD(P)H oxidase enzyme (Babior 
1999; Kenney et al 1993; Kuribayashi et al 1996; Leusen et al 2000). Many of the 
genetic studies of NAD(P)H oxidase have been in relation to the role of this enzyme in 
chronic granulomatous disease (Babior 1999).
There are now several reports, which suggest a relationship between variation in the 
NAD(P)H oxidase gene and cardiovascular risk. Inoue et al (1998) performed a case- 
control study, in which an association was found between the C242T polymorphism of
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the p22phox gene and a reduced susceptibility to coronary artery disease (Inoue et al
1998). These findings should be considered with some caution because of both the 
relatively small number of patients included in this study and the low frequency of this 
polymorphism in the Japanese population. Other studies have also failed to find any 
association between this polymorphism and the presence of atherosclerotic vascular 
disease (Gardemann et al 1999; Renner et al 2000; Saha et al 1999).
By contrast, genotyping of the patients from the Lipoprotein and Coronary Artery Study 
(LCAS) found an association between the C242T allele and the progression of coronary 
atherosclerosis (Cahilly et al 2000). In this prospective study, the sample size totalled 
368 subjects, the extent of coronary atherosclerosis was documented using quantitative 
coronary angiography and the period of follow up was 2.5 years. The presence of this 
polymorphism has also been associated with an increased risk of stroke in a Japanese 
population (Ito et al 2000).
More recently, other studies have provided evidence a functional effect of the C242T 
p22phox gene polymorphism in the blood vessels of patients with coronary heart 
disease. In studies in IMA and SV obtained from patients at the time of coronary artery 
bypass surgery, Guzik et al (2000a) demonstrated that O2' production was reduced in 
the blood vessels of patients with the CT/TT genotype compared to those with the CC 
genotype. Most recently, Schachinger et al (2001) investigated the vasodilator function 
of epicardial coronary arteries in patients with coronary heart disease in relation to 
genotype for the C242T polymorphism of the p22phox gene. They found that patients 
with the C242T allele had enhanced coronary endothelium-dependent vasodilation 
compared to those with the CC. genotype. These data suggest that the C242T mutation 
may lead to a functional inactivation of this protein, resulting in reduced vascular O2’ 
production.
1.10 Rationale for studies of ROS-generation and activity in 
human blood vessels
At the inception of this thesis, the body of data pertaining to the sources and 
mechanisms of vascular ROS generation existed primarily as a result of studies 
undertaken in experimental animal models (Griendling et al 1994; Li et al 1995; Li et al 
1995; McIntyre et al 1997; Mohazzab and Wolin 1994; Mohazzabh et al 1994; Mugge 
et al 1991c; Mugge et al 1994; Ohara et al 1993; Pagano et al 1995; Rajagopalan et al 
1996b; Wilson 1990; Li et al 1995; Li et al 1995). Human studies had previously 
demonstrated both the functional importance of endothelium-dependent vasodilation in
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the regulation of normal blood flow in vivo (Vallance and Collier 1994), and how this 
may be abnormal in a variety of cardiovascular disease states (Calver et al 1992b; 
Calver et al 1992a; Cox et al 1989; Creager et al 1990; Panza et al 1990).
As discussed above, the sources of O2 ' generation in the vasculature of a number of 
animal models of vascular disease, have been documented. The sources and 
mechanisms of ROS production in human blood vessels, and whether this may be 
altered in vascular disease, remain incompletely understood.
1.11 Strategies for reducing vascular oxidative stress
1.11.1 Oestrogen
Oestrogen has both rapid and longer-term effects on the blood vessel wall. Current data 
suggest that oestrogen treatment may enhance bioavailable, endothelial-derived NO 
(Mendelsohn and Karas 1999). Huang et al (2000) reported that oestrogen, via a 
receptor -  mediated pathway, upregulated eNOS gene expression and restored vascular 
responses in male SHR. Garcia-Duran et al (1999) examined neuronal (nNOS) 
expression in neutrophils from male and female human subjects. In premenopausal 
women nNOS expression and plasma oestrogen levels were higher in the ovulatory than 
the follicular stage of their menstrual cycle, whereas, in postmenopausal women nNOS 
expression was lower. Transdermal oestradiol therapy in these women increased 
neutrophil nNOS expression towards those observed in the follicular stage of the cycle 
in premenopausal women. Neutrophils from male subjects incubated with 17p 
oestradiol showed enhanced nNOS protein expression which was inhibited by 
tamoxifen, indicative of a receptor mediated mechanism. It has recently been suggested 
that oestrogen may also enhance eNOS activity by modulating O2 ' concentrations 
(Barbacanne et al 1999). Simoncini et al (2000) demonstrated that the oestrogen 
receptor isoform ERa binds to the P85a regulatory subunit of phospatidylinositol -3- 
hydroxyl-kinase (PI3K). Oestrogen enhanced the ERcc-associated PI3K activity, 
leading to activation of eNOS, independent of gene transcription.
1.11.2 Vitamins
The possibility that vitamin C therapy might enhance bioavailable NO and therefore 
improve abnormal endothelium-dependent vasodilator responses in vascular disease has
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investigated in a number of experimental animal and human studies. In a pig coronary 
balloon injury model, Nunes et al (1997) investigated whether or not dietary 
supplementation of these animals with vitamin C, vitamin E, both, or neither, could 
enhance attenuate vascular O2’ concentrations, as measured by lucigenin-enhanced 
chemiluminescence. Vitamin C & E plasma concentrations were increased in those 
groups receiving dietary supplements with these vitamins. After 7 days of supplements, 
animals sustained balloon injury to the left anterior descending (LAD) coronary artery 
balloon injury and were sacrificed 14 days later. Superoxide concentrations in LAD 
coronary segments were 2.5 times greater than in segments from either an uninjured 
part of the LAD, or from the right coronary artery (RCA) of the same animal. 
Furthermore, vascular O2 ' concentrations were reduced in both LAD and RCA 
segments in all vitamin-treated animals, compared with controls. In further studies, this 
group demonstrated that therapy with vitamins C & E in combination, but not alone, 
reduced plasma concentrations of lipid peroxides and attenuated intimal hypertrophy 
(intimal area : vessel area), compared to controls.
Taddei et al (1998) investigated whether treatment with vitamin C might improve 
attenuated in brachial artery endothelial-dependent dilator responses, as measured by 
forearm strain-gauge plethysmography, in a group of hypertensive patients. This study 
included 47 patients with essential hypertension (systolic blood pressure 155 ± 7 
mmHg; diastolic blood pressure 102 ± 4 mmHg) and 35 age-matched control subjects 
(systolic blood pressure 121 ± 4 mmHg; diastolic blood pressure 81 ± 3 mmHg). NO, 
or endothelium-dependent vasodilator responses were assessed by infusion of 
incremental concentrations of ACh. These studies demonstrated a blunted response to 
ACh infusion in hypertensive patients. Forearm blood flow (FBF) increased less, from 
3.6 ± 0.5 to a maximum of 16.5 ± 2.7 mL/lOOml forearm tissue per minute compared to 
normotensive subjects (3.6 ± 0.6 to a maximum of 22.8 ± 3.3 mL/100mL forearm tissue 
per minute). Endothelium-independent vasodilator function was assessed by infusion of 
sodium nitroprusside, with comparable responses obtained in both groups. In additional 
studies, co-infusion of vitamin C with ACh increased the maximum vasodilator 
response in hypertensive subjects (FBF increased from 3.5 ± 0.6 (mean ± SEM) to a 
maximum of 20.8 ± 2.6 mL/lOOml forearm tissue per minute; p<0.05), whereas vitamin 
C was without effect in normal subjects.
In further studies (Taddei et al 1998), the response to inhibition of NOS, by infusion of 
L-NMMA, was assessed both in the presence and absence of vitamin C. In healthy
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subjects, L-NMMA infusion caused a reduction in basal FBF (from 3.6 ± 0.4 to 2.2 ± 
0.2 mL/lOOml forearm tissue per minute; p<0.05), and also blunted the vasodilating 
response to ACh (saline, from 3.6 ± 0.5 to 22.7 ± 3.7 mL/lOOml forearm tissue per 
minute; L-NMMA, from 2.2 ± 0.2 to 9.9 ±1.8  mL/lOOml forearm tissue per minute; 
p<0.01 vs ACh alone). Co-infusion of vitamin C had no effect on either of these 
responses. By contrast, in hypertensive subjects, L-NMMA infusion caused a smaller 
decrease in FBF (from 3.5 ± 0.5 to 2.6 ± 0.2 mL/lOOml forearm tissue per minute; 
p<0.001), compared with normotensive subjects (39% vs 25%, respectively; p<0.01). 
Furthermore, L-NMMA infusion did not change the response to ACh (saline, from 3.6 ± 
0.5 to 16.7 ± 2.3 mL/lOOml forearm tissue per minute; L-NMMA, from 2.6 ± 0.2 to 9.9 
±1.9  mL/lOOml forearm tissue per minute; p<0.01 vs ACh during saline). When the 
effect of L-NMMA was retested in the presence of vitamin C, the NOS inhibitor 
attenuated the vasodilating response to ACh (from 2.6 ± 0.2 to 11.4 ± 1.8 mL/lOOml 
forearm tissue per minute; p<0.01 vs ACh during vitamin C co-infusion). Taken 
together, these data suggest that in hypertensive subjects, a reduction in bioavailable 
vascular NO is present due to increased activity of ROS. This could be improved by 
treatment with vitamin C. That vitamin C had no effect on basal FBF in either 
hypertensive or control subjects suggests that ROS are not tonically produced. In other 
studies of brachial artery FBF responses, vitamin C also improved impaired 
endothelium-dependent vasodilation in patients with diabetes (Timimi et al 1998), 
hypercholesterolaemia (Ting et al 1997) and coronary heart disease (Levine et al 1996).
The question as to whether anti-oxidant interventions are beneficial in the primary or 
secondary prevention of human vascular disease has been investigated in a number of 
large, randomised, placebo-controlled clinical trials, namely the Cambridge Heart Anti- 
Oxidant Study (CHAOS) Trial (Stephens et al 1996), and the Heart Outcomes 
PrevEntion (HOPE) study (Yusuf et al 2000). However, the potential of vitamin 
therapies has not translated into actual clinical benefits. By contrast, a recent 
randomised, placebo-controlled trial of vitamins C & E in 283 patients at risk of pre­
eclampsia (PET), reported a reduced incidence of PET in patients treated with vitamin 
C & E, compared to those given placebo (8% v 17%; p=0.002) (Chappell et al 1999)
1.11.3 Superoxide dismutase
Initial studies undertaken to investigate the effect of SOD infusion on the impaired 
endothelium-dependent ACh vasodilator response in hypertensive patients failed to
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demonstrate any improvement in this response (Garcia et al 1995). Possible 
explanations for this include a lack of bioavailable NO due to decreased production 
rather than increased breakdown of by O2" scavenging, a thesis recently supported by 
the findings of Forte et al (1997). Alternatively, exogenous SOD may have been 
inactive due to either its relatively short half-life or its poor intracellular penetrance. 
This is due to SOD being electrostaticically repelled from cell membranes as a result of 
its negative charge (Omar et al 1992).
For this reason, other studies were undertaken with SOD combined with polyethylene 
glycol (PEG-SOD). Initial investigations with this compound demonstrated that PEG- 
SOD can increase cultured porcine endothelial cell SOD activity therefore preventing 
oxidative damage by activation of XOR (Beckman et al 1988). Mugge et al (1991b) 
investigated whether or not treatment with PEG-SOD might improve impaired 
endothelium-dependent vasorexlaxation in atherosclerotic aortae obtained from 
cholesterol fed New Zealand White rabbits. The presence or absence of atherosclerosis 
was confirmed by histological analyses using Verhoeff and van Gieson stains. Isometric 
tension studies were undertaken and endothelium-dependent responses in aortae pre­
constricted to phenylephrine. In addition, total vascular SOD activity was also assessed 
using spectrophotometric techniques. PEG-SOD treatment increased total vascular SOD 
activity in both cholesterol fed and normal rabbits. Endothelium-dependent relaxations 
in response to ACh and the calcium ionophore A23187 were markedly impaired in 
atherosclerotic arteries (43 ± 7% and 54 ± 6%, respectively), compared with normal 
controls (80 ± 2% and 89 ± 2%, respectively). Treatment of cholesterol-fed rabbits with 
PEG-SOD improved the maximal relaxation in response to ACh and A23187 (65 ± 2 %  
and 73 ± 3%; p<0.05), respectively, whereas PEG-SOD had no vasorelaxant effect in 
normal rabbits.
Lipid permeable SOD analogues, however, have been shown to have acute vasodilator 
properties in rabbits, rats and most recently mice (Nakamura et al 1998). In one other 
study, treatment of SHR with tempol (4- hydroxy -2, 2, 6, 6- tetra methyl piperidinoxyl) 
resulted in reductions in blood pressure, glomerular filtration rate and renal excretion of 
8-iso- prostaglandin F2a - a marker of oxidative stress (Schnackenberg and Wilcox
1999).
A number of studies have been undertaken to investigate the possible cardioprotective 
effects of EC-SOD therapy in ischaemia/reperfusion injury. For example, Marklund et
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al (Wahlund 1992) demonstrated that EC-SOD reduced creatine kinase release in rats 
subjected to 10 minutes of coronary occlusion and 24 hours of reperfusion. Hatori et al 
(Hatori 1992) demonstrated that infusion of purified, recombinant EC-SOD into the 
great cardiac vein of pigs was associated with a reduction in infarct size.
1.11.4 Gene transfer
Several groups have now used vascular gene transfer in an effort to reduce ROS 
activities in the cardiovascular system, however, only some of these studies have 
demonstrated beneficial effects. One early study by Fang et al (Fang 1998) investigated 
the possibility that transfer of CuZn-SOD and Mn-SOD cDNA into bovine aortic 
endothelial cells (BAEC) could protect these cells from lipid peroxidation. Incubation 
of BAEC with 200 pg/mL of LDL for 18 hours resulted in a four-fold increase in the 
concentration of lipid peroxides, such as malondialdehyde, compared to controls (22.5 ± 
1.1 vs 6.3 ± 0.2 nmol malondialdehyde/mg LDL protein, respectively; p<0.05). In 
further studies, treatment of these cells with media containing a concentration of 100 
pg/mL of Cu/Zn-SOD reduced concentrations of oxidised LDL by 79%. In order to 
determine whether enhanced activity of intracellular SOD could prevent lipid 
peroxidation, these cells were transfected with either adenoviral vectors containing 
cDNA for CuZn-SOD and Mn-SOD, or no foreign DNA. In this case, incubation of 
CuZn-SOD and Mn-SOD-transfected cells with LDL resulted in a reduction in 
malondialdehyde concentrations by 77% and 32% respectively. These studies suggest 
that lipid peroxidation in cultured vascular cells is a O2' -mediated effect, which can be 
prevented by manipulations to increase exogenous or endogenous SOD activity through 
gene transfer.
These observations raised the question of whether SOD gene transfer might improve 
abnormal endothelium-dependent responses in intact blood vessels obtained from 
animal models of vascular disease. However, ex vivo gene transfer of either CuZn-SOD 
(Adenovirus cytomegalovirus (AdCMV) Cu Zn-SOD) or extracellular SOD (Ad CMV 
EC-SOD) to aorta from Watanabe heritable hyperlipidaemic rabbits failed to improve 
the impaired relaxation to ACh or calcium ionophore, despite successful transfer of the 
virus (Miller et al 1998). Similarly when segments of thoracic aorta obtained from 
rabbits made hypertensive by Ang II infusion were incubated with adenoviral vectors 
containing CuZn- or EC-SOD cDNA, no improvement in endothelium-dependent 
vasorelaxation was observed, compared to control arteries incubated with adnovirus
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containing cDNA beta-galactosidase (Nakane et al 2000). Furthermore, in studies 
performed in our laboratory, in vivo adenoviral gene transfer of CuZn-SOD to carotid 
arteries of SHRSP also showed no beneficial effect (Alexander et al 2000).
By contrast, gene therapy with EC-SOD has protective effects in rabbit models of 
reperfusion injury (Li et al 1998b) and myocardial infarction (MI) (Li et al 1998c). In 
this latter study, healthy rabbits were randomised into four groups. Animals in the first 
group (I) underwent instrumentation and coronary occlusion only. Ischaemic 
preconditioning has a cardioprotective effect (Bolli et al 1991), and therefore a second 
group (II) was included to serve as positive control. The animals in this group were 
exposed to a period of ischaemic preconditioning prior to coronary occlusion, which 
involved a sequence of six 4-minute coronary occlusions interspersed with 4 minutes of 
reperfusion performed 24 hours before the 30 minute coronary inclusion. Animals in the 
third group (III) served as controls, receiving replication-deficient adenovirus with LacZ 
reporter gene, prior to coronary inclusion. Intravenous heparin was infused 2 hours 
before coronary occlusion in order to release hepatic EC-SOD into the systemic 
circulation, with intravenous protamine being subsequently infused immediately prior to 
the occlusion to reverse the effects of heparin. The fourth group (IV) of animals 
received human EC-SOD cDNA incorporated into adenovirus and the 
herparin/protamine infusion prior to coronary occlusion. In this study, the liver was the 
principal target for gene transfer in order to both exploit the efficiency of adenoviral 
transfection of hepatocytes and to avoid the possibility of an inflammatory response 
within the heart. Myocardial infarction was defined on the basis of new ST-segment 
elevation and QRS changes on the electrocardiogram, and systolic wall thinning as 
detected by cardiac ultrasound. Northern blot analyses demonstrated that hepatocyte 
EC-SOD gene expression was substantially increased by this treatment. Myocardial 
infarct size was comparable between control groups I and III (57 ± 6% and 58 ± 5%, 
respectively), whereas infarct size was reduced in the EC-SOD gene therapy-treated 
animals by 25 ± 4% compared to the control virus-treated animals (p<0.01). This 
reduction was comparable to that which occurred in preconditioned animals, compared 
to instrumented controls [29 ± 3%, p<0.01]. This study was the first to demonstrate a 
beneficial effect of EC-SOD gene therapy in a model of either reperfusion or MI. The 
discrepancy between this and other studies which have investigated the same question 
may be due to the use of EC-SOD, rather than CuZn or MnSOD, as the former is 
excreted by cells and binds more readily to intra and extracellular membranes.
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An alternative approach involves vascular gene transfer of NOS. Nakane et al (Nakane
2000) showed that transfer of eNOS gene into aortic segments from rabbits that had 
been chronically infused with Ang II improved endothelium-dependent vasorelaxation. 
Similarly, studies in our laboratory have demonstrated that in vivo transfer of the eNOS 
gene improved vasomotor responses in the SHRSP (Alexander et al 2000). It seems that 
strategies aimed at modification of vascular function could also be targeted to the 
adventitia, as demonstrated by Tsutsui et al (Tsutsui 1998). In the future, use of vectors 
devoided of any immune or inflammatory responses, might facilitate these mechanistic 
studies.
1.11.5 Pharmacolgical agents with antioxidant effects
Some therapies which improve prognosis in hypertension and coronary heart disease, 
such as beta-blockers and angiotensin converting enzyme (ACE) (Lechat et al 1999; 
Yusuf et al 2000) may exert beneficial effects, in part, through anti-oxidant mechanisms 
(Chopra et al 1992; Lysko et al 2000). For example, these treatments are associated 
with improvements in endothelium-dependent vasodilation (Anderson et al 2000; 
Homig et al 1997). In the following section, the current and potential therapeutic anti­
oxidant interventions will be reviewed.
1.11.5.1 Inhibition of the RAAS
ACE-I have anti-oxidant properties in vitro (Benzie and Tomlinson 1998; Chopra et al 
1992; McMurray et al 1989; McMurray et al 1990; McMurray et al 1990). The 
mechanism for this effect is related to a sulphydryl (-SH) group present in some, but not 
all, of these drugs (Figure 1.7).
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Figure 1.7 Chemical structure of the angiotensin converting enzyme inhibitors, 
captopril and enalaprilat. Captopril has a sulphydryl (-SH) group whereas enalaprilat 
does not.
For example, in photo-oxidation studies undertaken by Chopra et al (1992) captopril, an 
SH-containing ACE-I, did not exhibit any significant scavenging of 0 2\  but effectively 
removed H2O2, singlet oxygen and HOC1. In this case, the SH group was oxidised on 
interaction with certain ROS. Blockade of the -SH group in captopril attenuated its 
ability to scavenge ROS. By contrast, both SH-containing and non-SH containing 
ACE-I (e.g. enalaprilat) inhibited ascorbate-induced lipid peroxidation in rat liver 
microsomes. This may be due to the ability of these compounds to chelate metal ions.
In addition, controlled clinical trials have recently shown that ACE-I therapy may 
improve endothelium-dependent vasodilation in patients with CHD (Anderson et al 
2000; Mancini et al 1996). Although these data support an anti-oxidant effect of ACE- 
Is, there are several other mechanisms, such as potentiation of bradykinin, which may 
explain this effect. In addition, ACE-Is reduce the production of Ang II. Results from 
experimental animal studies have demonstrated that Ang II is pro-oxidant (Rajagopalan 
et al 1996b). Consequently, this may be one additional mechanism whereby ACE-Is, 
and ARAs, may exert anti-oxidant effects. However, as yet, there are no data on the 
potential anti-oxidant effects, if any, of these drugs, in humans.
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1.11.5.2 Beta-blockers
Carvedilol is a non-specific, beta adrenergic receptor antagonist with alpha-blocking 
properties, whereas metoprolol is a betai-specific receptor antagonist. The anti-oxidant 
properties of carvedilol, and its metabolites, are attributed to the ROS scavenging 
properties of the carbazole moiety in this drug (Christopher et al 1998; Intengan and 
Schiffrin 2000). Carvedilol, by nature of its chemical structure rather than any receptor- 
mediated property, can scavenge free radicals and inhibit lipid peroxidation. In vitro, 
carvedilol is a more potent anti-oxidant than other beta-blockers which do not contain a 
cabazole moiety, such as metoprolol (Lysko et al 2000).
Certain studies in animal models of hypertension have demonstrated that carvedilol, but 
not metoprolol, results in reduced ROS activity and improved endothelium-dependent 
vasorelaxation (Intengan and Schiffrin 2000). These in vitro differences in experimental 
animal models have not been consistently reproduced in vivo. For example, one recent 
randomised, controlled trial of the effects of carvedilol, compared to metoprolol, on left 
ventricular ejection fraction (LVEF), exercise capacity and plasma concentrations of 
thiobarbituric acid-reactive substances (TBARS) (indirect markers of plasma anti­
oxidant capacity) in patients with CHF (Kukin et al 1999). In this study, LVEF and 
exercise capacity improved, and plasma TBARS concentrations decreased, to a similar 
extent in both groups. These observations confirm that beta-blockers have anti-oxidant 
properties in vivo, however, this may not be specific to one particular drug. The 
mechanisms for this anti-oxidant effect may include direct ROS scavenging, inhibition 
of the sympathetic nervous system, improvement in cardiac function, and/or anti­
cytokine effects (Berry and Clark 2000).
Nebivolol is one other beta-blocker which, in addition to beta-adrenergic receptor 
blockade, is reported to enhanced endothelium-dependent vasorelaxation through 
stimulation of eNOS activity (Bowman et al 1994; Broeders et al 2000; Dawes et al 
1999; Parenti et al 2000). Beta-blockers are sympathetic nervous system antagonists 
and consequently, inhibit the production of renin, leading in turn to a reduction in 
plasma Ang II concentrations. Consequently, this may, also lead to a reduction in Ang 
II-stimulated O2 ' production, which could be one putative, additional anti-oxidant effect 
of this class of drug.
5 9
1.11.5.3 Aspirin
Aspirin has, in addition to its known anti-platelet effects, anti-oxidant properties 
(Podhaisky et al 1997). In vitro studies with aspirin have shown that treatment of 
cultured bovine pulmonary artery endothelial cells with this drug leads to protection of 
these cells from the toxic effects of H2O2 . This mechanism is thought to occur through 
removal of iron by an aspirin-induced increase in ferritin synthesis (Oberle et al 1998). 
Ferritin sequesters free cytosolic iron, preventing its participation in ROS-generating 
reactions.
1.11.5.4 HMG-CoA reductase inhibitors
Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) enzyme inhibitors, or statins, have 
effects beyond inhibition of hepatic cholesterol synthesis (Maron et al 2000). Statins 
enhance vascular production of NO, through up-regulation of eNOS gene expression 
(Amin-Hanjani et al 2001; Hemandez-Perera et al 1998). The mechanisms involved in 
this effect may be mediated through both direct effects of the drug, independent of any 
reduction in plasma cholesterol concentration (Amin-Hanjani et al 2001), and indirect 
effects, mediated for example, through a reduction in plasma concentrations of oxidised 
LDL. This latter effect may be explained by results from in vitro studies, which have 
demonstrated that oxidised LDL, but not LDL, exerts an inhibitory effect on eNOS 
mRNA expression (Hemandez-Perera et al 1998). In this case, enhanced vascular 
production of NO, may lead to increased removal of ROS.
Statins may also have a direct inhibitory effect on ROS generation in vascular cells. 
Recently, in vitro studies in cultured human VSMC demonstrated that simvastatin, 
pravastatin, fluvastatin, and its metabolites, attenuated lysophosphatidylcholine- 
stimulated ROS production through inhibition of a phospholipase D/protein kinase Ca- 
mediated pathway (Yasunari et al 2001). Furthermore, this inhibition of ROS generation 
was associated with a reduction in VSMC migration. Finally, some statins, such as 
fluvastatin, may also have direct ROS-scavenging properties (Suzumura et al 1999).
1.12 Aims
The purpose of this investigation was to characterise the cellular and enzymatic sources 
of vascular ROS generation in humans. Specifically, I sought to determine the 
contribution of NAD(P)H oxidase, XOR and NOS to the basal production of O2' in
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IMA and SV obtained at the time of coronary artery revascularisation surgery. 
Secondly, I sought to determine which clinical and demographic parameters might be 
associated with basal ROS-generation in these blood vessels. The third aim was to 
investigate whether or not Ang II might stimulate O2" generation in human blood 
vessels, and if so by what mechanism. Finally, I sought to characterise the functional 
effects of ROS generation which may be stimulated by Ang II.
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2 Methods
2.1 Summary
This chapter provides a detailed description of how and from whom blood vessels were 
obtained, and secondly the laboratory and clinical techniques used in the studies 
described in this thesis. Laboratory studies were undertaken within the British Heart 
Foundation Blood Pressure Group, Department of Medicine and Therapeutics, and the 
Autonomic Physiology Unit, University of Glasgow.
2.2 Patients and healthy volunteers
The University of Glasgow is located adjacent to the Western Infirmary which is a 
tertiary healthcare centre. Healthy human blood vessels are extremely difficult to obtain. 
For this reason, we sought an alternative source of human vascular tissue. Coronary 
artery bypass surgery is a common procedure performed in the Western Infirmary, with 
approximately 1000 operations being performed per annum. Usually, distal segments of 
left internal mammary artery (IMA) and saphenous vein (SV) are surplus to requirement 
and are consequently discarded. In certain cases, the radial artery (RA) from the non­
dominant arm were used. This situation therefore presents an opportunity to obtain 
human blood vessels for the purposes of scientific research. Although these conduit 
blood vessels are obtained from patients with atherosclerotic vascular disease, these 
blood vessels are, in general, not affected by this process. All studies were fully 
approved by the West Ethics Committee of the Western Infirmary, on behalf of the 
North Glasgow Hospitals University NHS Trust. Healthy volunteers were identified 
from those patients who were undergoing elective inguinal hemiae repair. These 
patients were invited to consent to an abdominal skin biopsy at the time of their 
operation. All studies were fully approved by the West Ethics Committee of the North 
Glasgow Hospitals University NHS Trust.
Clinical details were recorded from case note examination. A history of current cigarette 
smoking, hypertension (defined as either current anti-hypertensive treatment or a blood 
pressure > 140/90 mmHg), diabetes mellitus (insulin treated or non-insulin treated) and 
hypercholesterolaemia (plasma cholesterol > 5 . 4  mmol/L) were considered as risk 
factors for CHD. Information on current medication was also documented at this point.
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2.3 Handling of human tissue sam ples
2.3.1 Conduit arteries and veins
IMA, RA or SV were collected on a tw ice-daily basis from the Cardiac Surgical Theatre 
Suites within the W estern Infirm ary. Distal segm ents o f  these blood vessels were 
im m ediately taken to the laboratory in Krebs buffer on ice. A t this point, and in these 
conditions, the blood vessels were then carefully dissected free o f  loose connective 
tissue, divided into 4-5m m  segm ents and weighed. The vessels w ere then incubated in 
Krebs buffer at pH 7.4 ± 0.22 and m aintained in atm ospheric conditions ( p 0 2 19 ± 4 
kPa; p C 0 2 3 ± 4 kPa) at 37 °C. In the case w here it was planned to isolate RNA, then 
the blood vessels were collected in RN A later (AM S Biotechnology [Europe] Ltd) on ice 
and stored at 4°C for 24 -  48 hours prior to isolation o f  RNA.
In some studies, the IM A were denuded o f  endothelium  by gentle rubbing w ithin the 
lumen with forceps. In the case where IMA were collected w ith a view  to being used in 
m olecular studies, biopsies o f  arteries w ithin connective tissue w ere placed in a sterile 
universal container containing hum an culture m edia m aintained at 37°C in a 
therm oflask. The connective tissue was rem oved by careful dissection. Endothelial cells 
were obtained from  these arteries by careful dissection and rem oval o f  the endothelial 
cell m onolayer under high-pow ered m icroscopic view. The studies in which IM A and 
SV were used are sum m arised in Figure 2.1.
.. . Semi - quantitative RNAtheatre , . ..detection using reverse
transcription polymerase 
Dissect blood vessel \  chain reaction techniques
Culture vascular cells
Enzyme localisation by 
immunohistochemical techniques
Laboratory
Superoxide measurement by use of 
lucigenin chemiluminescence
Figure 2.1 Schem atic diagram  o f handling and experim ental use o f  conduit arteries and 
veins obtained at the time o f  coronary revascularisation surgery
63
2.3.2 Skin biopsies
Small resistance arteries (SRA) from healthy subjects were obtained from skin biopsies. 
These biopsies were taken by from the abdominal wall of healthy male volunteers by 
the operating surgeon at the time of inguinal hernia repair. The biopsies were taken at 
the point of skin incision and prior to the use of electrocautery. Once made available, 
the biopsies were collected from the operating theatre and taken to the laboratory (less 
than 5 minutes by foot) in normal saline on ice.
At this point, the skin biopsy was transferred from cold 0.9% NaCl solution to ice cold, 
Krebs buffer solution (composition in mmol/L: NaCl 118.4, KC1 4.7, MgS0 4  H2O 1.2, 
KH2PO4 1.2, NaHC03 24.9, CaCl2 2.5, glucose 11.1, and EDTA 0.023, which gives a 
pH of 7.4 when aerated with a 5% CC>2/95% O2 mixture). Fresh Krebs buffer was 
prepared each day.
SRA can be identified by their helical shape and opaque wall, in contrast to veins which 
are rather more elongated, flaccid and transparent. On arrival in the laboratory, SRA 
were isolated from the skin biopsy by careful dissection using surgical grade 
instruments with the aid of a high power microscope. This was done with the biopsy 
placed in a Petri dish filled with ice cold Krebs buffer, which was regularly changed 
during the dissection process. A thorough inspection of the skin biopsy, and dissection 
of any SRA that were identified, could take anything up to two or three hours to 
complete. Thereafter, the SRA were placed in a universal container and stored in a 
fridge at 4°C overnight. Storage of resistance arteries in this way has been previously 
demonstrated to have no effect on the vasoactive properties of these blood vessels 
(McIntyre et al 1998).
2.4 Cell culture
Human aortic endothelial cells (HAEC; Clonetics), human coronary artery smooth 
muscle cells (HCASMC; Biowhittaker) were grown to subconfluence (80-90%) at 37°C 
under 5% CO2, 95% air. The HAEC and HCASMC were obtained from primary 
cultures in appropriate culture media containing bovine serum in 25 ml culture flasks 
and used between passages four and six in serum free conditions.
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2.4.1 Isolation of total cellular RNA from blood vessels or cultured 
cells
RNA was extracted from fresh, intact blood vessels and cultured cells. This was done 
according to a standard protocol, which involved four basic steps. The first involved 
homogenisation of blood vessels using RNAzol™ B (2 ml/100 mg tissue). The second 
step involved RNA extraction using 1 volume of homogenate: 0.1 volume of 
choloroform, which was then followed by RNA precipitation with 1 volume of 
isopropanol. The fourth step involved washing the RNA with 75% ethanol.
All glass and plasticware had been sterilised by treating with Diethylamine 
Pyrocabonate (DEPC) as 0.1% v/v solution to minimise degradation of RNA due to 
endogenous or contaminating RNAses, then autoclaved for approximately 15 minutes to 
remove traces of DEPC. All materials were handled using disposable rubber gloves.
The biopsies containing internal mammary arteries (and adherent tissue) were obtained 
immediately at the conclusion of revascularisation during CABG surgery. The tissue 
was placed on ice-cold saline, transferred to the laboratory and carefully cleaned of 
surrounding connective tissue under high-powered microscopic view. The blood vessel 
was then inserted into 1ml of RNAzol™ B (Biogenesis, UK) and placed on dry-ice.
RNAzol™ B is an RNA extraction agent that contains guanidinium thiocyanate and 
phenol. RNA molecules form complexes with the guanidinium thiocyanate and water 
molecules, preventing hydrophilic interactions with any DNA and protein present. The 
frozen blood vessel was then placed into a disposable cell culture dish (Nunclon™) on 
dry ice and manually macerated using a scalpel blade, and the frozen homogenate was 
then scraped into a microfuge tube (Townsend et al 1999). This mass of tissue was then 
further homogenised with a Kinematica polytron® homogeniser (Philip Harris 
Scientific, Aberdeen, UK). The polytron head was washed in 3% hydrogen peroxide 
then DEPC-treated distilled water (CIH2O) between samples. Choloroform was then 
added to the homogenate in a ratio of 1:10.
In order to extract RNA from the homogenate, the samples were vortexed for 10 
seconds and then left to stand on ice for 15 minutes. After this, the samples were 
centrifuged for 15 minutes at 12,000 g (4°C). This resulted in separation of the sample 
into an upper, colourless aqueous phase containing RNA, an intermediate DNA phase
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and a lower, blue organic phase, containing phenol-chloroform and protein. The upper 
aqueous phase was removed by careful pipetting and added to an equal volume of 
isopropanol (Fisher Scientific, UK). The sample was then vortexed and left to stand on 
ice for a minimum of 15 minutes, which was followed by centrifugation for 15 minutes 
at 12,000-g (4°C). The RNA precipitate forms a yellow-white pellet at the bottom of the 
tube. The RNA was then washed in 75% ethanol -  0.8 ml of ethanol per 50 -  100 pg 
RNA (Fisher Scientific, UK), vortexed, and subsequently centrifuged for 5 minutes at 
7500 g (4°C). The supernatant was then removed by careful pipetting, and the RNA 
pellet was air dried (1 minute at 37°C) and mixed with 15-20 pL of nuclease-free H2O 
(Promega, UK).
Similar steps were followed in the case of extraction of RNA from cultured cells. 
RNAzol™ B was added to cells in culture flasks in a ratio of 0.2 ml of RNAzol™ B: 1 x 
106 cells. It is estimated that once grown to confluence, there will be 1 x 107 cells in a 
250-300 ml flask (growth area = 75 cm2) and 2 x 107 cells in a 650-750 ml (growth area 
= 162-175 cm2). It is recognised that these values are approximations as animal cells 
can vary in length from 10-100 pm. After the addition of RNAzol™ B, the flasks were 
agitated and the cell suspension scraped off and aspirated into a 1.5ml Eppendorf tube. 
Total cellular RNA was then obtained by the phenol: choloroform extraction technique 
described above.
Each of the RNA samples was quantified by use of the RiboGreen™ RNA 
quantification assay (Molecular Probes, Europe). This is a fluorescent assay based on 
the Ribogreen™ reagent used in conjunction with a fluorescence microplate reader 
(Wallac 1420 Multilabel Counter). This assay has high sensitivity, compared to other 
techniques such as ethidium bromide or absorbance-based spectrophotometry assays. 
The RiboGreen™ assay affords detection of RNA concentrations as low as lng/ml, with 
a linear range extending to lpg/ml. This linearity is maintained in the presence of 
several compounds known to contaminate nucleic acid preparations, including 
nucleotides, salts and urea. The RiboGreen™ reagent is a dye solution dissolved in 
anhydrous dimethylsulfoxide (DMSO). A ribosomal RNA standard curve was prepared 
using a working solution of 2 pg/ml solution of RNA in 20X TE (200 mM Tris-HCL, 
20 mM EDTA, pH 7.5 in DEPC-treated dH20). The ribosomal RNA standard was 16S 
and 23 S rRNA from E. coli at a concentrated stock solution (100 pg/ml). Most single­
stranded RNA molecules yield approximately equivalent signals. The assay was 
performed at room temperature in disposable dark-adapted, plastic microplates.
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Qualitative assessment of RNA obtained from cell and tissue homogenates was also 
undertaken by electrophoresis on a 1.5% agarose gel (Life Technologies, UK).
2.4.2 Removal o f contaminating DNA
Genomic DNA contamination of the RNA would interfere with both the RNA 
quantification and rt-PCR quantification reaction. For example, the PCR reaction will 
amplify templates of genomic DNA as well as reverse-transcribed complementary DNA 
(cDNA). In order to remove contaminating genomic DNA, each RNA sample 
underwent treatment with RQ1 deoxyribonuclease (DNase). This endonuclease enzyme 
digests both double- and single-stranded DNA, but has no RNase activity, and therefore 
leaves the RNA intact. In the presence of Mg2+, DNase I cleaves each strand of DNA 
independently, and the sites of cleavage are random. Alternatively, in the presence of 
Mn2+, DNase I cleaves both strands of DNA at approximately the same site to yield 
fragments that are blunt ended, or have protruding termini only one or two nucleotides 
in length. The experiments in the present investigation were performed with RQ1 
RNase-Free DNase (Promega, UK) in the presenceof Mg .The DNase digestion 
reaction was as follows:-
RNA in dlUO or TE buffer 1-8 pL
RQ1 RNase-Free DNase 1 OX reaction buffer 1 pL
RQ1 RNAse-FreeDNase lpL/pgRNA
Nuclease-free dFLO to a final volume of 10 pL
The reaction mixture was incubated at 37°C for 45 minutes at which point lpL of RQ1 
DNase Stop Solution was added to terminate the reaction. The reaction mixture was 
then incubated at 65°C for 10 minutes to inactivate the DNase.
6 7
2.5 Reverse Transcription Polymerase Chain Reaction - semi- 
quantitative measurement of RNA
2.5.1 Principles o f Reverse Transcription Polymerase Chain 
Reaction
Reverse transcription of messenger RNA, coupled with polymerase chain reaction of 
cDNA, is a technique which affords information on gene expression. The reverse 
transcription polymerase chain reaction (RT-PCR) technique may be used to determine 
whether or not a particular gene is expressed in a cell type or tissue. Furthermore, RT- 
PCR may also yield quantitative information (Ferre et al 1994), and is sensitive to very 
low levels of mRNA abundance (e.g. femtomolar concentrations) (Chelly and Kahn 
1994). RT-PCR, therefore, may usefully detect very low levels of gene expression.
RT-PCR is based on the activity of a retroviral reverse transcriptase enzyme e.g Avian 
Myoblastosis Virus (AMV) (Goodman and MacDonald 1979). This enzyme utilises 
oligo deoxythymidine [oligo (dT)is] as a primer which hybridises to the poly (A) tail of 
total or poly (A)+ isolated mRNA to produce cDNA transcripts. The concentration of 
the reverse transcription reaction reagents should be adjusted to the type of reaction 
being performed. AMV Reverse Transcriptase can only hybridise to mRNA in its 
elongated secondary form, therefore the mRNA in its native coiled tertiary structure 
must be heated to temperatures of 45 - 50°C, which causes a conformational change to 
the secondary form. RT-PCR is sensitive to the concentration of magnesium sulfate. A 
magnesiun sulfate concentration in the range 1.0 - 2.5 mM is suitable for most 
applications, although this may require to be optimised for any particular experiment. 
The activity of the reverse transcriptase enzyme is optimal at 42°C. The hybridisation 
reaction should take place for 15 - 45 minutes. Subsequently, the sample should be 
heated to 99°C for 5 minutes to inactivate the AMV Reverse Transcriptase and prevent 
it binding to the cDNA (Chelly and Kahn 1994; Ferre et al 1994).
PCR is an efficient and rapid in vitro method for the amplification of specific DNA 
sequences (Mullis et al 1986). The principle of PCR is based on the properties of 
thermostable Taq polymerase, which may amplify DNA by adding nucleotides (dNTPs) 
according to specific forward and reverse primer sequences which flank the target DNA 
sequence. In RT-PCR, second strand synthesis takes place using first strand cDNA, 
generated from mRNA, as a template. These sequences should be designed to amplify
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the specific region of genomic DNA of interest. The primer sequences are 
complementary to that of the template cDNA.
PCR involves a repetitive series of cycles which, because the strand synthesised in one 
cycle serves as the template for the next, can result in a million-fold increase in the 
DNA amount from a series of 20 cycles. PCR involves initially a template denaturation 
step, typically by heating to 94°C for 2 minutes, prior to the initiation of the PCR cycle 
(Mullis et al 1986). This is then followed by second cDNA strand synthesis and 
amplification. This process consists of a cycle of denaturation at 94°C, a 
template/primer annealing step (range - 42° - 60°C) and an extension step (68°C). The 
annealing temperature (Tm) of a primer is determined by its nucleotide content. For 
primers with a high Tm it may be advantageous to increase the suggested annealing 
temperatures. Higher temperatures minimise non-specific primer-template, thereby 
increasing the amount of specific product produced. The PCR cycle is repeated, up to a 
maximum of 40-50 cycles, which results in amplification of the two-stranded cDNA 
product. The increase in cDNA product is initially linear, reaching a plateau. A 
minimum of 1 minute is usually required for every lkb of amplimer. A final period of 
extension at 68°C improves the quality of the final product by extending the truncated 
product to full length (Mullis et al 1986).
Accurate determination of absolute abundance of a specific transcript by RT-PCR 
necessitates the use of competitive RT-PCR (Chelly and Kahn 1994). This technique 
makes use of exogenous RNA transcript added during the RT reaction. This technique 
requires equal efficiency of the PCR conditions for both the competitor and target RNA. 
It is a more rigorous technique and is costly in terms of both time and consumables. 
Semi-quantitative PCR may be undertaken whereby the RT-PCR cDNA of the target 
mRNA product resolved on an agarose gel may be expressed as a ratio of an RT-PCR 
product of an internal control, such as p-Actin or glyceraldehyde -  3 -  phosphate 
dehydrogenase.
2.5.2 Reverse transcription experimental protocols
The RT reaction was performed using total cellular RNA according to a standard 
protocol (Promega 2001a). A 20 pi reaction mixture was prepared, consisting of 4 pi of 
MgCb (25 mmol/L), 2 pi of Reverse Transcription 10X Buffer, 2 pi of dNTP mixture 
(10 mmol/L), 0.5 pi of Recombinant RNasin® Ribonuclease Inhibitor, 15U of AMV
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Reverse Transcriptase, 0.5pg of Oligo (dT)i5 primer, < lpg of total RNA. The reaction 
was made up to a final volume of 20 pi by the addition of nuclease-free dH20 . First 
strand cDNA synthesis was typically performed using lOOng of total RNA. The reaction 
was set up with parallel negative controls, where the AMV RT was replaced with an 
equal volume of nuclease-free dH20 . Samples were incubated at 42°C for 30 minutes, 
then heated at 99°C for 5 minutes and finally kept at 4°C.
The final concentration of the reaction components was therefore: 5mM MgCl2, IX 
Reverse Transcription Buffer (10 mM Tris-HCL [pH 9.0 at 25°C], 50 mM KC1, 0.1% 
Triton® X-100, 1 mM dNTP, 1 p/pl Recombinant Rnasin® Ribonuclease Inhibitor, 
15p/pg AMV Reverse Transcriptase (High Concentration), 0.5pg 01igo(dT)i5 Primer 
per microgram of RNA. Pipetting steps were minimised by making up a master mix of 
these reagents using sterilised RNase-free and DNAse-free pipette tips (Gilson, U.K.).
2.5.3 PCR experimental protocols
PCR was performed, using cDNA products generated by the RT reaction, according to 
standard protocols (Promega 2001b). The first strand cDNA obtained from the RT 
reaction was diluted to IOOjliL with nuclease-free dH20 . A 50pL PCR amplification 
reaction mix was prepared. This was made up with lOpL of first strand cDNA, 2pL of 
MgCl2 (25 mmol/L), 4 \xL of Reverse Transcription 10X Buffer, 50 pmol upstream 
primer, 50 pmol of downstream primer, 2.5 units of Taq DNA polymerase and made up 
to a final volume of 50 pL by the addition of nuclease-free dH20 . Individual PCR 
preparations were aliquoted into DEPC-treated, autoclaved PCR tubes and covered with 
molecular biology-grade mineral oil (Sigma, U.K.) prior to thermal cycling. This took 
place in a Hybaid Omnigene thermal cycler according to programmes specific for each 
primer sequence.
The final concentration of the reaction components was therefore: <10ng/pL first-strand 
cDNA reaction, 200pM cDNA reaction dNTPs (carry-over from the first-strand RT 
reaction), 2mM MgCl2 (with contribution from the first-strand cDNA reaction), IX 
Reverse Transcription Buffer (lOmM Tris-HCL [pH 9.0 at 25°C], 50mM KC1, 0.1% 
Triton® X-100).
Specific primer sequences were selected for vascular cell p22 phox, p67 phox, p47phox 
and gp 91 phox. Human neutrophil and vascular cell phox DNA sequences have been
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cloned and have a high degree (>90%) of homology (Bayraktutan et al 2000). The 
forward and reverse phox primer sequences were therefore selected according to 
published DNA sequences for human neutrophil phox proteins (Jones et al 1995), and 
synthesised by Oswel DNA service, University of Southampton.
PCR primer sequences were designed for amplification of p22 phox, p67 phox, 
p47phox and gp 91 phox, based on the published human sequences. The primer 
sequences used in the present investigation were as follows:
p22 phox forward - 5'-GTTTGTGTGCCTGCTGCAGT-3'
reverse- 5' -TGGGCGGCTGCTTG ATGGT-3'
p47 phox forward - 5' -ACCCAGCCAGCACTATGTGT-3'
reverse- 5' - AGT AGCCTGTG ACGTCGTCT-3'
p67 phox forward- 5' -T ACTTCC AACG AGGG ATGCTC-3'
reverse - 5'-AGCTTTCCTCCTGGGGCT-3'
gp91 phox forward - 5'-GGTGCGGTTTTGGCGATCTCA
reverse - 5'-GGCATGTGGTCCCGGCACAG-3'
Control studies with the house-keeping genes glyceraldehyde -  3 -  phosphate 
dehydrogenase (GAPDH) and p-Actin were undertaken by simultaneously using a PCR 
reaction with specific forward and reverse primer sequences for either one or the other 
control. In this case, the primers sequences for GAPDH and P-Actin were:
GAPDH forward - 5'-ACCACAGTCCCATGCCATC-3'
reverse - 5'-TCCACCACCCTGTTGCTG-3'
p-Actin forward - 5'-TCATGAAFTGTGACGTTGACATCCGT-3'
reverse - 5'-CCTAGAAGCATTTGCGGTGCACGATG-3'
The annealing temperature (Tm) was calculated according to the following formula:
Tm= 81.5 + [16.6 x (logio [Na+]) + 0.41 x (%G+C) -  675/n
Where [Na+] is the molar salt concentration; [K+] = [Na+] and n = number of bases in 
the oligonucleotide.
PCR conditions were denaturation at 94°C for 5 minutes, annealing at 55 - 58°C for 1 
minute, and extension at 72°C for 2 minutes. This cycle was repeated 30 times, and was
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then followed by an extension at 72°C for 10 minutes. Initial RT-PCR studies were 
undertaken using cycles (n=10 - 30) in order to establish the conditions for a linear 
range. In all cases, PCR products were electrophoresed on a 1.5% agarose gel (Life 
Technologies, UK). Semi-quantative analysis was undertaken using phosphoimaging 
analysis (Biorad), with expression of the amplicon products as a ratio of either GAPDH 
or actin products.
2.6 Oxidative Fluorescent Microtopography
This technique allows the in situ localisation of O2 ' in intact blood vessels (Carter et al 
1994; Miller et al 1998). Hydroethidine (HEt) is a dye which in the presence of O2' is 
oxidised to ethidium bromide (Et). Fluorescence can then be assessed microscopically 
after exciting at 585nm wavelength. HEt is made up in dimethylsulphoxide (DMSO) as 
a 2X10-4 mol/L solution and diluted to 2x1 O'6 mol/L in PBS before use. IMA and SV 
segments (5pm) were placed on coverslips and the dye topically applied. The sections 
were then incubated at 37°C for 30 min before visualising the fluorescence under a 
microscope. The localisation of the oxidised Het, which reflects O2’ production, was 
then observed.
2.7 Immunohistochemistry
2.7.7 Background
Immunohistochemistry (IHC) is an in vitro technique which affords the detection of 
proteins within isolated tissues, by treatment with specific anti-bodies (Harlow and 
Lane 1988). Monoclonal antibodies are generated from unique hybridoma cell lines, 
which are immortal somatic cells, typically generated by the fusion of an antibody 
secreting cell and a myeloma cell (Kohler and Milstein 1975). Monoclonal antibodies 
are characterised by specific binding properties, homogeneity and their ability to be 
synthesised in unlimited amounts. IHC is, therefore, a powerful technique for the 
identification of a specific epitope within different tissues and cell types. Monoclonal 
antobodies may be expensive, difficult to use and have a low antigen affinity. As such 
certain monoclonal antibodies may not be sensitive for epitope detection in certain 
tissue preparations. In such instances, polyclonal antibodies may be a more suitable 
alternative (Harlow and Lane 1988). Antibody-antigen binding should take place in a 
solid phase matrix, unless the primary antibody is biotinylated, in which case it may
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bind to the antigen in solution. In this case, the primary antibody can be detected by 
labelled reagents, such as avidin or streptavidin, which are biotin-binding proteins. 
Immunodetection studies may be direct, in which a primary antibody is labelled, or 
indirect, in which case the primary antibody must be bound by a secondary, labelled, 
anti-immunoglobulin. The direct technique may be less sensitive, but easier to use, 
whereas the indirect technique utilises primary antibodies which have not been modified 
(and therefore have optimal activities) and secondary, labelled antibodies with a wide 
range of applications. In terms of chromogenic labels, enzymes such as horse-radish 
peroxidase (HRP), have a high degree of sensitivity, a reasonably long shelf life and 
direct visualisation is possible, although may not yield sufficient resolution for 
cytochemical analyses. In this case, HRP-labelled antibodies can be revealed by 
treatment with substrates such as diaminobenzidine (DAB), which readily reacts with 
HRP, yielding a brown reaction product. Biotin labels have high sensitivity, a long 
shelf-life and have universal application in different tissues and cells (Kohler and 
Milstein 1975). Avidin and streptavidin have tetravalent binding sites which means the 
additional binding sites can be used to increase the strength of the detection complex.
2.7.2 Immunodetection methods
Immunodetection studies were performed in frozen and paraffin-embedded 5 pm 
sections of intact IMA. P22phox and gp91phox were identified using specific mouse 
monoclonal antibodies (kindly provided by Dr MT Quinn, Montana State University, 
MT) whereas, p47phox and p67phox proteins were identified by use of rabbit anti-sera 
(Upstate Biotechnology, N.Y.). Slides were placed in acetone for 15 minutes then 
washed in phosphate buffered saline (PBS; Sigma, UK). Sections were demarcated on 
the glass slide by a ring made with a wax pen. Endogenous peroxidase activity in the 
sections was quenched by incubation with 3% hydrogen peroxide:methanol (1:1) for 30 
minutes. Non-specific antibody binding was blocked by incubation of the tissue sections 
with antigen unmasking solution. This blocking buffer was made with 10% serum of the 
species in which the secondary antibody was raised. Secondary antibodies (biotinylated 
anti-mouse and biotinylated anti-rabbit) were applied for 30 minutes. The sections were 
then treated with streptavidin-horseradish peroxidase (Sigma), diluted to 1:400 in PBS 
and treated with 3,3'-diaminobenzidine (Sigma, UK) in 0.01% hydrogen peroxide in 
PBS (pH 7.6) for 1 hour in the dark. Finally, slides were treated with haematoxylin and 
eosin and fixed with dibutylpthalate xylene (DPX) (BDH Laboratory Supplies, UK). 
Experiments were performed between 3 and 5 times with each vessel providing its own,
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untreated control.
In addition, immunohistochemical studies were undertaken in order to determine the 
presence or absence of macrophages and granulocytes within sections of IMA. 
Immunocytochemical detection of CD68, (1:100) Mac 387 (1:500) and Kpl (1:100) was 
performed on formalin fixed paraffin embedded sections of IMA along with light 
microscopic evaluation of haematoxylin and eosin stained sections (Townsend et al 
1999).
2.8 Isometric tension studies in small resistance arteries
Resistance arteries are those blood vessels which contribute the greatest resistance to 
blood flow, and are therefore most involved in regulating blood flow and capillary 
pressure (Mulvany and Aalkjaer 1990). SRA wire myography is an in vitro technique 
which allows resistance arteries with a diameter of 100 -  500pm to be studied under 
precise and standardised conditions. Use of this technique yields information on the 
contractile or relaxant properties, and morphology, of SRA under isometric tension 
(Mulvany and Aalkjaer 1990; Mulvany and Halpem 1977). In the present investigation, 
functional studies were undertaken with SRA because of the physiological importance 
of these blood vessels. Wire myography was employed for these studies because this is 
an established technique in our laboratory (Hillier et al 1999; Padmanabhan et al 1999), 
in which several arteries may be studied at any one time, using one or more protocols.
Human SRA were isolated from within the subcutaneous fat obtained at the time of 
inguinal hernia repair. A single biopsy may yield several blood vessels (average 2 -  4). 
Isolated SRA were divided into segments approximately 2mm long. When possible, 
four resistance arteries, were carefully mounted on two 40 pm-diameter stainless steel 
wires and mounted in the bath of a 4-channel myograph (Halpem & Mulvany, Aarhus), 
in which the wires are attached to a force transducer and micrometer, respectively. The 
bath contained Krebs buffer which had been gassed and pre-heated at 37°C, and these 
conditions were maintained for the duration of the experiment. In addition the Krebs 
buffer was regularly changed throughout the experiment.
2.8.1 Set-up and normalisation procedures
After a rest period of 30 minutes, a normalisation procedure was followed for each 
artery to determine the normalised internal diameter (ID), L0, at which contraction is
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thought to be optimal, and the vessel was set to that diameter (Mulvany and Halpem 
1977). In the present study, arteries with a normalised ID of 200 -  400pm were used. 
After a rest period of 30 minute each artery was stretched at 1 minute intervals to 
determine the passive exponential, wall tension-internal circumference (L) relationship. 
From the Laplace equation, where P=T/r (P is the effective pressure, T is the wall 
tension and r is the internal radius), the equivalent circumference (Lioo) for a transmural 
pressure of lOOmmHg, was calculated for each artery by an iterative computer method. 
Each artery was then set to the normalised internal diameter, Li=0.9 xL ioo/tt, at which 
contraction is thought to be optimal (Mulvany and Aalkjaer 1990; Mulvany and Halpem 
1977).
Following normalisation, the vessels were left for a further hour. They were then 
exposed to a high (123 mM) concentration of potassium (KPSS, solution identical to 
PSS except that sodium was replaced by potassium on an equimolar basis) for a series 
of 5 minute periods until repeatable maximal contractions were achieved, and then once 
to 10 pmol/L of norepinephrine (NE). After a plateau contraction had been attained with 
NE, 3 pmol/L of acetylcholine (ACh) was added to stimulate endothelium-dependent 
vasodilatation. Arteries that were unable to contract to either KPSS or NE or showed no 
relaxation to ACh (and were therefore considered to have no functionally intact 
endothelium) were discarded. The arteries were then incubated for a further 30 minutes 
in Krebs solution prior to the commencement of the concentration-response curves 
(CRC) incorporated in the study protocol.
2.9 Measurement of free radical concentrations in human 
blood vessels
Of the variety of free radicals which are generated within vascular tissue, the O2’ and 
OH anion radicals are reported to be present in physiologically important 
concentrations (Wolin 2000). Superoxide, in particular, is reported to be an important 
determinant of bioavailable NO.
This chapter describes studies undertaken to characterise the nature of lucigenin- 
enhanced chemiluminescence. Lucigenin-enhanced chemiluminescence has recently 
been criticised due to the potential for redox cycling by lucigenin. In this case, in vitro 
studies have suggested that in certain conditions, lucigenin may act as a reducing agent, 
by serving as a potential source of electrons for the reduction of molecular oxygen to
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O2' (Liochev and Fridovich 1997; Liochev and Fridovich 1998). At the inception of this 
study, the author was not aware of any data on the direct measurement of O2’ 
concentrations in human blood vessels using lucigenin-enhanced chemiluminescence. 
For these reasons, a series of systematic validation studies were undertaken in order to 
characterise lucigenin enhanced chemiluminescence as a measure of O2' production in 
intact human blood vessels.
2.9.1 Chemiluminescence
Lucigenin-enhanced chemiluminescence is a widely-used technique for the 
measurement of 0 {  concentrations in vitro. Previous studies used lucigenin-enhanced 
chemiluminescence to measure O2’ concentrations in vitro using either cultured cells, or 
in vascular tissues obtained from experimental animals.
The amount of lucigenin-enhanced chemiluminescence in vascular tissue is a function 
of both the rate of O2 ' production by endogenous enzymes, and the rate of O2' removal, 
by for example, dismuation by SOD. Brandes et al (1997) attempted to characterise O2’ 
production in intact pig coronary artery segments, using lucigenin-enhanced 
chemiluminescence. In these studies, artery segments were approximately 3 mm long, 
were placed in 600 pL of aerated Krebs buffer at pH 7.4 and the light reaction between 
O2'  and lucigenin (250 pM) was detected in a scintillation counter during a 5 minute 
period. The counts for this period were corrected by background subtraction. Counts per 
minute were plotted against a xanthine- xanthine oxidase calibration curve and 
expressed as production of O2' (pmol) per minute per milligram of dry-blotted tissue.
The experimental conditions in this system were characterised and validated (Brandes et 
al 1997). A cell-free xanthine-XOR assay for O2’ generation was investigated and 
found to generate O2' with linear increments in association with increasing 
concentrations of xanthine, provided the concentration of XOR was low (< ImU/ml). 
This signal could be completely inhibited by co-treatment with the XOR inhibitor, 
oxypurinol, or the specific O2' scavenger (4-5 dihydroxy-1, 3-benzene disulphonic acid 
salt [Tiron], 10 mmol/L). In addition the protocols also included measurement of the 
effect of pH, and stimulation or inhibition of vascular O2" production. Acid-base status 
of the phosphate buffer was adjusted by the addition of either NaOH or HC1 to various 
pH values in a range from 7.0 to 8.0. An increase in pH was associated with an increase 
in chemiluminescence signal with a change of 200% across this range. In studies in 
intact pig coronary arteries, these investigators also observed that treatment with
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substrates for enzymes believed to be involved in O2’ production, namely NAD(P)H 
oxidase and XOR, were associated with increases in the chemiluminescence signal, 
these being inhibited by co-treatment with Tiron. There are few data on the direct 
measurement of ROS concentrations in human blood vessels. Given the findings of 
Brandes et al (1997), the experimental conditions in relation to the measurement of O2" 
concentrations in human blood vessels using lucigenin-enhanced chemiluminescence 
were also characterised and validated.
2.9.2 Characterisation o f lucigenin-enhanced chemiluminescence
An initial subset of twenty conduit blood vessels underwent analysis by an experienced 
vascular pathologist, who confirmed the presence of an intact endothelium and the 
absence of atherosclerotic disease.
In order to investigate the effects of temperature, pH, lucigenin concentration and 
incubation time on O2’ concentrations in vascular tissues, a number of exploratory 
studies were also performed. Given the limited availability of human vascular tissue, 
fresh aortic segments obtained from Sprague Dawley rat were studied. As a first step, 
the effects of environmental factors, such as pH and temperature, on 0 2 ' concentrations, 
as measured by lucigenin-enhanced chemiluminescence, were determined in both a 
cell/tissue-free system, and in other studies using rat aortic segments. Lucigenin (Sigma, 
UK) was added to Krebs buffer, which had been maintained at either room temperature 
(18°C) or body temperature (37°C), in liquid scintillation vials (Packard, U.K.) in order 
to make a final lucigenin concentration of either 5 pM or 250 pM. The vials were then 
maintained at either room temperature or were placed in an incubator at 37°C prior to 
being placed in a scintillation counter.
2.9.3 Effects of pH, temperature and lucigenin concentration on 
superoxide concentrations in a cell-free system
I first sought to determine the effect of pH, temperature and lucigenin concentration on 
the chemiluminescence signal measured in the absence of cells or tissues. This 
‘background signal’ is represented by ROS generation within the aqueous buffer. The 
data in Table 1. represent results of chemiluminescence studies undertaken using Krebs 
buffer alone. Liquid scintillation vials were filled with 2 ml of Krebs buffer and placed 
in an incubator and maintained at 37°C for either 1 hour or 4 hours prior to the addition
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of lucigenin and quantification of counts in a liquid scintillation counter (Hewlet 
Packard Tricarb 2100TR).
In these studies (Table 2.1), buffer pH was comparable between vials maintained at 
either 18°C or 37°C. By contrast, there was a tendency for the pH of the buffer to rise 
with increasing concentrations of lucigenin. At 37°C, counts tended to fall, be it in the 
absence or presence of either 5 pmol/L or 250 pmol/L lucigenin, with duration of 
incubation. Furthermore, when studies were performed after incubation of the vials for 
1 hour, counts in vials allowed to stand on the bench till the buffer temperature fell 
18°C tended to be lower than those measured in vials maintained at 37°C. These data 
suggest that chemiluminescence counts may be affected by duration of incubation and 
buffer temperature.
2.9.4 Effect o f pH , temperature and lucigenin concentration on 
superoxide concentrations in vascular tissues
In order to determine whether or not pH, temperature and lucigenin concentration 
affected chemiluminescence counts from vascular tissues, experiments were undertaken 
using rat aortae. In this case, rat tissues were used given the limited availability of 
human blood vessels. Fresh aortae, which had been harvested from sacrificed, Sprague 
Dawley rats, were divided into segments approximately 5 mm length, weighed and 
placed into scintillation vials containing 2 ml of Krebs buffer. The vials were then 
incubated at 37°C for either 1 hour or 4 hours which was then followed by the addition 
of lucigenin and quantification of counts in the scintillation counter. Data are presented 
as either the results of single measurements or in summary form (mean +/- standard 
error of the mean).
The results of these studies are presented in Table 2.2. In every case, the pH was higher 
in vials maintained at 18°C compared to those at 37°C, which was in contrast to earlier 
studies undertaken with buffer alone. As before, buffer pH tended to rise with duration 
of incubation. Although absolute counts increased with duration of incubation, no 
differences were observed when these values were corrected for tissue weight.
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Table 2.1 Effect of lucigenin concentration, pH of the incubation buffer, and 
temperature on chemiluminescence counts in the absence of vascular tissue.
Time
(hours)
Lucigenin
concentrations
(pmol/L)
pH at 37°C pH at 18°C CL count 
at 37°C
CL count 
at 18°C
0 0 7.55 7.65 83312
5 7.68 7.68 110018
250 7.72 7.72 108612
1 0 7.56 7.57 81304 78325
5 7.45 7.45 90056 84172
250 7.76 7.76 80240 76596
4 0 7.55 7.55 52248
5 7.82 7.82 51348
250 7.55 7.55 51892 56700
CL - chemiluminescence
2.9.5 Selective augmentation and depletion o f superoxide 
concentrations in human blood vessels
It has been previously reported that lucigenin-enhanced chemiluminescence is both a 
sensitive and specific measure of O2’ production from neutrophils (Gyllenhammar 
1987). I sought to determine, therefore, whether this might also be the case in human 
blood vessels.
Simple pharmacological studies were undertaken in order to determine whether
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selective augmentation and depletion of vascular O2’ concentrations in human blood 
vessels could be predictably measured using lucigenin-enhanced chemiluminescence 
techniques. Lucigenin itself has been reported to generate O2’ at higher concentrations 
(Liochev and Fridovich 1997; Liochev and Fridovich 1998). Therefore, a range of 
lucigenin concentrations was also used to assay O2" in a series of samples from single 
vessels using xanthine/xanthine oxidase (Sigma, UK) calibration curves, with the 
appropriate concentration of lucigenin in each sample.
Fresh IMA and SV were divided into 5 mm segments and weighed. Initially, studies 
were undertaken to determine whether or not lucigenin-enhanced chemiluminescence 
might increase when O2* concentrations are enhanced. Paired segments from the same 
blood vessel were placed in scintillation vials in either the absence (2 ml of Krebs 
buffer) or presence 100 pmol/L of the SOD inhibitor, DETCA (Sigma, UK). 
Superoxide concentrations were then quantified by lucigenin-enhanced 
chemiluminescence. In both IMA and SV, counts were increased by this treatment 
(Figure 2.2). Treatment with lOOpmol/L of DETCA increased O2 ' steady state 
concentrations in IMA (control 853 ± 208, DETCA 100 pmol/L 1492 ± 347; n=8, 
p=0.021, 95% Cl 186, 1149 and SV (control 551 ± 145, DETCA 100 pmol/L 945 ± 
245; n=14, p=0.002, 95% Cl 67, 694).
These data demonstrate that pharmacological inhibition of SOD in IMA and SV results 
in an increase in lucigenin-enhanced chemiluminescence, in keeping with the rise in 
vascular O2" concentrations that will have occurred with this treatment. Furthermore, 
these data also demonstrate that O2 ' production is greater in conduit arteries, than in 
veins. One reason for this may be because these arteries have a proportionately greater 
content of VSMC, than do veins.
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There is considerable inter- and intra-individual variation in O2’ production by both 
arteries, and veins. This is reflected by the considerable variability in O2’ concentrations 
that was observed in these vascular tissues. This intra- and inter-subject variation in 
vascular O2 ' concentrations may arise for a number of reasons. These tissues are ex vivo. 
In addition, there are several ‘handling’ steps, including surgical manipulation, variation 
in time to harvest, transfer to the laboratory, and subsequent handling, including, for 
example, debridement of surrounding connective tissue and variation in time to 
measurement. For these reasons, every effort was made to standardise the handling steps 
for these blood vessels in the laboratory.
In other studies, undertaken to determine whether or not lucigenin-enhanced 
chemiluminescence might detect a reduction in vascular 0 {  concentrations, paired blood 
vessels were incubated in the absence (2 ml of Krebs buffer) or presence of the free 
radical scavenger (4-5 dihydroxy-1, 3-benzene disulphonic acid salt [Tiron], 10 mmol/L; 
Sigma, UK) and incubated at 37°C for 1 hour. In this case, the counts were reduced by 
this treatment (Figure 2.3). Tiron 10 mmol/L, reduced basal O2 ' concentrations in both 
IMA (control 1937 ±412, Tiron lOmmol/L 901 ± 94; n=9, p=0.018, 95% Cl -1919, - 
238) and SV (350 ± 85, Tiron lOmmol/L 149 ± 39; n=13, p=0.002, 95% Cl -311, -95). 
In this case, treatment of these blood vessels with a scavenger of O2’, was associated 
with a reduction in concentrations in both IMA and SV.
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□  IMA C ontro l
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□  S V  C ontro l
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IMA SV
DETCA - diethylenethiocarbamate, an inhibitor of superoxide dismutase;
IMA - internal mammary artery; SV - saphenous vein;
Figure 2.2 The effect o f inhibition o f SOD in IM A (n=8) and SV (n=14) by treatm ent 
w ith 100 pm ol/L  o f  DETCA. Each colum n represents m ean O 2 generation in 
pm ol/m in/m g tissue. Error bars represent standard error o f  the m ean (SEM ).
2.9.6 Effect of different concentrations of lucigenin on superoxide 
concentrations in human blood vessels
In other studies, O 2 ' concentrations were com pared in sam ples obtained from  a single 
blood vessel. Superoxide production in IM A w as sim ilar w ith  either a lucigenin 
concentration o f  5 pm ol/L  (1715 ± 343 pm ol/m in/m g) or 250 pm ol/L  (1410 ±  93 
pm ol/m in/m g; n=6, p=0.59). In SV, sufficient tissue was available to assess the effect o f 
lucigenin on O 2 ' production at a range o f  lucigenin concentrations (5, 15, 50, and 250 
pm ol/L). In this case, in each experim ent all SV segm ents were obtained from  a single 
length o f  blood vessel such that variation in 0 {  concentrations betw een sam ples was 
m inim ised given. Superoxide production* was 311 ±  67 pm ol/m in/m g w ith 5pm ol/L  
lucigenin, 208 ± 27 pm ol/m in/m g with 15 pm ol/L  lucigenin, 300 ±  33 pm ol/m in/m g with 
50 pm ol/L  lucigenin and 241 ± 50 pm ol/m in/m g w ith 250 pm ol/L  (n=10 for each
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lucigenin concentration; NS between all groups).
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Figure 2.3 The effect o f  superoxide scavenging by treatm ent o f  IM A (n=9) and SV 
(n=13) w ith 1 m m ol/L  o f  Tiron. Each colum n represents m ean O 2 ' generation in 
pm ol/m in /m g tissue. E rror bars represent standard error o f  the m ean (SEM ).
2.9.7 Summary of validation studies of lucigenin-enhanced 
chemiluminescence in human blood vessels.
T he data obtained from the studies o f lucigenin-enhanced chem ilum inescence in a cell 
and  tissue free system , suggested that the lucigenin-enhanced chem ilum inescence counts 
fell w ith duration o f  incubation. H igher concentrations o f  lucigenin tended to be 
associated  w ith higher values o f  pH, although this was not consistently  the case with 250 
p M  o f  lucigenin after 4 hours incubation. Interestingly, in these studies, the counts were 
n o t greater w ith higher concentrations o f lucigenin. This latter observation contrasts with 
o ther reports w hich observed that counts increased with increasing concentration o f  
lucigenin , which could be attributed to redox cycling by lucigenin itse lf (Liochev and
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Fridovich 1997; Liochev and Fridovich 1998).
In the present study, the data obtained from using different concentrations of lucigenin in 
human IMA and SV demonstrate that O2’ production in these blood vessels was not 
affected by the concentration of lucigenin under these conditions. Lucigenin-enhanced 
chemiluminescence has been previously used in our laboratory in order to measure 
vascular (V  concentrations in other experimental animal studies (Grunfeld et al 1995; 
Kerr et al 1999). The data obtained from measurements using this technique have 
generated reproducible results which have been utilised in a variety of pharmacological 
studies of vascular ROS in the SHRSP and WKY rats.
In other studies, pharmacological manipulation of vascular O2’ concentrations resulted in 
predictable increases and reductions in chemiluminescence counts. These conclusions are 
based on the fact that treatment with DETCA causes specific inhibiton of SOD, and 
therefore a selective increase in O2' concentrations, whereas treatment with Tiron results 
in selective scavenging of O2'. DETCA is a copper-chelating compound which augments 
vascular O2* concentrations through inhibiton of both intra -  and extracellular Cu/Zn 
SOD. In vitro studies in rabbit aortae by Mackenzie and Martin (1998) confirmed that 
low concentrations (300 pmol/L) of DETCA selectively inhibit extracellular Cu/Zn 
SOD, as impaired ACh-induced, NO-dependent vasorelaxation could be restored by 
treatment with SOD (250 U/ml). At higher concentrations of DETCA (e.g. 3 mmol/L), 
the predominant effect of this treatment was inhibition of intracellular Cu/Zn SOD, as 
impaired vasorelaxation could only be reversed by treatment with a membrane permeant 
SOD mimetic (MacKenzie and Martin 1998). Only a very minor component of the pro­
oxidant effect of DETCA is due to non-selective effects, such as depletion of glutathione 
and generation of lipid peroxides (Kelner et al 1989). On the other hand, Tiron is a 
selective, membrane permeant scavenger of O2’ (Ledenev et al 1986). Lucigenin- 
enhanced chemiluminescence, has therefore, resulted in observations in keeping with the 
expected pharmacological effects of these treatments. Taken together, these data indicate 
that lucigenin-enhanced chemiluminescence is both a sensitive and specific tool for the 
detection and measurement of O2' concentrations in human IMA and SV.
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3 Sources of superoxide production in hum an blood 
vesse ls
3.1 Summary
The enzymatic sources, and distribution, of ROS generation, in human blood vessels are 
not known. In this chapter, experiments undertaken to characterise the enzymes involved 
in O2’ production, and their location in human conduit blood vessels, will be described. 
In addition, studies were undertaken to characterise endogenous ROS scavenging 
systems in these blood vessels.
3.2 Methods
IMA, RA and SV samples were prepared for measurement of O2" production by 
lucigenin-enhanced chemiluminescence according to methods described in section 2.1,
2.2.1 and 2.5.3. Firstly, O2' concentrations were measured in a consecutive series of 
IMA, RA and SV. Secondly, a series of basic pharmacological studies were undertaken 
using IMA and SV, in which inhibitors of NAD(P)H oxidase, XOR and eNOS were used 
to determine whether or not these enzymes contributed to basal O2 ' production. Thirdly, 
oxidative microtopography studies were undertaken in IMA and SV in order to 
characterise the location and distribution of O2’ production within the wall of these blood 
vessels. Finally, an additional aim was to quantify the amount of SOD protein present in 
arteries and veins using western blotting techniques in order to assess whether SOD 
expression might account for any differences in O2 ' measured.
3.2.1 Pharmacological studies
In order to investigate the enzymatic sources of O2’ generation in human blood vessels, 
IMA and SV were incubated for 1 hour at 37°C in the absence (control) or presence of an 
inhibitor of NAD(P)H oxidase, diphenyleneiodonium ([DPI; Sigma, UK], 10 pmol/L, 
100 pmol/L and 200 pmol/L), an inhibitor of eNOS (N®-Nitro-L-arginine methyl ester,
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[L-NAME; Sigma, UK] 100 pmol/L), or an inhibitor of XOR (allopurinol [ALP; Sigma, 
UK] lmmol/L). DPI and ALP were dissolved in dimethylsuphoxide (DMSO), whereas 
all other drugs were dissolved in Krebs buffer. For studies with DPI and ALP, the 
appropriate concentration of DMSO was added to control samples. In addition, some 
vessels were denuded of endothelium by careful rubbing of the vessel lumen with fine 
forceps. The absence of the endothelium and integrity of the vessel wall was confirmed 
by histological analysis in a subset of 20 vessels.
3.2.2 Protein quantification studies
Five millimeter segments of vessels were homogenised in 200 pi of a boiling vanadate 
buffer (1% SDS, 1 mmol Na3V0 4 , 10 mM Tris, pH 7.4). Following centrifugation at 
14,000 g for 60 seconds the supernatant was withdrawn and the protein concentration 
measured. Ten micrograms of protein and pre-stained molecular weight standards were 
separated by sodium dodecyl sulphate polyacrylamide gel electrophoresis using a 12% 
gel (Life Technologies, UK). The proteins were transferred overnight onto a 
polyvinylidene difluride (PVDF) membrane and sequentially probed with sheep 
monoclonal anti-CuZn SOD, or rabbit polyclonal anti -MnSOD or anti-actin antibodies. 
Protein bands were visualised using enhanced chemiluminescence (GS-525 Biorad- 
Laboratories Ltd). Anti-human MnSOD was a gift-from Professor Taniguchi (University 
of Osaka, Japan) and anti- human CuZn SOD was purchased from Calbiochem (UK).
3.2.3 Oxidative microtopography
IMA and SV segments (5 pm) were placed on coverslips and the hydroethidine dye 
topically applied. The sections are then incubated at 37°C for 30 mins before visualising 
the fluorescence under a microscope. The localisation of the oxidised Het, which reflects 
O2' production, was then observed.
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3.2.4 Statistical analyses
Data are described as mean +/- S.E.M or as % change from controls to facilitate 
comparison between groups. Statistical analyses of vascular O2' concentrations were 
undertaken using the Wilcoxon Signed-Rank Test. The relationships between risk factors 
and basal vascular O2' concentrations were determined by use of the Pearson’s 
correlation coefficient (r). Results of statistical analyses are presented with both a 
probability (P) value and 95% confidence intervals (95% Cl). A P value of < 0.05 was 
considered statistically significant.
3.3 Results
3.3.1 Patient characteristics
The study population consisted of two hundred and forty four patients with CAD who 
consecutively underwent CABG in our hospital over a 14 month period. Data on age, 
sex, risk, factors for atherosclerotic vascular disease, and drug therapy are given in Table 
3.1. Patient age ranged from 33 to 80 years. Seventy five percent of patients had one or 
more risk factor for CHD and 92% of patients were on one or more type of anti-anginal 
therapy.
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Table 3.1 Patient characteristics, including risk factors and therapy.
Males, n (%) 179 (73)
Females, n (%) 66 (27)
Mean age, y 62±8
Risk factors, n (%)
Smoking 43 (18)
Hypertension 82 (34)
Diabetes mellitus 26(11)
Hypercholesterolemia 180 (74)
Plasma cholesterol, mmol/L (mean±SD) 5.4 ±1.4
Medication, n (%)
Aspirin 203 (83)
p-Blockers 136 (56)
Calcium channel blockers 145 (60)
HMGCoA Reductase Inhibitors 127 (52)
Nitroglycerin 148 (61)
Renin angiotensin system inhibitors 54 (22)
3.3.2 Measurement o f superoxide anion concentrations in IMA, RA 
and SV
Mean O2’ production was greater in arteries than in veins: IMA 1922±235 pmol/min/mg 
(n=55), SV 662±179 pmol/min/mg (n=58); pO.OOOl (Figure 3.1).
9 0
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2000i
0.0001
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■  IMA
1000- □  RA
g  SV
500-
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n=28 n=7 n=35
V e s s e  I
Figure 3.1 M ean O 2 ' production in internal m am m ary arteries (IM A), radial arteries 
(RA) and saphenous veins (SV). Error bars represent standard error o f  the m ean (SEM ).
3.3.3 Characterisation of the sources o f superoxide anion production
The N A D (P)H  oxidase inhibitor, DPI (concentration range 10-200 pm ol/L ), attenuated 
0 2' generation in both arteries (Figure 3.2; Table 3.2) and veins (Table 3.3). The effects 
o f endothelial denudation by rubbing, and inhibition o f  eNO S by incubation with L- 
NA M E, on O 2" concentrations in IM A and SV were m ore variable (Table 3.2 & 3.3). 
NOS inhibition (Figure 3.4) was associated with a sm all reduction in basal O 2 ' 
concentrations in both IM A and SV, which approached statistical significance. 
Incubation o f  IM A with 100 pm ol/L  o f  L-N A M E and endothelial denudation reduced 
O 2" concentrations in 7/10 and 6/10 patients respectively. In SV, these treatm ents
in IMA and SV
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corresponded with a reduction in O2’ concentrations in 12/16 and 10/14 patients. 
Sufficient tissue was available in veins to study the effects of L-NAME treatment and 
endothelium removal by rubbing in vessel segments from the same patients. In these 
studies, both manipulations had similar effects on O2’ concentrations in individual 
patients (r = 0.85; n=12 p<0.001). Furthermore, the difference in O2' concentrations 
between IMA and SV was maintained after both endothelial denudation and eNOS 
inhibition.
Table 3.2 Effect of inhibition of NAD(P)H oxidase, xanthine oxidase and nitric 
oxide synthase and of endothelial denudation on O2' production in IMA.
O2- generation 
(pmol/min/mg)
Treatment n Control Treated % Change p value and 95% Cl
DPI lOpM 8 965±150 616±212 -36±17 0.14; -808, 239
DPI lOOpM 8 2723±696 1568±430 -39±13 0.03;-2515,-137
ALP 1 mmol/L 9 2120±629 1024±290 -42±10 0.013;-2020, -330
L-NAME lOOpM 10 1990±508 1420±304 -29 ±16 0.1;-1421, 67
ED 10 643±134 647±145 -3±10 0.55;-183, 153
Data are shown as mean ± SEM. Saphenous vein (SV). Diphenyleneiodonium (DPI), 
allopurinol (ALP) and N^-Nitro-L-arginine methyl ester, (L-NAME) are inhibitors of 
NAD(P)H oxidase, xanthine oxidase and endothelial nitric oxide synthase enzymes, 
respectively. ED -  endothelial denudation
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Table 3.3 Effect of inhibition of NAD(P)H oxidase, xanthine oxidase and nitric 
oxide synthase and of endothelial denudation on O2’ production in SV.
O2- generation 
(pmol/min/mg)
Treatment n Control Treated % Change p value and 95% Cl
DPI lOpM 10 184±25 116±28 -34±16 0.037; -124, -7
DPI lOOpM 14 759±140 469±94 -37±6 0.001;-519,-103
DPI 200pM 8 452±126 228±73 -47±7 0.014; -394, -59
ALP ImM 13 759±173 426±107 -32±8 0.003; -673, -57
L-NAME lOOpM 16 284±44 214±36 -20 ±13 0.06; -148, 5
ED 14 324±48 250±40 -15 ±9 0 0 1 1 OO
ED + DPI lOOpM 9 787±259 477±136 -29±9 0.018; -671,-3
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F igure  3.2 Effect of NAD(P)H oxidase inhibition on mean 0 2 concentrations in IMA 
and SV.
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F igure  3.3 Effect of XOR inhibition on 0 2 concentrations in IMA and SV. Treatment 
allopurinol (ALP, 1 mmol/L), attenuated 0 2 production in both IMA and SV.
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Figure 3,4 Effect of NOS inhibition on superoxide concentrations in IMA and SV.
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Figure 3.5 Effect of endothelial denudation on O 2 concentrations in IMA and SV. 
Endothelial denudation had no effect on O 2 'concentrations in either IMA or SV
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3.3.4 Oxidative microtopography
Superoxide production was demonstrated throughout the wall of both IMA and SV. 
These images suggest that ROS generation occurs throughout the vascular wall, 
including the adventitia and endothelial layers (Figure 3.6).
Lum en
Lum en
Internal Mammary Artery Saphenous Vein
Figure 3.6 Identification of O 2 production in a section IMA and SV with 
hydroethidine fluorescence.
3.3.5 Quantification of SOD proteins
Immunoblotting showed that single bands were detected for both M nSOD and CuZn 
SOD (Figure 3.7). The intensity of CuZn SOD bands relative to an actin control was 4.04 
± 0.31 in arteries vs. 3.59 ± 0.23 in veins (p=0.055). Mn SOD expression was found to 
have relative intensities of 3.14 ± 0.25 vs. 3.87 ± 0.42 (p=0.056) in arteries and veins 
respectively.
96
A B
CuZn SOD
Arbitrary 4 
Units of o 
SOD
Relative to 2 
Actin
IMA i
CuZn SOD □  
MnSOD m
Figure 3.7 Quantification o f  intracellular SOD proteins in hum an IM A and SV. (A) 
Scanned images o f  representative western blots o f  CuZn SOD, M nSO D  and actin 
proteins. (B) D ensitom etric quantification o f  CuZn SOD and M nSO D  w estern blots 
expressed as a ratio o f  actin.
3.4 D iscussion
W e have shown that basal 'O 2* concentrations are greater in hum an IM A  than SV and 
have dem onstrated that both N A D (P)H  oxidase and X O R  enzym es contribute to basal 
O 2" production in these vessels. Furtherm ore, we report that SOD proteins are 
quantitatively sim ilar in hum an IM A  and SV.
W e sought to characterise the m echanism s o f  O 2’ production in hum an IM A and SV. 
Endothelial NOS activity was inhibited by rem oval o f  the endothelium  by rubbing and 
by incubating vessels w ith L-NA M E, however, these treatm ents failed to reduce O 2’ 
steady state concentrations in all patients. The lack o f  effect o f  these treatm ents on 02* 
production in the blood vessels o f  some patients suggests that V SM C and adventitial 
fibroblasts were alternative sources o f  O 2’ generation. Conduit arteries have a
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proportionately greater content of VSMC than conduit veins, which may explain the fact 
that O2 ' generation is greater in arteries, compared to veins. Inhibition of NAD(P)H 
oxidase and XOR, by incubation of arteries and veins with DPI and ALP respectively, 
resulted in similar reductions in basal O2' steady state concentrations in both of these 
tissues. This suggests that both NAD(P)H and XOR are sources of O2’ generation in 
human arteries and veins.
The balance between O2’ generation and degradation determines O2 ' steady state 
concentrations. In this study, the levels of MnSOD and CuZn SOD proteins were 
qualitatively different in arteries and veins, but overall, total SOD protein was 
quantitatively similar. Taken together with our results this would suggest that the 
elevated concentrations of O2" observed in arteries compared with veins were not a 
consequence of a reduced capacity for enzymatic removal, but occurred through 
increased O2" production.
Observations from in vitro studies suggest that the activity of XOR may be increased in 
endothelial cells subject to ischemia-reperfusion injury (Harrison 2000; Phan et al 1989). 
Findings from in vivo human studies suggest that patients with risk factors for CAD also 
have increased vascular XOR-mediated O2" production, which may contribute to 
impaired endothelium dependent vasodilation in these patients (Cardillo et al 1997). 
When considered with our findings, this suggests that XOR may be an important source 
of vascular O2 production in patients who have CAD.
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4 Effect of angiotensin II on superoxide anion 
concentrations in human blood v esse ls
4.1 Summary
Given that the enzymatic sources of O2’ production in human blood vessels had been 
described, I subsequently sought to determine whether or not vascular O2' concentrations 
might be augmented by vasoactive hormones, such as angiotensin II (Ang II). This 
chapter provides a detailed description of the experiments performed using lucigenin- 
enhanced chemiluminescence to characterise the effect of Ang II on O2’ concentrations 
in human IMA and S V.
4.2 Methods
4.2.1 Lucigenin-enhanced chemiluminescence
IMA and SV samples were prepared for measurement of O2" production by lucigenin- 
enhanced chemiluminescence according to methods described in Chapter 2 (sections
2.5.1 and 2.5.6). Blood vessels were incubated in the absence (control) or presence of 1 
pmol/L, 1 nmol/L and 1 pmol/L of Ang II for 1 and 4 hours. Functional integrity of the 
vessels was not compromised by this incubation. IMA were also incubated with 1 
pmol/L of Ang II for 15 minutes. In order to assess the effects of a positive control, IMA 
were incubated in the absence or presence of 1 pmol/L of norepinephrine (NE), for 4 
hours.
Additional studies were undertaken in order to determine whether or not any effect of 
Ang II on O2' production could be receptor specific. IMA were co-incubated with 1 
pmol/L of Ang II and either an ATi specific and competitive receptor antagonist
1 ft(losartan 1 pmol/L) or a non-specific receptor antagonist (sar thre Ang II 1 pmol/L) 
(Criscione et al 1990). NE and [sar1, thre8]-Ang II and were purchased from Sigma
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(Poole, UK), whereas, losartan was obtained as a gift from Merck, Sharpe and Dome 
(UK). In subsequent studies, the role of the AT2 receptor in relation to vascular ROS 
generation was also explored. In this case, IMA were treated with 1 pmol/L of Ang II, in 
the presence or absence of PD 123319, an AT2 selective antagonist (Garcha et al 1999).
Finally, in studies designed to investigate intracellular pathways, the effect of inhibition 
of NAD(P)H oxidase was investigated by co-treatment of IMA with Ang II and DPI. In 
other studies, the effect of inhibition of protein synthesis was also investigated by 
treatment of IMA with cyclohexamide (Sigma, UK), a protein synthesis inhibitor. Due to 
the limitation in availability of IMA biopsies, and their relatively small length, IMA were 
divided into two and treated with either an ARA, an inhibitior of NADP(H) oxidase, or 
an inhibitor of protein synthesis, in the presence or absence of Ang II.
4.2.2 Statistical analyses
All data are presented as mean +/- S.E.M or as % change from controls to facilitate 
comparison between groups. Statistical analyses of vascular O2" concentrations were 
undertaken using the Wilcoxon Signed-Rank Test.
4.3 Results
4.3.1 Effect o f Ang II on superoxide anion concentrations in human 
arteries and veins
In IMA, Ang II stimulated an increase in O2" production in both a concentration (Table 
4.1, Figure 4.1) and time (Table 4.1, Figure 4.2) dependent manner. Ang II had no effect 
on O2' production after 15 minutes incubation (control 1173±239 pmol/min/mg tissue, 1 
pmol/L of Ang II 918±170 pmol/min/mg; n = ll p=0.12; 95% Cl -680, 155), but 
increased O2’ production after 1 and 4 hours, respectively (Figure 4.2). Ang II stimulated 
an increase O2’ production in IMA but not SV (Figure 4.3, Table 4.1). NE (1 pmol/L), 
which was used as a vasoconstrictor control, had no significant effect on O2 ' generation
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in  IM A  (control 1581±899 pm ol/m in/m g, N E 738±241; n = l l ,  p=0.45, 95%  C l -3590 , 
164) or SV (control 360±218 pm ol/m in/m g, NE 249±118 pm ol/m in/m g; n=7 p=0.18 
95%  C l -3 9 1 ,4 5 ) .
% increase 
in 0 2 * production
150 i
100
50 -
0
p = 0.11
n = 14
p = 0.004 
n = 11
p = 0.0001
n =27
picomolar nanomolar micromolar 
Concentration of Ang II
Figure 4.1 Effect o f  treatm ent o f  IM A with different concentrations o f  Ang II for 4 
hours on vascular O 2" production, com pared to artery rings from  the blood vessel treated 
w ith  vehicle. D ata are expressed as a percent change from  control. The effect o f  Ang II 
o n  O 2 ' production in IM A occurred at pharm acological concentrations (1 pm ol/L , 1 
nm ol/L ), whereas a trend approaching statistical significance was observed with 
physiological concentrations (1 pm ol/L) o f  Ang II.
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Figure 4.2 Effect o f  duration o f  exposure with 1 pm ol/L  o f  A ng II on O 2’ production 
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Figure 4.3 Effect o f  4 hrs treatm ent with 1 pm ol/L  o f  either A ng II or norepinephrine 
(NE) on O 2 ' concentrations in internal m am m ary arteries and saphenous veins. A lthough 
Ang II stim ulated an increase in O 2 ' production in IM A, it had no effect on O 2 ' 
production in veins.
4.3.2 Mechanisms of Ang II -  stimulated superoxide anion production 
in human arteries and veins
Losartan, a com petitive AT 1 specific receptor antagonist, at a concentration o f  1 pm ol/L, 
had no effect on basal O 2’ production but blocked the Ang II -  m ediated increase o f  O 2’ 
production (Figure 4.4). [Sar1, th re8]-Ang II 1 pm ol/L , a non-specific A ng II receptor 
antagonist, also blocked Ang II -  m ediated increase o f  O 2’ production (1 pm ol/L  o f  
[sar1, th re8]-Ang II 1252±276 pm ol/m in/m g, 1 pm ol/L  o f  [sar1, th re8]-A ng II + 1 pm ol/L  
o f  Ang II 1281±204; n=15, p=0.63, 95%  C l -2 0 0 , 305). Incubation o f  IM A  for 4 hours 
w ith DPI 100 pm ol/L , but not DPI 10 pm ol/L , blocked A ng II -  m ediated increase o f  
O 2’ production (Figure 4.5). Treatm ent with an A T 2 receptor antagonist had no effect on 
Ang II-stim ulated O 2’ production in IM A (PD 552±127 counts/m in/m g; PD + Ang II
104
665=138 counts/min/mg; n=16, P = 0.1).
Finally, in order to determ ine whether or not A ng II -  stim ulated N A D (P)H  oxidase 
activation m ight involve an increase in the synthesis o f  this m ultim eric protein, IM A 
were treated with the protein synthesis inhibitor, cyclohexam ide. T reatm ent o f  IM A  with 
cyclohexam ide had no effect on basal O 2 '. IM A were therefore treated  w ith 1 pm ol/L  o f 
Ang II, in the presence or absence o f  100 pm ol/L  o f  cyclohexam ide. Inhibition o f  protein 
synthesis by treatm ent w ith 100 pm ol/L  o f  cyclohexam ide com pletely abrogated A ng II 
-  stim ulated O 2* production (cyclohexam ide 460 ± 100 pm ol/m in/m g and cyclohexam ide 
plus Ang II 430 ± 130 pm ol/m in/m g o f  tissue; n=8; Figure 4.6).
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F igu re  4.4 Effect o f  the AT 1 specific receptor antagonist, losartan, on Ang II - 
stim ulated O 2* production. Paired segm ents o f  IM A were treated for 4 hours in the 
presence or absence o f  1 pm ol/L  o f Ang II. In parallel studies, IM A  w ere treated with 1 
pm cl/L  o f  the angiotensin type 1 receptor antagonist, losartan, in the presence or absence 
o f  Ang II.
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Figure 4.5 Effect o f  N A D (P)H  oxidase inhibition on A ng II-stim ulated ( V  
production in IMA. Paired arteries were treated with either 10 pm ol/L  or 100 pm ol/L  o f 
diphenyleneiodonium , in the presence or absence o f  1 pm ol/L  o f  A ng II. Data are 
expressed as percent change from untreated controls ± SEM.
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Figure 4.6 Effect o f  protein synthesis inhibition on Ang II-stim ulated CV production 
in IMA. Paired segments (n=8) o f IMA .were treated w ith  a 100 m icrom olar 
concentration o f  cyclohexim ide, in the presence or absence o f  100 m icrom olar 
concentration o f  Ang II, for 1 hour.
4.4 D iscussion
This is the first dem onstration that Ang II can increase O 2" production in hum an arteries. 
This effect is ATi receptor-dependent as it was com pletely blocked by an ATi receptor 
antagonist. W e have also dem onstrated that this Ang II -  m ediated increase o f  O 2’ is 
m ediated by NA D(P)H oxidase as it was inhibited by DPI. This is a clinically im portant 
observation as physiological concentrations (pm ol) o f  A ng II tendend to increase O 2 ' 
production in hum an arteries, and this effect was blocked by losartan.
Ang II increased O 2 ' production in arteries, but not in veins. These effects are unlikely to 
be due to a reduction in AT 1 receptor expression in veins as the constrictor effect o f  Ang 
II in hum an saphenous veins, which is known to be ATi dependent (Li et al 1997b), m ay
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be greater in SV than IMA (Borland et al 1996). Ang II exerts different effects in distinct 
vascular beds. For example, in experimental animal models of hypertension, Ang II has 
renal vasodilator effects mediated through AT2 receptor activation (Siragy et al 1999; 
Siragy and Carey 1998). One explanation for our observations may be that the 
intracellular mechanisms by which Ang II activates NAD(P)H oxidase may differ in 
human arteries and veins. The mechanism of Ang II -  mediated increase of O2' 
production may also differ between species. ATi dependent Ang II -  mediated increase 
of O2’ production has been reported in the aortae (Rajagopalan et al 1996b), and 
mesangium (Jaimes et al 1998) of Sprague Dawley rats and aorta of 
hypercholesterolemic rabbits (Pagano et al 1997a). However, Ang II -  induced increase 
in O2 ' production in normocholesterolemic rabbit aortic adventitial fibroblasts is 
mediated by a non ATi-non AT2 receptor mechanism (Pagano et al 1998). The species 
differences in the mechanism of Ang II -  mediated increase in (V  production make 
human investigations important.
Experimental studies have demonstrated that Ang II -  mediated increase in O2' 
production is of functional importance. Ang II -  stimulated increase in O2" production 
contributes to its trophic effect of on rat VSMC (Griendling et al 1994) and mesangial 
cells (Jaimes et al 1998) and also contributes to the pressor effect of this hormone in a 
hypertensive rat model (Rajagopalan et al 1996b). The observations in the present study 
may also be substantiated by a report that the pressor effect of intra-brachial artery 
infusion of Ang II in humans is attenuated by the co-infusion of vitamin C (Dijkhorst- 
Oei et al 1999). This study however failed to identify a specific Ang II receptor or to 
evaluate a positive control (i.e. another vasoconstrictor such as norepinephrine).
Treatment of IMA with the protein synthesis inhibitor, cyclohexamide, prevented Ang II 
stimulated increase in O2' concentration in these arteries. This observation supports the 
conclusion that Ang II mediates NAD(P)H oxidase activation through an increase in 
synthesis of one, or more, of the subunits of this enzyme. In other studies, inhibition of 
the AT2 receptor had no effect on vascular O2 ' concentrations, suggesting that this 
receptor does not contribute to O2' generation in IMA. Alternatively, the trend to an
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increase in O2' concentrations in IMA co-treated with PD 123319 and Ang II suggests 
that the AT2 receptor may have a tonic inhibitory effect on ATi receptor-dependent O2’ 
generation in human arteries.
In conclusion, we have characterised cellular and enzyme sources of O2' production in 
human arteries and veins. We have demonstrated that Ang II increases O2 ' production at 
pharmacological concentrations in human arteries. Furthermore, physiological 
concentrations of Ang II tended to increase O2’ production in IMA. This effect, which is 
NAD(P)H oxidase mediated, is completely inhibited by the ATi receptor antagonist 
losartan. These observations suggest a putative therapeutic role for ATj receptor 
antagonists in reducing oxidative stress in cardiovascular disease.
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5 Immunodetection stud ies for NAD(P)H oxidase and 
xanthine oxidoreductase proteins in hum an blood 
vesse ls
5.1 Summary
This chapter provides a description of the immunohistochemical studies undertaken to 
identify the presence and distribution of the subunits of NAD(P)H oxidase in human 
IMA. Using monoclonal antibodies and antisera, p22phox, gp91 phox (or a homologue), 
p67phox and p47 phox are identified within the endothelium, vascular smooth muscle 
cell layer and adventitia. Xanthine oxidoreductase was identified in the endothelium and 
adventitial layers of IMA. These observations suggest that enzymes capable of 
generating ROS are distributed throughout the wall of human conduit arteries.
5.2 Methods
5.2.1 Blood vessel preparation and cell culture
Left IMA was obtained at the time of coronary artery revascularisation surgery and taken 
to the laboratory in Krebs buffer on ice. Segments of IMA were carefully dissected free 
of loose connective tissue and cut into 4 - 5  mm lengths, and incubated for 4 hours at 
37°C in Krebs buffer, in the presence or absence of 1 pmol/L of Ang II. After this, the 
blood vessels were either immediately embedded in frozen in Tissue Tek® (O.C.T. 
compound, Miles Scientific, IL), or embedded in paraffin, whilst taking care to ensure 
that the blood vessel was not deformed in any way. Sections, approximately 5 pm thick, 
were then cut using a microtome.
Human coronary artery smooth muscle cells (HCASMC; Biowhittaker) were grown in 
25 ml culture flasks and used between passages 4 -  6 in serum free conditions.
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5.2.2 Immunohistochemistry
Immunohistochemical studies were performed in both frozen and paraffin-embedded 
5pM sections of intact IMA, according to the methods described in chapter 2 (Section 
2.7.1). P22phox and gp91phox were identified using specific mouse monoclonal 
antibodies (kindly provided by Dr MT Quinn, Montana State University, MT) at a 
dilution of 1:100. P47phox and p67phox proteins were identified by use of rabbit anti­
sera (Upstate Biotechnology, N.Y.), at a dilution of 1:500. In each experiment, negative 
controls treated with non-immune antibody or antisera were included to assess for non­
specific staining. Biotinylated secondary anti-mouse antibody, in the case of p22phox 
and gp91phox, and anti-rabbit antibody, in the case of p47phox and p67phox, were used. 
Ten percent horse or goat block was used according to the species that the antibodies 
were raised in. XOR was identified using a specific mouse monoclonal antibody (kindly 
provided by Professor R. Harrison, University of Bath) at a dilution of 1:100. In each 
experiment, negative controls treated with non-immune mouse IgG antibody were 
included to assess for non-specific staining. Secondary antibodies were biotinylated anti­
mouse (1:50) with 10% horse block. Experiments were performed between 3 and 5 times 
with each vessel providing its own, untreated control. In addition, immunocytochemical 
studies were undertaken in order to determine the presence or absence of macrophages 
and granulocytes within sections of IMA (Section 2.7.1).
5.2.3 Western Blotting
Western blotting was performed by extracting samples in lysis buffers containing 
protease inhibitors. Homogenates were centrigufed at 14,000 g at 4°C. The supernatant 
fraction (20 jig of protein) was loaded onto 12% of SDS polyacrylamide gel and 
transformed to PVDF membrane (Boerhinger Mannheim). Membranes wer blocked in 
5% non-fat milk and incubated with mase monoclonal antibody diluted 1:1000 for 1 hour 
at room temperature. They were then washed and incubated with an anti-mase 
horseradish peroxidase -  conjugated antibody, diluted 1:5000 for 1 hour at room 
temperature and washed extensively. The membranes were then exposed to ECL
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(Enhanced chemiluminescence, [Amersham,UK]), exposed to film and developped.
5.3 Results
5.3.1 Patient characteristics
Table 5.1 Clinical characteristics. The clinical information presented in this table 
represent data describing patients who provided blood vessels that were used in Chapters 
5 and 6.
Number (%)
Mean age, yrs 62±12
Males, n (%) 8(57)
Females, n (%) 6(43)
Risk factors, n (%)
Diabetes mellitus 2(14)
Hypertension 6(43)
Hypercholesterolaemia 7(50)
Smoking 4(29)
Medication, n (%)
Aspirin 13 (93)
P-Blocker 11 (79)
Calcium channel blocker 6 (57)
HMGCoA Reductase Inhibitor 7(57)
Nitroglycerin 11 (86)
Angiotensin converting enzyme inhibitor 5(36)
P-Blockers -  beta-blocker; HMGCoA Reductase Inhibitor - 3-Hydroxy-3 -
methylglutaryl coenzyme A reductase inhibitor.
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5.3.2 Immunohistochemical identification of NAD(P)H oxidase
subunits in IMA
Figure 5.1 shows typical im m unohistochem ical features o f a frozen section o f IMA. 
In this case, the IM A was treated with non-im m une m ouse antibody (control), or a 
m onoclonal antibody specific for gp91 phox (treated).
Mouse lgG1: negative control Immunostaining with anti-human gp91phox antibody
Figure 5.1 Im m unohistochem istry o f IMA treated with specific monoclonal 
antibodies to gp91phox. The sections are shown at a m agnification o f x20 and m  
represents the media. The inset image shows staining for gp91phox, at a 
m agnification of x40. The image on the left is a negative control where the primary 
antibody has been replaced with non-im m une m ouse IgG l. Brown staining represents 
the chrom ogenic reaction product arising from the interaction betw een HRP-labelled 
secondary antibodies (bound to to the prim ary anti-gp91phox anti-bodies) and 
diam inobenzidine (DAB). This brown staining therefore represents im m unodetection 
o f gp91phox. Results shown are typical o f those seen in 4 experim ents.
It is apparent that there is dense staining throughout the vessel wall, including the 
media, in contrast to the control section from the same vessel. In the case of 
gp91phox, staining appeared m ost abundant within the vascular sm ooth m uscle layer,
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but was also evident within the adventitia and endothelium . W ax sections o f IMA 
failed to dem onstrate any staining with this antibody. One explanation for this is that 
im m unohistochem ical studies undertaken on wax sections are much less sensitive for 
the detection of candidate proteins than is the case with frozen sections, this being due 
to the effect of parraffin on the tissue sections.
Additional im m unohistochem istry studies using w ax-em bedded sections of IMA, 
treated with anti-sera for either p47phox (Figure 5.2) or p67phox (Figure 5.3) proteins 
revealed staining throughout the blood vessel wall, which was particularly m arked 
within the adventitial and endothelial layers. Control studies, in which studies were 
perform ed with the appropriate prim ary non-im m une antibody or anti-sera were 
perform ed in every case (not shown).
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Figure 5.2 Coronal, paraffin-em bedded sections o f IM A treated with anti-sera for 
p47phox protein, (a) x4 m agnification (b) xlO  m agnification (c & d) x40 
m agnification. In this case, the sections were also stained with haem atoxylin and 
eosin.
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Figure 5.3 Coronal, paraffin-em bedded sections o f IMA treated with anti-sera for 
p67phox protein, (a) x4 m agnification (b) xlO  m agnification (c) and x40 
magnification.
Im m unodetection studies for p22phox protein dem onstrated staining within the 
sm ooth muscle layer and endothelium  (Figure 5.4 [a & b]).
p22phox
(a) (b) (c)
*
Figure 5.4 Coronal paraffin-em bedded sections o f IMA treated with anti-p22phox 
m onoclonal antibody, (a) - x4 m agnification (b) xlO  m agnification (c) and (d) x40 
m agnification.
Segm ents of IMA were also treated with 1 pm ol/L  o f Ang II for 4 hours. These
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experim ents were perform ed on paired sam ples from betw een 3 - 5  vessels with 
representative data shown. Control experim ents w ith either non-im m une m ouse IgG 
or rabbit sera show ed no staining. Q ualitative assem ent o f  the effect o f  this treatm ent 
on the abundance o f  p22phox protein (Figure 5.4) in IM A  sections was perform ed by 
scoring the density o f  im m unostaining by an independent observer w ho was unaw are 
o f  the nature o f  each slide. Representative im ages for p22phox (Figure 5.4) 
im m unostaing are shown below. In this case, the intensity o f  this staining appeared to 
be greater after treatm ent with Ang II.
In separate studies, no light m icroscopic or im m unocytochem ical positivity  for 
m acrophages (anti-CD 68, anti-m ac387 or an ti-K p l), or granulocytes w ere identified 
in any o f  the vessels investigated (data not shown).
5.3.3 Immunodetection of gp91phox (or a homologue) by western 
blotting techniques
Figure 5.7 shows typical results o f  western blotting o f  cultured HCA SM C. A m ajor 
band was detected at approxim ately 90 kD, w hich was absent w hen the prim ary 
antibody was om itted.
Figure 5.5 W estern blotting o f  gp91phox in hum an coronary V SM C using a 
m onoclonal antibody against gp91phox. M represents m olecular w eight m arkers.
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5.3.4 Immunodetection of xanthine oxidase in IMA
Figure 5.4 shows a representative, wax-em bedded section o f an IMA. In this case the 
IMA was treated with non-im m une mouse IgG antibody (control), or a m onoclonal 
antibody specific for XOR (treated). There is staining evident within the endothelium  
and adventitia, but by contrast, the smooth m uscle layer is spared. These features 
contrast those o f the control section from the same vessel, in which staining is absent.
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Figure 5.6 (a) Im m unohistochem istry o f IMA treated with specific m onoclonal
antibodies to xanthine oxidase. The sections are shown at a m agnification o f x20 and 
m represents the media. The inset image dem onstrates staining for xanthine oxidase, 
at a m agnification o f x40. (b) Staining was absent in negative control section, where 
the primary antibody has been replaced with non-im m une mouse Ig G l. Results shown 
are typical of those seen in 4 experim ents.
5.4 D iscussion
In these studies, p47phox, p22phox and p67phox proteins were identified in the 
endothelium , m edia and adventitial layers o f IMA. Furtherm ore, gp91phox, or a 
protein hom ologue, was detected using a m onoclonal antibody directed against 
gp91phox. This protein was evident throughout the artery wall including the medial 
layer.
The data in the present study suggest that gp91phox is abundant within human 
VSM C. This conclusion is dependent on the specificity o f this antibody for gp91phox, 
rather than one o f its hom ologues. In order to verify this result, western blotting was 
perform ed, using the same m onoclonal antibody, in cultured HCASM C. In these
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studies, protein bands of the anticipated molecular weight for gp91phox protein were 
identified. This observation supports the assertion that gp91phox is present in human 
VSMC. Although it might be argued that the expression of this protein in IMA could 
be ascribed to the disease status of these patients, the cultured VSMC were obtained 
from individuals with no history of cardiovascular disease. This is in agreement with 
observations by Suh et al. (Suh et al 1999) who reported that the noxl protein 
(formerly mox-1), a homologue of gp91phox, was present in rat VSMC.
More recently, Lassegue et a l (Lassegue et al 2001) characterised the expression of 
three nox family members, noxl, nox4 and gp91phox in rat VSMC. Using 
quantitative PCR, they found that the number of RNA molecules of noxl and nox4 
were approximately 3000 times greater than gp91phox, which was just above the limit 
of detection in this assay. This result contrasts the earlier findings by this group (Suh 
et al 1999). In these studies, northern blotting techniques failed to identify any 
gp91phox mRNA, however, this technique is much less sensitive than PCR. The nox 
family of proteins are functionally important, not only for O2' production, but also for 
the regulation of vascular growth and hypertrophy, and belong to a growing number 
of Nox family members (Lambeth 2000). Taken together, these data suggest that noxl 
and nox4, rather than gp91phox, are functionally active homolgues in NAD(P)H 
oxidase in this cell type. Studies of the relative expression of the nox family members 
in human vascular cells have not yet been reported.
Initial studies with wax-embedded sections of IMA failed to demonstrate any staining 
using the anti-gp 91phox monoclonal antibody, in contrast to subsequent studies 
undertaken in frozen sections. This may be due an effect of processing. Wax, or 
paraffin-embedded, sections typically reveal greater definition of tissue architecture 
than is the case with frozen tissue sections. By contrast, this latter type of processing 
affords greater sensitivity for immunohistochemical identification of target molecules 
and cells (Harlow and Lane 1988).
A striking difference was observed between the distribution of gp91phox and 
p22phox proteins, which were evident throughout the artery wall, and the distribution 
of p47phox and p67phox, which appeared to be concentrated within the endothelium 
and adventitial layers. There are several possible explanations for this observation. 
Firstly, it may be that p47phox and p67phox proteins are much less abundant within
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vascular smooth muscle cells, than is the case with gp91phox and p22phox. Secondly, 
these latter proteins together constitute the cytochrome b558 membrane complex, 
whereas, by contrast, p47phox and p67phox are both cytosolic proteins. Thus, the 
difference in cellular location of these proteins may give rise to the observed 
difference in staining arising with this technique. Finally, one additional explanation 
for these appearances may also be that, in the case of gp91phox and p22phox, a 
monoclonal antibody was used for immunodetection of these proteins, whereas in the 
case of p47phox and p67phox proteins, anti-sera were used. It may be, for example, 
that these anti-sera are less sensitive to binding phox proteins within the media, than 
is the case with monoclonal antibodies.
In other immunohistochemical studies, XOR protein was identified within sections of 
IMA, with staining most pronounced within the endothelium and adventitia. 
Interestingly, the distribution of this protein is comparable with that of p47phox and 
p67phox. In this case, immunodetection studies for XOR were undertaken with a 
monoclonal antibody for this protein. Taken together, these observations suggest that 
the observed distribution of p47phox and p67phox proteins in human IMA is valid, 
rather than being a function of the methods (and antisera) employed.
That XOR protein could be readily demonstrated in IMA by immunodetection 
techniques supports the earlier findings of a functional enzyme, capable of generating 
ROS in these arteries. This raises the question as to the source of XOR in these 
arteries. One possibility is that XOR, synthesised within the liver, is released into the 
systemic circulation whereupon this protein may bind with the endothelium, and may 
also penetrate into the adventia by passing from adventitial vasa vasorum. One 
alternative possiblity is that vascular cells, and endothelial and adventitial cells in 
particular, can synthesise this protein. This latter possibility could be addressed in 
further studies using RT-PCR techniques to detect XOR mRNA in these cells.
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6 Effect of Ang II on the abundance of m essenger 
RNA for NAD(P)H oxidase phox subun its  in human 
vascular cells and blood vesse ls
6.1 Summary
In this chapter, studies of the effects of Ang II on the abundance of cDNA transcripts 
o f the subunits of NAD(P)H oxidase are reported. Here we demonstrate that treatment 
with Ang II is associated with an increase in the abundance of cDNA transcripts of 
p22phox, which was attenuated by co-treatment with either actinomycin D, an 
inhibitor of gene transcription, or losartan, an ATi receptor antagonist. These data 
support the possibility that Ang II stimulates an increase in the synthesis of the 
subunits of NAD(P)H oxidase in human vascular cells by an ATi receptor -dependent 
increase in gene transcription.
6.2 Methods
6.2.1 Blood vessel preparation and cell culture
IMA were obtained from patients at the time of coronary artery revascularisation 
surgery. In this case, however, the arteries were collected from the cardiac theatre in 
sterile universal containers containing serum-free cell culture medium (Clonetics), 
maintained at 37°C inside a thermos flask. The flasks were taken directly to the 
laboratory where the arteries were dissected free of surrounding connective tissue and 
cut into 4 - 5  mm lengths whilst bathed in pre-warmed culture media. The arteries 
were then immediately placed in an incubator.
Human aortic endothelial cells (HAEC; Clonetics) and coronary artery smooth muscle 
cells (HCASMC; Biowhittaker) were grown in 25 ml culture flasks and used between 
passages 4 -  6 in serum free conditions.
6.2.2 Pharmacological studies
IMA were divided into pairs of segments 4 - 5  mm lengths and were incubated for 4
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hours at 37 °C in serum-free culture media in the presence or absence of 1 pmol/L of 
Ang II. In other studies, cultured HCASMC and HAEC were incubated in 25 ml 
flasks in a similar fashion, but in this case, these cells were also pre-treated and co­
incubated with 1 pmol/L of the ATi receptor antagonist, losartan, or actinomycin D, 
an inhibitor of transcription. The studies with cultured cells were performed in 
triplicate on each occasion.
6.2.3 Reverse transcription polymerase chain reaction
In order to generate first strand cDNA, total RNA underwent reverse transcription 
which resulted according to methods described in Chapter 2 (section 2.4). This 
product was used as a template for the polymerase chain reaction using primers for 
p22phox and GAPDH. Qualitative assessment of RNA obtained from cell and tissue 
homogenates was undertaken by electrophoresis of the cDNA products on a 1.5% 
agarose gel (Life Technologies, UK). Semi-quantitative analysis was undertaken 
using phospho-imaging analysis (Biorad), by expression of the ratio of p22phox 
amplicons to GAPDH or actin cDNA products.
6.2.4 Statistical analyses
All data are presented as mean +/- S.E.M or as % change from controls to facilitate 
comparison between groups. Statistical analyses of vascular O2’ concentrations were 
undertaken using a paired Student’s t-test. A probability value of P<0.05 was taken as 
significant.
6.3 Results
RT-PCR studies undertaken in HAEC (Figure 6.1), in HCASMC (Figure 6.2), and 
IMA (Figure 6.3) demonstrated the abundance of p22phox cDNA transcripts to be 
increased by treatment with 1 pmol/L of Ang II for 4 hours.
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p22phox
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F ig u re  6.1 Effects o f  treating hum an aortic endothelial cells for 4 hours with 
either 1 pm ol/L  o f  Ang II, or vehicle, on the abundance o f  p22phox m RNA. (C, 
control; '+ ' represents cDN A which was form ed through treatm ent o f  m RN A  with 
reverse transcriptase, whereas represents controls, w hich were treated w ith vehicle, 
instead o f  reverse transcriptase; lkB  represents the m olecular w eight DNA m arker).
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Figure 6.2 Effects o f  treating HCSM C for 4 hours w ith either a 1 pm ol/L  o f  Ang 
II, or vehicle, on the abundance o f  p22phox cD N A  transcripts in these cells (C, 
control; represents cDN A form ed through treatm ent o f  m RN A  w ith reverse 
transcriptase, w hereas represents controls, treated w ith vehicle, instead o f  reverse 
transcriptase; M represents the m olecular w eight DN A m arker).
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Figure 6.3 Effects o f  treatm ent with either 1 pm ol/L  o f  A ng II, or vehicle, for 4 
hours, on the abundance o f  p22phox m RN A  in the IM A  from 4 different patients. (A) 
A scanned image o f  R T-PC R cDNA transcript products for p22phox and p-actin after 
agarose gel (1.5% ) electrophoresis. (B) This data was quantified using the 
phosphorim ager, as described in the text (C, control).
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The different baseline levels o f  p22phox are striking, despite the relatively even 
am plification o f  the house-keeping gene. In the case o f  IM A, each treated segm ent 
was com pared w ith an untreated segm ent derived from  the sam e vessel. In 
unstim ulated IM A, p22phox expression relative to actin, in arbitary densitom etric 
units, was 527 ± 31 w hereas in Ang II -  stim ulated arteries this was 680 ± 33 
(p=0.048, 95%  confidence interval 2.7 to 302, n=5). In sim ilar studies in HAEC, the 
increase in abundance o f  p22phox transcripts by treatm ent w ith 1 pm ol/L  o f  either 
losartan or actinom ycin D, com pletely prevented the previously  observed Ang II -  
induced increase in abundance o f  p22phox transcripts (Figure 6.4).
np22phox
g
GAPDH
j
C Ang II Ang II + Ang II + 
act D losartan
C - control; Ang II - angiotensin II; act D - actinomycin D;
GAPDH glyceraldehyde-3 phosphate dehydrogenase
Figure 6.4 Effects o f  treatm ent o f HAEC with either 1 pm ol/L  o f  A ng II, or 
vehicle, for 4 hours, in the presence or absence o f  either 1 pm ol/L  o f  actinom ycin or 
losartan, on the abundance o f  p22phox m RNA in hum an aortic endothelial cells. A 
scanned im age o f  R T-PC R  cDN A transcript products for p22phox and G A PD H  after 
agarose gel (1.5% ) electrophoresis (C, control; A ct D, actinom ycin D).
6.4 D iscussion
W e investigated the m olecular m echanism s that m ay be involved in Ang II - 
stim ulated activation o f  N A D (P)H  oxidase in hum an arteries and cells. In previous
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studies, we demonstrated that Ang II stimulates increased O2" production by an AT 1 
receptor and NAD(P)H oxidase -  dependent mechanism.
In the present in vitro study, the effect of treatment with Ang II on the abundance of 
p22phox cDNA transcripts in human vascular cells and tissues was investigated. 
These transcripts are representative of the amount of p22phox mRNA present in these 
cells. Messenger RNA is the transcribed molecular product formed as a result of gene 
expression. The abundance of mRNA is determined by the rate of gene transcription, 
and the rate of mRNA degradation (or half-life). Messenger RNA provides the 
template for translation and synthesis of the protein product, and consequently, 
increased abundance of mRNA will lead to an enhanced amount of the protein 
product. In the present case, NAD(P)H oxidase is a multimeric protein, which when 
activated, is composed of p22phox, gp91phox, p47phox, p67phox and, p40phox 
proteins. An increase in the abundance of these subunits, and in particular those 
involved in electron transport (such as p22phox), is associated with enhanced 
abundance of the ‘activated’ NAD(P)H oxidase multimer. This, in turn, will augment 
electron transport and O2’ production.
Treatment of both HAEC and HCASMC with 1 pmol/L of Ang II for 4 hours, was 
associated with an increase in the abundance of p22phox cDNA transcripts in these 
cells. The mechanism for this Ang II effect may be due to either an increase in the rate 
of gene transcription, leading to enhanced production of p22phox mRNA, or 
prolongation of the half life of this molecule. In further studies, using IMA obtained 
from 4 different patients, treatment of vascular tissue with 1 pmol/L of Ang II, or 
vehicle, for 4 hours, was also associated with a significant increase in the abundance 
of p22phox cDNA transcripts. This suggests that the effect of Ang II on p22phox 
mRNA is operative in intact human arteries.
Further molecular studies sought to determine the mechanisms that may be involved 
in the effect of Ang II on p22phox mRNA. HAEC were again treated with 1 pmol/L 
of Ang II, or vehicle, for 4 hours in the presence or absence of either the AT 1 receptor 
antagonist, losartan, or an inhibitor of transcription, actinomycin D. In this case, co­
treatment with losartan, prevented the observed increase in abundance of p22phox 
cDNA transcripts associated with Ang II treatment. This observation is in keeping 
with the earlier observations, by this laboratory and elsewhere (Griendling et al 1994;
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Rajagopalan et al 1996b), that ATi receptor blockade prevents Ang II -  stimulated 
O2' production. In addition, inhibition of gene transcription by treatment of these cells 
with actinomycin also prevented the previously observed increase in abundance of 
p22phox cDNA transcripts arising from treatment with Ang II.
Recently, studies by Lassegue et al. (2001) investigated the effects of treatment of rat 
VSMC with Ang II on the abundance of nox (i.e. gp91phox and homologues) mRNA 
abundance. Treatment of these cells with different concentrations of Ang II lead to a 
dose- and time-dependent increase in the abundance of noxl (gp91phox), but not 
nox4, mRNA (EC50 3nmol/L and a maximal response at lpmol/L). The increase in 
noxl mRNA was detectable within the first hour and increased to a maximum at 4 
hours. These observations are in keeping with those of the present study.
Taken together, these findings suggest that exposure of human vascular cells to Ang II 
leads to an increase in the abundance of p22phox cDNA. Consequently, this may lead 
to enhanced synthesis of p22phox protein in human vascular cells and blood vessels. 
These observations also support the thesis that Ang II may augment O2" production in 
human blood vessels through an ATi receptor -  dependent activation of NAD(P)H 
oxidase.
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7 Functional significance of Ang II -  stim ulated 
superoxide anion production in hum an resistance 
arteries
7.1 Summary
Ang II-stimulated O2' production contributes to the vasopressor effect of this 
hormone in rats made hypertensive by infusion of Ang II (Rajagopalan et al 1996b). 
In this study, we tested the hypothesis that enhanced ROS production might 
contribute to the vasoconstrictor effect of Ang II in human subcutaneous resistance 
arteries (SRA). The results did not support this hypothesis.
7.2 Methods
Resistance arteries are, in functional terms, the most important type of blood vessel 
for the regulation of peripheral vascular resistance, and therefore, blood flow 
(Mulvany and Aalkjaer 1990). For this reason, I sought to explore whether or not Ang 
II -  stimulated O2' production might contribute to the vasopressor effect of this 
hormone in human SRA.
Subcutaneous resistance arteries (SRA) were isolated from abdominal wall skin 
biopsies, according to the methods described in Chapter 2 (section 2.2.2). Isometric 
tension studies were undertaken in these arteries according to the methods described 
in Chapter 2 (section 2.8) (Mulvany and Aalkjaer 1990; Mulvany and Halpem 1977). 
The SRA underwent a standard normalisation process and ‘wake-up protocol’. As part 
of this protocol, the SRA were initially exposed to a 123 mM of KPSS for a series of 
5 minute periods until repeatable maximal contractions were achieved, and then once 
to 10 pmol/L of norepinephrine (NE). After a plateau contraction had been attained 
with NE, 3 pmol/L of acetylcholine (ACh) was added to stimulate endothelium- 
dependent vasodilatation. Arteries that were unable to contract to either KPSS or NE 
or showed no relaxation to ACh (and were therefore considered to have no 
functionally intact endothelium) were discarded. The arteries were then incubated for 
a further 30 minutes in Krebs solution prior to the commencement of the 
concentration-response curves (CRC) incorporated in the study protocol. SRA were
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treated with lmmol/L of the ROS scavenger, Tiron, or vehicle, and a cumulative 
concentration response curve (CRC) for NE was performed, followed by a further 
treatment with 3 pmol/L of ACh. SRA were then co-treated with 1 pmol/L of Ang II 
for 1 hour to stimulate O2 ' production, and a second CRC for NE was performed (for 
summary of protocol see Figure 7.1).
1 mmol/L of Tiron
PROTOCOL I NE
(single
dose)
NE
CRC
1 mmol/L of Tiron 
1 nmol/L of Ang II
followed by 
3 (imol/L o f ACh
NE
CRC
PROTOCOL 2 NE
(single
dose)
Vehicle
NE
CRC
1 nmol/L of Ang II
followed by 
3 jimol/L o f ACh
NE
CRC
Figure 7.1 Schematic representation of the protocol undertaken in human small 
resistance arteries.
These studies were undertaken with paired vessels from the same patient in every 
case. Statistical analyses were undertaken using a paired t test with log-transformed 
data.
7.3 Results
After initial preconstriction with 10 pmol/L of NE, mean relaxation of all SRA to 3 
pmol/L of ACh was 86±3% (n=20). SRA which did not relax fully, and therefore did 
not have functional endothelium, were not included in this study. Contractile 
responses obtained after each NE CRC are expressed as a percentage of the maximum 
response obtained after initial treatment with a single dose of 10 pmol/L of NE. After 
treatment with vehicle, or Tiron, the maximum contraction (Emax) to NE, compared to
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the initial response obtained after treatment NE, was 94 +/- 7 % and 98 +/- 1.7%, 
respectively (Figure 7.2).
- o - N E  crc  + T iron  1 
m m o l/L
N E  + v e h ic le1 2 0  -i
P< 0.04100  -
d)
</> 8 0  - c
I  6 0  -0)
X 4 0  - 
(0
E
^  20  -  0s*
- 8.00 - 7.00 - 6.00- 9.00 - 5.00-20 J
Log [NE], M
Figure 7.2 This figure shows concentration response curves for NE in SRA 
incubated in the presence or absence of 1 mmol/1 of Tiron.
PD2 (-log EC50) values for the CRCs for NE undertaken in the presence and absence 
of 1 mmol/L of Tiron were (6.5 +/- 0.03 vs. 6.1 +/- 0.03, Tiron vs. vehicle, 
respectively; P=0.036). After incubation with either vehicle or 1 pmol/L of Ang II for 
1 hour, the maximum contraction (Emax) to NE was 98.4 +/- 6 % and 84.6 +/- 6.6%, 
respectively (P=0.1) [Figures 7.3].
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Figure 7.3 Concentration response curves to NE after treatment with vehicle or 1 
micromole of Ang II for 1 hour (n=8)
In this case, the pD2 values for the NE CRCs in the absence and presence of Ang II 
were 6.5 +/- 0.06 and 6.3 +/- 0.08, respectively (P=0.5). After incubation of SRA with 
1 mmol/L of Tiron, in the absence or presence of 1 pmol/L of Ang II for 1 hour, the 
Emax of CRC for NE was 94.9 +/- 2.3% and & 97.5 +/- 7.4%, respectively (Figure
7.4).
- 9.00 - 8.00 - 7.00 - 6.00 - 5.00
Log [NE], M
Figure 7.4 Concentration response curves to NE after treatment with vehicle or 1 
pmol/L of Ang II for 1 hour in the presence of 1 mmol/L of Tiron (n=10).
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7.4 Discussion
In this study, treatment of SRA with the 1 mmol/L of the ROS scavenger, Tiron, 
resulted in a shift to the right of the CRC for NE. The maximum contractile responses 
for these two groups were comparable. Alternatively, treatment with 1 pmol/L of Ang 
II for 1 hour failed to augment either the sensitivity of SRA, or their maximum 
contractile response, to NE, compared with responses to vehicle treated SRA. In fact, 
if anything, there appeared to be a trend in favour of an attenuated NE CRC response 
by SRA after treatment with Ang II, compared to those treated with vehicle. Finally, 
incubation of Tiron-treated SRA with 1 pmol/L of Ang II for 1 hour had no effect on 
the CRC for NE.
These observations do not support the hypothesis that Ang II -  stimulated O2" 
production might contribute to the constrictor effect of this hormone in human SRA. 
This hypothesis was based on the supposition that NO is an important vasodilator in 
these arteries, and that bioavailable NO would be modulated by ROS activity. The 
complex protocol in this study (Figure 7.1) was designed to test this hypothesis using 
SRA obtained from a single skin biopsy. The protocol included an initial CRC for NE 
to be undertaken in the presence or absence of Tiron, followed by an incubation 
period of 1 hour in which SRA were exposed to a pharmacological concentration of 
Ang II in order to stimulate vascular NAD(P)H oxidase activation and ROS 
production.
Only SRA which relaxed fully to ACh, therefore indicating the presence of functional 
endothelium, were included in this study. Treatment of SRA with the ROS scavenger, 
Tiron, resulted in a shift to the right of the NE CRC, compared to that of vessels 
treated with vehicle. This observation suggests that a reduction in ROS activity, and 
therefore less NO scavenging, led to an increase in bioavailable NO. In this case, 
higher concentrations of NE were required to achieve a given increment in tension, 
compared to SRA treated with vehicle. These findings suggest that ROS activity may 
contribute to resting vascular tone in human SRA, possibly through removal of 
bioavailable NO.
The lack of potentiation of NE -  induced vasoconstriction by treatment with Ang II in
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these studies is in contrast to observations in some, but not all (Creager et al 1984; 
Nicholls et al 1981), studies in both experimental animals and humans. For example, 
in vivo studies by Qiu et al. (1994) demonstrated that superfusion of exteriorised rat 
mesenteric arteries with PE was associated with a reduction in both vessel diameter 
and blood flow within these arteries. This effect was attenuated by co-treatment (by 
topical superfusion) of these arteries with an ACE-I, or ARA, or both.
Evidence for adrenergic facilitation by Ang II has been provided from studies in both 
normotensive and hypertensive subject, whereas evidence against this effect has also 
been provided. Studies by (Seidlin et al 1991) provided some information which 
helped to clarify the possible effect of Ang II on adrenergic tone. In these studies 
healthy human subjects were exposed to lower-body negative pressure (15 mmHg) 
which resulted in a rise in blood pressure, without any change in heart rate. In this 
case, forearm vasoconstriction, measured by strain-gauge plethysmography, occurred 
due to an increase in sympathetic activity. Intra-brachial artery infusion of 
norepinephrine (NE; 37.5 -  150 pmol/min) was also undertaken, which induced 
comparable reductions in forearm blood-flow. In subsequent studies, infusion of a 
non-pressor concentration of Ang II (320 fmol/min) was associated with an enhanced 
reduction in forearm blood flow to lower-body negative pressure (i.e. sympathetic 
nervous system activation), whereas Ang II had no effect on NE-induced 
vasoconstriction. These observations suggest that in human blood vessels, Ang II -  
induced adrenergic facilitation is a pre-synaptic phenomenon. This effect may be 
mediated through augmentation of NE release, or perhaps through an inhibition of NE 
re-uptake. These data, taken together with observations from the present study, 
suggest species differences may exist in the regulation of adrenergic control of 
vascular tone.
Given this lack of potentiation, subsequent manipulation of ROS activity in these 
arteries was unlikely to have yielded any data which might have been informative as 
regards the question of whether Ang II -  stimulated 0 {  production might contribute 
to vasomotor tone in human blood vessels. Given the microscopic size of these 
arteries, it was not possible to quantify ROS concentrations either within the wall of 
these SRA, or in the bath. The lack of information on whether or not ROS activity 
was actually enhanced in these SRA by treatment with Ang II makes interpretation of 
these findings difficult. Nevertheless, there are several possible explanations for our
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findings. Firstly, the oxidant-generating properties of human SRA are poorly 
characterised. It is possible, for example, that NAD(P)H oxidase may not be 
quantitatively or functionally important in these blood vessels. The effect of ROS 
scavenging in these SRA by treatment with Tiron does suggest that basal ROS 
generation has a tonic constrictor effect in these SRA, possibly through removal of 
NO.
The importance of NO in the regulation of vascular tone in human SRA is a subject of 
current debate (Buus et al 1998). In these studies, human SRA were threaded with 
stainless steel wires and mounted in a wire myography. NO concentrations in the 
lumen of the artery were measured by use of a electrochemical microelectrode which 
had a high selectivity for NO and a sensitivity of approximately 1 nmol/L of NO. The 
diameter of this microelectrode was approximately 30 -50 pm. The SRA were pre­
constricted with 5 pmol/L of NE, and then treated with incremental, cumulative 
concentrations of ACh. Stimulation of these arteries with ACh resulted in a mean 
relaxation of 64 ± 7% (n=4), however, no detectable increases in NO concentration 
were observed. By contrast, treatment of these SRA with the NO donor, S-nitroso-vV -  
acetylpenicillamine (SNAP,) resulted in a comparable relaxation, and an increase in 
NO concentration by 32 ± 8 nM. These effects were attenuated by co-treatment with 
the NO scavenger, oxyhaemoglobin. Further studies of intracellular electrical 
potentials in these arteries demonstrated that ACh-induced vasorelaxation resulted in 
hyperpolarisation of the VSMC in these arteries, which was not inhibited by co­
treatment with the NO synthesis inhibitor, L-NOARG. These observations confirm 
the presence of an L-arginine/NO pathway in human SRA, but demonstrate that ACh 
-  induced relaxation in these arteries is predominately mediated by hyperpolarisation, 
which is NO-independent, suggesting the involvement of an endothelium-dependent 
hyperpolarising factor (EDHF).
These findings are supported by observations in our own laboratory. Kelly et a l 
(Kelly et al 2000) undertook studies in human SRA obtained by gluteal fat biopsy 
from healthy subjects and patients with polycystic ovarian syndrome. These 
investigators studied the mechanisms of insulin-mediated vasodilation in NE- 
preconstricted SRA. Concentration response curves for NE were undertaken in the 
presence and absence of the NO synthesis inhibitor, L-NMMA. They found that the 
contractile responses to NE in SRA treated with L-NMMA were no different to those
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of SRA treated with vehicle. This suggests that NO-mediated vasodilation is not 
important in human SRA. This conclusion has also been supported by observations in 
Hillier’s laboratory in which EDHF has been demonstrated to be the dominant 
vasodilator in human SRA (Coats et al 2001). That NO-mediated vasodilatation may 
not be important in human SRA suggests that Ang II-stimulated 0 {  production does 
not modulate at least short-term changes in vasomotor tone, which is in keeping with 
the findings of the present study.
Future studies of the functional effect of Ang II-stimulated O2’ production in human 
blood vessels should focus, therefore, on studies using alternative blood vessel types 
and methods of investigation. One alternative blood vessel to study might have been a 
conduit artery, such as the IMA. Endothelium-dependent vasorelaxant responses in 
these arteries are recognised to be poorly reproducible. Other explanations for our 
findings may be related to the experimental procedures involved in the present study. 
It may be, for example, that this in vitro technique is insufficiently sensitive to elicit 
any functional component of Ang-II stimulated O2’ generation. In addition, the period 
of incubation with Ang II may have been too short to result in any important 
activation of NAD(P)H oxidase in these SRA. Alternatively, the use of a 
pharmacological concentration of Ang II may have had adverse effects on the 
contractile properties of these arteries. The concentration of Ang II used in this study 
was selected on the basis of our earlier findings in IMA, in which it was demonstrated 
that for a treatment period of 1 hour, only micromolar, but neither nanomolar or 
picomolar, concentrations of Ang II were associated with a statistically significant 
increase in vascular O2’ concentrations.
In vitro contractile responses of human arteries to Ang II are associated with 
tachyphylaxis (Thomson and Johnson 1987). This is an attenuation of the contractile 
response with increasing concentrations and duration of exposure to Ang II. The 
mechanisms giving rise to tachyphylaxis are poorly understood, but may involve 
desensitisation of the ATi receptor as a result of agonist-induced phosphorylation, and 
receptor internalisation (Hunyady 2001). The pharmacological concentration of Ang 
II used in this study may therefore have resulted in desensitisation of these blood 
vessels to additional agonist-induced contraction. The fact that the cumulative 
concentration response curves were undertaken with NE, rather than Ang II, mitigates 
against this being an important factor in the present investigation. The effect of Ang
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II-stimulated O2 ' production in human blood vessels could also be investigated using 
different functional techniques. One such technique that is thought to represent a more 
physiological method of vascular assessment is perfusion myography (Falloon et al 
1995). This technique differs from wire myography in a number of ways. In perfusion 
myography, the resistance artery is cannulated and pressurised. In this case, vascular 
responses to pharmacological agents are enhanced, compared to those observed from 
arteries under isometric tension (Falloon et al 1995). One disadvantage of pressure 
myography studies is that only one resistance artery may be studied at any one time. 
Clearly, in vivo techniques such as studies of blood flow in either the forearm, or 
dorsal hand veins, using forearm strain-gauge venous occlusion plethysmography.
In conclusion, therefore, this study fails to support the hypothesis that Ang II- 
sitimulated 0 {  production contributes to the constrictor effect of this hormone in 
human SRA. The reasons for this are not clear. Further studies are warranted, ideally 
using in vivo techniques.
136
8 Relationship between IMA superoxide anion 
concentrations and clinical risk factors and 
treatm ent type
8.1 Summary
Angiotensin converting enzyme (ACE) inhibitors have recently been demonstrated to 
reduce major atherosclerotic events in patients at risk of coronary heart disease 
(CHD). In this prospective study of consecutive patients undergoing coronary artery 
bypass grafting (CABG) we found vascular free radical concentrations were lower in 
those patients who were treated with a renin-angiotensin-aldosterone system (RAAS) 
inhibitor compared to those who were not. This may be one additional mechanism 
which contributes to the beneficial effects of these drugs in patients with CHD.
8.2 Methods
The aim of the present study was to determine, which, if any, risk factors and drug 
therapies, were associated with altered free radical concentrations in the arteries of 
CHD patients undergoing CABG. Seventy-nine consecutive patients who were 
undergoing CABG were prospectively included in this study. Patient clinical 
characteristics and risk factors for cardiovascular disease (defined in Chapter 2, 
section 2.1) were determined by review of case records.
Superoxide concentrations in distal segments of IMA obtained at the time of CABG 
were measured by lucigenin-enhanced chemiluminescence in a liquid scintillation 
counter, as described in section 2.5.6. Statistical analyses of vascular O2' 
concentrations after log-transformation were undertaken using the non-parametric 
Mann-Whitney Test. Step-wise multiple regression analysis was also performed. A 
probability value of P< 0.05 was considered statistically significant.
8.3 Results
Data On age, sex, risk factors and drug therapy are given in Table 1.
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Table 8.1 Patient characteristics, including risk factors and therapies.*
RAAS Inhibitor No RAAS Inhibitor
N 19 60
Mean age, y 61±9 62±8
Males, n (%) 13 (68) 45 (75)
Females, n (%) 6(33) 15 (25)
Risk factors, n (%)
Smoking 3(16) 10(17)
Hypertension 9(47) 21(35)
Diabetes mellitus 2(10) 4(7)
Hypercholesterolaemia 14 (73) 41(68)
Plasma chol, mmol/L (mean±SEM) 5.9±1.2 5.2±0.9
Medication, n (%)
Aspirin 14(74) 48 (80)
P-Blockers 13 (68) 33 (55)
Calcium channel blockers 11 (58) 34 (57)
HMG-CoA* reductase inhibitors 7(37) 31 (52)
Nitroglycerin 12(63) 34 (57)
Data on different classes of drug therapies in relation to the presence or absence of an 
ACE-I or ARA are presented in Table 2.
* Renin-angiotensin system inhibitor (includes 16 patients taking an ACEI and 3 patients taking an 
ARA); * Hydroxymethyl-glutaryl-CoA (HMGCoA) reductase
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Basal O 2’ production in hum an IMA was w eakly associated w ith patient age (r = 
0.19, p<0.1). N o other relationships existed betw een basal O 2" production in either 
IM A or SV, and any other patient risk factor. The profiles o f  risk factors and different 
classes o f drug therapies w ere sim ilar betw een patients w ho were taking an A C E-Ior 
ARA, com pared to those w ho were not taking these therapies. An A CEI or ARA was 
prescribed in 16 and 3 patients, respectively. The m edian rate o f  production o f  O 2 ' in 
IM A was 1137 (interquartile range, IQR 1290) pm ol/m in/m g. Superoxide 
concentrations were low er in those patients taking either an ACE-I or an A R A  (857, 
IQR 670 pm ol/m in/m g; n=  19) com pared to those w ho w ere not (1600, IQ R  1511 
pm ol/m in/m g; n= 60; p=0.002; 95%  confidence interval for m edian difference 487, 
1228 pm ol/m in/m g [Figure 8.1]).
Superoxide
pmol/min/mg |--------- P = 0.002
6000  -
5000
4000  -
3000  -
2000  -
1000
ACEI + ARA Other therapies
Figure 8.1 Box-plot graphical representation o f  superoxide concentrations 
(pm ol/m in/m g) in IM A from patients undergoing coronary artery bypass surgery who 
were taking either an ACE-I or an ARA, com pared to those patients not taking these 
therapies. M eans are indicated by solid circles, rectangles represent the lower and 
upper lim its o f the interquartile range and m edian values are dem arcated inside the
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rectangles. The vertical lines (or “whiskers”) represent the spread of the data. The 
upper line represents the upper, or 3rd quartile, plus 1.5 (interquartile range) and the 
lower line represents the lower, or 1st quartile, minus 1.5 (interquartile range). The 
asterisks (*) represent outlying values which lie between 1.5 and 3 times away from 
the middle 50% of the data.
No other associations between age, sex, risk factors, or individual drug therapies, and 
O2’ concentrations were identified.
8.4 Discussion
In this analysis, we demonstrated that O2" concentrations were lower in patients 
treated with either an ACE-I or an ARA, compared to those who were not. The 
clinical characteristics of both of these groups were similar such that the observed 
differences in vascular O2' concentrations were unlikely to be explained by any other 
patient characteristic or therapy. It is of interest that despite the fact that a large 
proportion of these patients were taking drugs with putative anti-oxidant properties, 
such as aspirin, beta-blockers and HMGCoA reductase inhibitors, vascular free 
radical concentrations were detected at physiologically important concentrations. The 
absence of any important anti-oxidant effect of these other therapies suggests that the 
sample size may not be sufficiently large to detect what may be a lesser anti-oxidant 
effect of these drugs.
In the current study, basal O2’ concentrations in IMA were weakly related to patient 
age. The variation in basal vascular O2’ concentrations observed in this and other 
human studies (Guzik et al 2000b; Huraux et al 1999), and the lack of correlation of 
O2 ' production with some atherosclerotic risk factors, treatment with nitrates and 
other therapies, may be due to the heterogeneous clinical characteristics of patients 
with CAD. Such patients have differences in their genetic background, their 
atherosclerotic risk factors, their disease duration and severity, and their drug therapy.
Our observations raise two questions. The first is how does such treatment exert this 
effect? Though some ACE-Is may have direct free radical scavenging properties this 
effect has been difficult to show at therapeutic concentrations in humans (Chopra et al 
1992). A more plausible explanation is that the anti-oxidant effect of this therapy is
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due to inhibition of the effects of Ang II. The second question is what, if any, might 
be the therapeutic significance of this effect of RAAS inhibitors? A reduction in 
vascular free radical production associated with RAAS inhibition, as is the case in the 
current study, may lead to enhanced bioavailable nitric oxide.
Taken together, these observations suggest that RAAS inhibition leads to a reduction 
in oxidative stress in patients with CHD. Given the damaging effects of increased free 
radical activity in the vasculature, the anti-oxidative effects of these therapies may be 
one further mechanism which may contribute to their beneficial effects in patients 
with CHD.
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9 General d iscussion
The objectives of this thesis were to characterise the sources of O2’ production in 
human blood vessels, and the mechanisms involved in ROS generation. The 
preliminary findings of this investigation demonstrated that O2* concentrations could 
be measured in human conduit blood vessels ex vivo in a reproducible fashion. The 
principal findings of this thesis include evidence of higher basal O2" concentrations in 
human arteries compared to those in veins, and that both NAD(P)H oxidase and XOR 
enzymes contribute to basal O2* production in these vessels. By contrast, NOS 
appeared to contribute to vascular '02* production only in some individuals. In 
addition, it was demonstrated that SOD protein levels are quantitatively similar in 
human IMA and SV. In subsequent studies, it was shown that Ang II augments 
vascular O2’ production by ATi receptor-dependent, NAD(P)H oxidase-mediated 
pathway. Immunodetection studies demonstrated this enzyme to be present 
throughout the vascular wall. Additional observations from other molecular 
investigations support the thesis that this pathway involves an enhanced abundance of 
mRNA of the subunits of NAD(P)H oxidase, and an increase in protein synthesis. 
Furthermore, inhibition of the AT2 receptor did not prevent Ang II-stimulated increase 
in 02* production in IMA, suggesting that this receptor does not contribute to O2* 
generation in human arteries. In vitro studies failed to demonstrate any contractile 
effect of Ang II-stimulated O2* production in human subcutaneous resistance arteries. 
By contrast, multivariate analyses of the relationship between risk factors and 
treatments for CHD demonstrated that treatment with an ACE-I or ARA was 
associated with reduced vascular O2' concentrations.
Superoxide production may be greater in IMA, compared to SV, because of the 
proportionally greater content of vascular smooth muscle in these arteries. One reason 
for this difference between conduit arteries and veins may be due to the presence of a 
thicker, muscular tunica media in arteries, where NAD(P)H oxidase was demonstrated 
to be abundant. Furthermore, that endothelial denudation had no effect on basal O2’ 
concentrations suggests that the endothelium is not an important source of O2 ' 
generation overall. Alternatively, the observation that inhibition of eNOS, by 
treatment of blood vessels with L-NAME, and endothelial denudation, tended to
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reduce O2* concentrations in the same patients (r = 0.85; n=12, p<0.001. [see Section 
3.3.3), suggests that the endothelium, and eNOS in particular, may be an important 
source of O2' generation in some, but not all, individuals.
This possibility is supported by studies of endothelial function in both experimental 
animals and humans. In studies of the SHRSP compared with normotensive control 
animals, Kerr et al (1999) demonstrated that the vascular endothelium was a source of 
enhanced O2' generation in aortic segments from the SHRSP, in which there was an 
enhanced abundance of NOS mRNA. Treatment with tetrahydrobiopterin, a co-factor 
for L-arginine biosynthesis, attenuated the difference in O2' generation. Earlier 
investigations by our group (Grunfeld et al 1995; McIntyre et al 1999) demonstrated 
impaired endothelium (NO)-dependent vasorelaxation in the SHRSP, compared to 
normotensive control animals. Taken together, these observations suggest that in this 
model of genetic hypertension, abnormalities in vascular function may be due to 
enhanced O2’ generation within the endothelium. In humans, endothelial dysfunction, 
or impaired NO-mediated vasodilatation, has been demonstrated a variety of disease 
states such as hypertension (Nakazono et al 1991), hypercholesterolaemia (Creager et 
al 1990), atherosclerosis (Cox et al 1989), diabetes (Calver et al 1992a), and heart 
failure (Kubo et al 1991). A reduction in bioavailable NO may be due to impaired 
production, increased removal, or an attenuation in its activity. Our observations 
suggest that, in this case, endothelium-dependent O2' generation in human conduit 
blood vessels may be less important for NO breakdown than in other species.
By contrast, O2' generation by VSMC and adventitial cells may be more important in 
terms of NO degradation in human blood vessels. This is supported by observations 
from our immunohistochemical studies which demonstrated that NAD(P)H oxidase 
and XOR appeared are most abundant within the vascular smooth muscle and 
adventitial layers in IMA and SV. The pro-oxidative activity of VSMC (Griendling et 
al 1994; Mohazzab and Wolin 1994), and the consequent effect on vascular tone 
(Nowicki et al 2000; Rajagopalan et al 1996b), is well recognised, however, the role 
of the adventitia as a source of ROS production has only recently emerged.
Pagano et al (1997a; 1998) explored the potential importance of adventitial O2’ 
production in the modulation of vascular tone. In one of these studies (Wang et al
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1998), rat thoracic aortic rings were mounted in an organ bath such that either the 
adventitial or endothelial surfaces of the artery were orientated outwards. This was 
achieved by carefully inverting the artery over a rubber tube. In this study, therefore, 
there were three groups, including a control group of arteries which had been inverted 
twice to control for any cellular injury induced by this manipulation. The presence of 
an intact endothelium was determined by treatment with ACh (10'6mol/L). Arteries 
were stretched to attain a resting tension of 5g, and after equilibration for 1 hour, they 
were pre-contracted with PE(10'6mol/L). In order to assess NO-dependent and 
independent vasorelaxation in conditions of normal or reduced vascular ROS activity, 
cumulative concentration response curves were performed with either exogenous NO 
(10'loto 10'6mol/L) or sodium nitroprusside (10'10to 10'6mol/L), in the presence and 
absence of SOD (150 U/mL). Studies in control vessels demonstrated comparable 
vasorelaxant responses were no different before or after inversion. NO-dependent 
vasorelaxation was less in rings with the adventitia facing outward, compared with 
those in which it faced inward, whereas the responses to sodium nitroprusside were 
not affected by the orientation of artery. This suggests that NO is inactivated to a 
greater extent when the adventitia is exposed externally, than when it is inverted 
internally. Furthermore, in the presence of SOD, this difference was attenuated. 
Further studies using DPI demonstrated that NAD(P)H oxidase was an important 
source of adventitial 02* generation. This study suggests that the adventitia regulates 
bioavailable NO through generation of ROS. Other studies by this group in different 
animal species demonstrated NAD(P)H oxidase within adventitial fibroblasts to be a 
source of O2* generation (Pagano et al 1997b; Pagano et al 1998; Wang et al 1999).
These observations are consistent with our own findings. We failed to detect 
cytochemical markers for leucocytes within the adventitia of IMA. This suggests that 
fibroblasts are the cellular source of ROS generation in the adventitia of human 
conduit blood vessels. The adventitia has also been the focus of interventional studies, 
designed to modulate vascular tone. For example, Tsutsui et al (1998) demonstrated 
that in vivo infusion of an adenoviral vector encoding recombinant eNOS 
(AdCMVeNOS) results in high levels of transgenic expression in adventitial 
fibroblasts of infused arteries. This was associated with preserved vasorelaxation 
responses to bradykinin in endothelium-denuded arteries and increases in cGMP 
production.
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The enzymatic sources of O2' generation were also investigated in this study. 
Inhibition of either NAD(P)H oxidase or XOR, was associated with a reduction in O2’ 
concentrations in both arteries and veins. DPI is, however, an inhibitor of flavin- 
dependent enzymes, which include both NOS, and XOR (Sanders et al 1997). It is 
plausible, therefore that DPI may also have inhibited O2" generation by these 
enzymes. This possiblity is unlikely, given that, for example, selective inhibition of 
eNOS by treatment with L-NAME, had no effect on 0 2 ' concentrations in either IMA 
or SV. Our observations are also supported by those of Guzik et al (2000b) who 
demonstrated that treatment of IMA with similar concentrations of DPI resulted in 
comparable reductions in basal O2’ concentrations in both IMA and SV. The lack of 
specificity of this agent may be one limitation of this study, however, DPI remains the 
standard pharmacological tool used to investigate vascular O2’ generation by 
NAD(P)H oxidase. Current investigations in our laboratory to test the effects of 
apocynin, an antagonist which may cause more specific inhibition of NAD(P)H 
oxidase, in both rat and human blood vessels, confirm the central role of this enzyme 
for vascular O2’ production (Hamilton et al 2001).
Studies in animal models of vascular disease have provided evidence of the central 
role of NAD(P)H oxidase-mediated ROS generation in relation to vascular 
dysfunction animals (Rajagopalan et al 1996b; Zalba et al 2000). For example, in 
studies undertaken in genetically hypertensive rats, Zalba et al (2000) demonstrated 
that the enhanced O2’ generation measured in the aortae of these animals, compared 
with that of age-matched, normotensive controls, was NAD(P)H oxidase-dependent. 
Furthermore, this was also associated with increases in the abundance of p22phox 
mRNA, media thickness and cross-sectional area. Studies by Hamilton et al (2001) 
recently demonstrated that NAD(P)H oxidase -  dependent O2’ generation was greater 
in old rats, compared to young rats. This in turn was associated with enhanced 
immunostaining for p22phox protein and reduced bioavailable NO in the old rats, 
compared to the young rats.
One of the principal findings of the present investigation was that treatment of human 
arteries with Ang II leads to enhanced O2' production, by an ATi receptor-dependent 
mechanism. This effect was dependent on both the concentration of Ang II and the 
duration of exposure. Furthermore, we observed that treatment with even
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physiological, or picomolar, concentrations of Ang II tended to increase O2’ 
production in IMA, suggesting that this mechanism may occur in vivo. These 
observations are consistent with other investigations of Ang II-stimulated O2' 
production in cultured rat VSMC (Griendling et al 1994), and in vivo studies in rat 
models of hypertension (Rajagopalan et al 1996b; Zalba et al 2000) and a rabbit 
model of atherosclerosis (Wamholtz et al 1999). In studies of rat models of 
hypertension, co-treatment with an ARA improved elevated blood pressure and 
endothelium-dependent vasorelaxation (Rajagopalan et al 1996b; Zalba et al 2000), 
whereas in the rabbit atherosclerosis model, co-treatment with an ARA improved 
endothelial dysfunction, normalised vascular O2’ concentrations and NAD(P)H- 
oxidase activity, decreased macrophage infiltration, and reduced early plaque 
formation (Wamholtz et al 1999).
ATi receptor activation triggers a variety of intracellular signaling cascades with 
differing temporal courses, which result in the vasoactive effects of this hormone 
(Berry et al 2001a). Acute effects, for example vasoconstriction, are due to altered 
protein kinase C and phospholipase enzyme activity and increases in intracellular 
Ca2+ ion concentrations, whereas slower, more sustained effects, such as promotion of 
gene transcription, are due to the effects of tyrosine kinase activation and intracellular 
protein phosphorylation (Berry et al 2001a). In the case of of ATi receptor-induced 
NAD(P)H oxidase activation, both in cultured rat VSMC (Griendling et al 1994) and 
in intact human blood vessels (Berry et al 2000a), increased O2' concentrations were 
detectable within one hour, and were sustained for over 4 hours.
The present study also included an investigation of the biochemical and molecular 
mechanisms that may be involved in Ang II -  stimulated O2’ production in human 
blood vessels. Inhibition of NAD(P)H oxidase by treatment with DPI attenuated Ang 
II-stimulated O2' production in human IMA, implicating this enzyme as the source of 
O2' generation. This finding was consistent with those of other investigations in 
experimental animals (Rajagopalan et al 1996b; Wamholtz et al 1999). Subsequent 
molecular investigations in this study demonstrated that treatment of either cultured 
vascular cells or intact arteries with Ang II was associated with an increase in the 
abundance of mRNA of p22phox. Furthermore, in HAEC, this was prevented by co­
treatment with either losartan, or actinomycin, and inhibitor of gene transcirption.
147
This latter finding suggests that Ang II may augment the rate of transcription of the 
p22phox gene in these cells.
Studies in Griendling’s laboratory have investigated the intracellular siginaling 
pathways that may be involved in ATi receptor-mediated NAD(P)H oxidase 
activation. Griendling originally described a temporal relationship between the 
duration of exposure to Ang II and altered VSMC O2' production (Griendling et al 
1994). The latter increased within the first few minutes of treatment with 100 nmol/L 
of Ang II. VSMC O2’ production also increased, following a similar timecourse, after 
treatment with fatty acids, such as arachidonic and linoleic acids (Griendling et al
1994). Ang II stimulates prostaglandin metabolism, which results in hypertrophy of 
VSMC (Natarajan et al 1994). Given that ROS activation also results in trophic 
cellular changes (Rao and Berk 1992), it is plausible that the trophic properties of Ang 
II (Berk et al 1989), may be mediated, in part, by an ATi receptor -  induced activation 
of prostaglandin metabolism and ROS production.
This thesis was explored by Zafari et al (200Q). In these studies, cultured rat VSMC 
were treated with 100 nmol/L of Ang II, which was associated with increases in [3H] 
AA and O2' concentrations, and hypertrophy of these cells. These effects were 
attenuated by co-treatment of these cells with either 5,8,11,14-eicosatetraynoic acid, a 
general inhibitor of AA metabolism, or nordihydroguaiaretic acid, an inhibitor of 
lipoxygenase metabolism, but not indomethacin, which is a cyclooxygenase inhibitor. 
Further experiments demonstrated that these effects were phospholipase A2 
dependent (Zafari et al 2000). In addition, some VSMC were transfected with 
antisense p22phox, in order to prevent Ang Il-induced NAD(P)H oxidase activation 
(UshioFukai et al 1996). In this case, treatment with Ang II had no effect on AA 
metabolite or O2' concentrations, and prevented hypertrophy of these cells. Taken 
together, these data indicate that AT 1 receptor-stimulated vascular cell O2 ' production 
occurs by a phospholipase A2-mediated increase in lipoxygenase (and possibly 
CYP450 monoxygenase) metabolites, which in turn, mediate NAD(P)H oxidase 
activation. These metabolites induce NAD(P)H oxidase activation, by causing 
exposure of the phox SH3 binding domains, which is required for the assembly of 
these subunits (Sumimoto et al 1994).
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More recently, studies by Lassegue et al (2001) in the same laboratory investigated 
the effects of Ang II on the differential expression of nox family members (i.e. 
gp91phox homologues) in rat VSMC. Treatment of these cells with different 
concentrations of Ang II lead to a dose- and time-dependent increase in the abundance 
of noxl, but not nox4, mRNA (EC50 3nmol/L and a maximal response at lpmol/L). 
The increase in noxl mRNA was detectable within the first hour and increased to a 
maximum at 4 hours. This was sustained for up to 12 hours after exposure to 100 
nmol/L of Ang II. Co-treatment with 12,13-phorbol myristate acetate, an inhibitor of 
protein kinase C, and transfection of antisense noxl, prevented these effects.
These investigations, taken together with observations from the present study, confirm 
that Ang II increases the abundance of mRNA transcripts for the phox subunits of 
NAD(P)H oxidase. It is not entirely clear, however, whether this effect is mediated by 
an increase in gene transcription, or a reduction in mRNA degradation as a result of 
enhanced stability of these molecules. In the present study, treatment of HAEC with 
actinomycin D prevented the Ang II-stimulated increase in abundance of p22phox 
mRNA, which suggests that Ang II may promote an increase in the rate of p22phox 
gene transcription. This possiblity is supported by observations in other studies of 
how Ang II promotes enhanced SOD activity (Fukai et al 1999). In these 
investigations, Ang II enhanced SOD protein expression in rat VSMC, through an 
increase in the rate of EC-SOD mRNA transcription and a prolongation of the half life 
of these molecules.
The data presented in this thesis are also supported by observations by Zhang et al 
(1999). In these studies, cultured human umbilical artery endothelial cells (HUVECs) 
were treated with micromolar and nanomolar concentrations of Ang II for up to 3 
hours. In this case, O2' production peaked at 60 minutes. Furthermore, treatment of 
these cells with NADH was associated with a greater rise in 0 {  generation, than was 
observed by treatment with NADPH. This suggests that human vascular NAD(P)H 
oxidase has greater affinity for NADH, than NADPH. In summary, therefore, there 
are now compelling data which collectively underline the importance of vascular 
NAD(P)H oxidase-mediated ROS generation in vascular damage, both in animal 
models and in humans.
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In the present study, it was also demonstrated that AT2 receptor activation does not 
contribute to O2" production in human arteries. Investigations in animal models 
previously demonstrated that stimulation of the AT2 receptor is associated with 
increased generation of bradykinin (Siragy et al 1998), NO (Siragy et al 1998), and 
cGMP (Siragy and Carey 1996), all of which have vasodilatory properties. In the 
present study, the trend toward an increase in O2" production in IMA treated with 
PD123319 suggests that this receptor may have a tonic, inhibitory effect on ATi 
receptor-dependent O2 production. It is possible that, in humans, AT2 receptor 
stimulation will lead to vasodilation through a signalling pathway that involves 
bradykinin and an increased production of NO. This, therefore, could be one 
mechanism whereby activation of the AT2 receptor may lead to scavenging of ROS as 
result of NO generation. At present, however, data on the presence, distribution and 
functional activity of AT2 receptors in human blood vessels are lacking. Recently, 
Ytterberg and Edvinsson (2001) failed to identify any AT2 receptor mRNA in human 
subcutaneous resistance arteries obtained from healthy subjects. Furthermore, AT2 
receptor antagonism, by co-treatment of arteries (which had been denuded of 
endothelium) with PD 123319 (1,10 nmol/L), had no effect on ANG II concentration- 
response curves (Ytterberg and Edvinsson 2001). Taken together, these in vitro 
observations suggest that in human resistance arteries, at least in healthy subjects, the 
AT2 receptor may have little functional importance in these blood vessels. Other 
studies of this receptor elsewhere in the human cardiovascular system nevertheless 
remain important.
One other purpose of this investigation was to investigate the functional significance, 
if any, of Ang II-stimulated O2’ generation in human blood vessels. As discussed 
earlier (Chapter 7), data obtained from in vitro studies in subcutaneous resistance 
arteries did not support this thesis. The reasons for this are not entirely clear. As 
discussed in Chapter 7, the lack of any demonstrable effect of Ang II-stimulated to 
O2’ production in these protocols may be due to the vessel type, experimental 
conditions, or the fact that this pathway does not contribute to vasomotor tone in these 
arteries. Forearm blood flow studies in healthy subjects demonstrated that the 
reduction in forearm blood flow with infusion of Ang II was attenuated by co-infusion 
of vitamin C (Dijkhorst-Oei et al 1999). Although these observations suggest that the 
vasoconstrictor effect of Ang II may be partly due to enhanced ROS production, this
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study did not quantify ROS concentrations in the blood of these patients. Further 
studies are therefore required to confirm this hypothesis.
Ang II has well documented trophic effects (Berk et al 1989), which are 
predominately mediated through tyrosine kinase activation, which in turn, promote 
enhanced gene transcription and protein synthesis (Berk and Corson 1997; Berry et al 
2001a). Recently, however, a number of investigations have demonstrated that many 
of the intracellular trophic signalling pathways which are activated by Ang II, are in 
fact, regulated by oxidant activity (Berry et al 2001a). For example, ATi receptor- 
induced receptor transactivation, is effected by cSrc-mediated tyrosine 
phosphorylation, a process which is dependent on oxidant activity (Ushio-Fukai et al 
2001). ROS are pleiotropic intracellular signals, which modulate a variety of 
pathways involved in vascular cell growth regulation (Irani 2000; Frank et al 2000a), 
and ROS may also be second-messengers for ATi receptor activation (Viedt et al 
2000; Rao 1996; Eguchi and Inagami 2000a) (see Chapter 1, section 1.4.1). The 
activity of NFkB is also regulated by ROS (Barnes and Karin 1997). Recent studies 
have demonstrated that ATi receptor-induced ROS production can result in activation 
of NFkB which lead, in turn, to enhanced VCAM-1 expression and monocyte 
activation (Pueyo et al 2000). These observations arising from in vitro and 
experimental animal studies suggest that Ang II-stimulated O2" generation in human 
blood vessels may well have non-pressor effects which could contribute to vascular 
inflammation and atherosclerosis.
Other observations in this study confirm that xanthine oxidase is important source of 
O2" generation in human blood vessels. The chemical structure of xanthine oxidase 
incorporates both molybdenum and iron/sulphur and FAD redox centres, such that 
this enzyme may utilise both xanthine and NAD(P)H as reducing substrates for O2’ 
generation (Harrison 2000; Sanders et al 1997). Electron donation from reducing 
substrates occurs at the molybdenum site (see Chapter 1, section' 1.1.2.1, Figure 1.4). 
The observation that XOR may contribute to basal O2* generation in human blood 
vessels is perhaps surprising, given previous reports that XOR was present only under 
conditions of ischaemia-reperfusion (Gimpel et al 1995; Harrison 2000; Tan et al
1995). Under these conditions, circulating XDH is converted to XO, which has a 
greater potential for generation. It is possible that the blood vessels used in this
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study may have been subject to ischaemia during surgical handling and laboratory 
manipulation, and under such conditions, XO would be activated. Nevertheless, our 
demonstration of XOR within the wall of IMA supports the concept that this protein is 
ubiquitously distributed throughout the cardiovascular system, and that under certain 
conditions, XOR can be an important source of O2’ generation. This thesis is 
supported by evidence of a functional activity of XOR both from studies in animal 
models (de Jong et al 2000; Ishimoto et al 1997; Nielsen et al 1994) and from in vitro 
(Patetsios et al 2001) and in vivo human studies (Cardillo et al 1997; Hellsten et al 
1997).
Most recently, studies undertaken by Patetsios et al (2001) demonstrated uric acid and 
XOR protein to be present in carotid arteries obtained from human cadavers during 
organ harvesting. Furthermore, studies undertaken in excised carotid endarterectomy 
specimens demonstrated uric acid and XOR protein to be more abundant in carotid 
arteries affected by atherosclerosis, than in unaffected arteries obtained from 
cadavers. Only a limited amount of immunohistochemical data was presented in this 
paper, however, these authors did demonstrate staining with their polyclonal anti- 
XOR antibody within the medial layer of these arteries. These investigations should 
be interpreted with some caution as the specificity of this polyclonal antibody for 
XOR was not reported. By contrast, a monoclonal antibody to XOR was used in the 
present study. Nevertheless, taken together with our own observations, these findings 
do support a role for XOR in the pathogenesis of atherosclerotic vascular disease. 
This raises the question as to whether or not therapeutic inhibition of XOR, for 
example with allopurinol, might be might be cardioprotective in humans.
Given that XOR has NAD(P)H reducing properties, it is plausible that Ang II may 
augment vascular ROS production by activation of this enzyme. This possibility was 
explored by Zhang et al (1999). In these in vitro studies, however, the addition of 
xanthine to human vascular endothelial cells pre-treated with Ang II had no effect on 
0 2 ' generation, suggesting that the activity of XOR may not affected by Ang II.
I also sought to characterise the endogenous ROS scavenging systems in human IMA 
and SV. In these studies, it was demonstrated that the total amount of EC and MnSOD 
proteins were quantitatively similar in human IMA and SV. This suggests that the
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observed differences in O2’ concentrations between arteries and veins are due to 
enhanced O2 ' production in arteries, rather than reduced scavenging in veins. One 
limitation of this study is the lack of information on SOD activity in these blood 
vessels. By contrast, other studies have demonstrated that the activity and amount of 
EC-SOD protein are significantly higher in human arteries than veins (Oury et al
1996). The differences between this and the present study could be explained by the 
use of different blood vessels and methods of protein quantification.
The fact that Ang II augments vascular ROS production raises the question as to 
whether or not this property might be shared by other vasoactive peptides. One 
candidate is endothelin, which is a pleiotropic hormone with potent trophic and 
pressor effects. Deuerrschmidt et al (2000) recently investigated whether or not 
endothelin (ET) might also have pro-oxidative effects. In this study, HUVECs were 
treated with 10 nmol/L of endothelin-1 (ET-1) for a up to 24 hours. ROS production 
by these cells was quantified using chemiluminescence techniques using both 
lucigenin (10 pmol/L), and the novel luminophore, coelenterazine. Treatment with 
ET-1 was associated with enhanced ROS production, which peaked at approximately 
3 hours. This effect was attenuated by co-treatment with both SOD and DPI, 
suggesting that ET-1 stimulated O2" production by an NAD(P)H oxidase-dependent 
mechanism. In addition, RNA expression studies were also performed, using 
competitive RT-PCR techniques. Treatment of these cells with ET-1 resulted in a 
dose-dependent increase in the abundance of gp91phox, which was attenuated by co­
treatment with the ETb receptor antagonist BQ-788. These in vitro studies provide 
mechanistic information which suggests that ET may also promote ROS activity in 
human blood vessels.
The possibility that ET might stimulate CVproduction in human blood vessels was 
also investigated in other studies in our laboratory (Brett et al 2001). IMA and SV 
were incubated at 37°C with 100 nmol/L of ET-1 for 4 hours. The vasopressor effects 
of ET used in this study were confirmed in isometric tension studies undertaken in 
these blood vessels.. Superoxide production was quantified by both lucigenin and 
coelenterazine - enhanced chemiluminescence. Using two different methods, O2" 
concentrations in both arteries and veins treated with ET were found to be similar to 
vehicle-treated controls from the same blood vessels. The lack of effect of ET may be
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due to a number of reasons. Firstly, it may be that although ET has been shown to 
stimulate ROS production in cultured HUVECs, this effect does not occur in intact 
human blood vessels. One other reason may be due to the possible ET-stimulated 
increase in vascular NO production (Hirata and Emori 1993; Ikeda et al 1996), 
leading to scavenging of O2’. Vascular NO concentrations were not quantified in this 
study. Other alternative explanations for the lack of effect of ET on vascular O2" 
concentrations include the concentration of ET used, or the duration of treatment. 
These observations do raise the possibility that the ability to stimulate vascular FR 
production may be a property specific to some (e.g. Ang II) but not all, vasoactive 
hormones.
Other findings in this study included the observation that patients who were treated 
with either an ACE-I or ARA had lower vascular O2’ concentrations compared with 
other patients who were not treated with these therapies (Berry et al 2000b). This 
finding supports our in vitro observations of ATi receptor-dependent 0 2 " generation 
in IMA. These observations are clinically relevant as physiological concentrations 
(pmol) of Ang II tended to increase production in human arteries and this effect 
was blocked by losartan. Inhibition of the RAAS has been proven to have beneficial 
therapeutic effects in a variety of cardiovascular disease states. However, ACE-I are 
used in the treatment of hypertension (Gohlke and Unger 1994), attenuate the 
progression of nephropathy in diabetic renal disease (Tripathi 1997), and reduce 
morbidity and mortality in chronic heart failure (Swedberg 1987; Yusuf 1991). ACE-I 
are now recognised to have therapeutic effects beyond simple blood pressure 
reduction. Evidence of this possibility was provided in data from the Studies of Left 
Ventricular Dysfunction Treatment Trial (SOLVD-T) (Yusuf 1991). In this trial, 2569 
patients with mild to moderate CHF were randomised to either enalapril (n=1285) at 
doses of 2.5 to 20mg per day, or placebo (n=1284). During the follow-up period of 41 
months, there were 510 deaths in the placebo group (39.7 %), as compared with 452 
in the enalapril group (35.2 %) (relative risk reduction, 16 %; 95% Cl, 5 to 26 %; p = 
0.0036). Although reductions in mortality were observed in several categories of 
cardiac deaths, the largest reduction occurred among the deaths attributed to 
progressive heart failure (251 in the placebo group vs. 209 in the enalapril group; 
relative risk reduction, 22 percent; 95 % Cl, 6 to 35 %). The addition of enalapril to 
conventional therapy reduced both mortality and hospitalisations for heart failure in 
patients with CHF. Surprisingly, however, there was a trend to a reduction in death
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from myocardial infarction. In the placebo group, 53 deaths occurred, whereas in the 
enalapril-treated group deaths 40 deaths occurred (relative risk reduction 28% ; 95% 
Cl, -8 to 52%, p<0.07). This unexpected observation suggested that ACE-I may have 
anti-atherogenic properties.
The cardiovascular protective properties of ACE-I were formally addressed in the 
Heart Outcomes Prevention and Evaluation (HOPE) study. The HOPE study (Yusuf 
et al 2000), was a randomised, controlled study of the effects of the ACE-I, ramipril, 
with or without vitamin E, compared to placebo, in patients at high risk of future 
cardiovascular events. In this trial, ramipril alone was associated with a 22% 
reduction (95% Cl, 0.7 to 0.86; p<0.001) in all-cause mortality. There were 
significantly fewer patients who had a myocardial infarction in the ramipril-treated 
group (460), compared to the placebo group (567; relative risk 0.8; 95% Cl 0.71 to 
0.91 p<0.001). These results support the assertion that ACE-I have an anti- 
atherosclerotic effect. The mechanisms for this may include atherosclerotic plaque 
stabilisation, a reduction in vascular cell apoptosis, or an increase in bioavailable NO. 
All of these effects may also be promoted by a reduction in ROS activity, as may 
occur through treatment of patients with RAAS inhibitors, thereby attenuating the 
pro-oxidant vascular effects of Ang II (Berry et al 2001b).
The conclusions of the HOPE study have been challenged by others who have argued 
against the investigators’ conclusion that the beneficial effects of ramipril were 
largely due to the non-pressor effect of this treatment (Gavras 2000; O'Rourke and 
Nichols 2000). However, a reduction of 3/2 mmHg in the ramipril-treated group, 
compared to the placebo group, could at most account for 25% of the difference in the 
primary endpoint between the two groups (Yusuf et a/ 2000). This suggests that the 
non-pressor, or anti-atherogenic, effects of this ACE-I may account for some of its 
beneficial effects in this study.
Ang II-stimulated O2' generation may contribute to a variety of trophic and pro- 
atherogenic processes, which in turn, are involved in the pathogenesis of 
cardiovascular disease. The observations in the present study support the thesis that 
Ang II-stimulated O2 ' generation may occur in human blood vessels. This suggests an 
additional pathophysiological effect of this hormone. Importantly, the observation that
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ARAs may attenuate Ang II-stimulated O2’ generation in human blood vessels 
suggests a putative therapeutic role for ARAs in reducing oxidative stress in patients 
with cardiovascular disease.
9.1 Future studies
At present, the only study which has investigated the putative vasopressor effects of 
Ang II - stimulated O2’ generation in humans in vivo, was that undertaken by 
(Dijkhorst-Oei et al 1999). These investigators used forearm strain gauge 
plethysmography to study the vasoactive effects of Ang II in the forearm circulation 
of healthy volunteers. They found that the vasoconstrictor effect of Ang II was 
attenuated by co-infusion of vitamin C. Further studies might attempt to reproduce 
these findings, both in health and disease. In addition, other studies might also be 
undertaken in order to investigate the importance, if any, of this pathway in the 
regulation of normal blood flow in other vascular beds, such as in the heart and skin.
Future studies may also investigate further the exact mechanism of how Ang II 
induces an increase in the abundance of phox mRNA in vascular cells. In order to 
address this question, other techniques which may be informative include, nuclear 
run-on analyses and RNA protection assays. Nuclear run-on analysis is a technique 
which yields specific information on gene transcription, whereas RNA protection 
assays yield information on RNA stability. Other studies may also investigate the 
effects, if any, of Ang II on translational, or post-translational pathways, which may 
also contribute to Ang II -  induced NAD(P)H oxidase activation.
Finally, recent reports suggest that HMGCoA reductase inhibitors, in addition to 
inhibiting cholesterol synthesis, also have anti-oxidant properties. One mechanism for 
this effect, in addition to other established anti-oxidant properties (see Section
1.11.5.4) may be through direct inhibition of phox gene expression (Wassmann et al 
2001). These preliminary findings in animal models merit further investigation in 
humans.
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